

PATENT COOPERATION TREATY

PCT

NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

Assistant Commissioner for Patents
United States Patent and Trademark
Office
Box PCT
Washington, D.C. 20231
ETATS-UNIS D'AMERIQUE

in its capacity as elected Office

Date of mailing (day/month/year) 12 April 2000 (12.04.00)	
International application No. PCT/US99/17595	Applicant's or agent's file reference 40750-5002WO
International filing date (day/month/year) 04 August 1999 (04.08.99)	Priority date (day/month/year) 04 August 1998 (04.08.98)
Applicant GOUT, Ivan et al	

1. The designated Office is hereby notified of its election made:

☒ in the demand filed with the International Preliminary Examining Authority on:

03 March 2000 (03.03.00)

☐ in a notice effecting later election filed with the International Bureau on:2. The election ☒ was☐ was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Facsimile No.: (41-22) 740.14.35	Authorized officer Sean Taylor Telephone No.: (41-22) 338.83.38
---	---

PATEI.. COOPERATION TREATY

RECEIVED

JAN 18 2000

From the INTERNATIONAL SEARCHING AUTHORITY

POT MORGAN, LEWIS & BOCKIUS LLP

To:

MORGAN, LEWIS & BOCKIUS LLP
Attn. Adler, R.
1800 M Street, N.W.
Washington, D.C. 20236-5869
UNITED STATES OF AMERICA

NOTIFICATION OF TRANSMITTAL OF
THE INTERNATIONAL SEARCH REPORT
OR THE DECLARATION

(PCT Rule 44.1)

Date of mailing (day/month/year) 11/01/2000	
Applicant's or agent's file reference 40750-5002W0	FOR FURTHER ACTION See paragraphs 1 and 4 below
International application No. PCT/US 99/17595	International filing date (day/month/year) 04/08/1999
Applicant LUDWIG INSTITUTE FOR CANCER RESEARCH et al.	

1. ☒ The applicant is hereby notified that the International Search Report has been established and is transmitted herewith.

Filing of amendments and statement under Article 19:

The applicant is entitled, if he so wishes, to amend the claims of the International Application (see Rule 46):

When? The time limit for filing such amendments is normally 2 months from the date of transmittal of the International Search Report; however, for more details, see the notes on the accompanying sheet.

Where? Directly to the International Bureau of WIPO
34, chemin des Colombettes
1211 Geneva 20, Switzerland
Fascimile No.: (41-22) 740.14.35

Case 40750-5002 W0

Due Date 3-11-00

Action Articles 19 Amendment

For more detailed instructions, see the notes on the accompanying sheet. By

RSB

Onk

Key

2. ☐ The applicant is hereby notified that no International Search Report will be established and that the declaration under Article 17(2)(a) to that effect is transmitted herewith.

3. ☐ With regard to the protest against payment of (an) additional fee(s) under Rule 40.2, the applicant is notified that:

☐ the protest together with the decision thereon has been transmitted to the International Bureau together with the applicant's request to forward the texts of both the protest and the decision thereon to the designated Offices.


☐ no decision has been made yet on the protest; the applicant will be notified as soon as a decision is made.

4. **Further action(s):** The applicant is reminded of the following:

Shortly after **18 months** from the priority date, the international application will be published by the International Bureau. If the applicant wishes to avoid or postpone publication, a notice of withdrawal of the international application, or of the priority claim, must reach the International Bureau as provided in Rules 90bis.1 and 90bis.3, respectively, before the completion of the technical preparations for international publication.

Within **19 months** from the priority date, a demand for international preliminary examination must be filed if the applicant wishes to postpone the entry into the national phase until 30 months from the priority date (in some Offices even later).

Within **20 months** from the priority date, the applicant must perform the prescribed acts for entry into the national phase before all designated Offices which have not been elected in the demand or in a later election within 19 months from the priority date or could not be elected because they are not bound by Chapter II.

Name and mailing address of the International Searching Authority  European Patent Office, P.B. 5818 Patentlaan 2 NL-2280 HV Rijswijk Tel. (+31-70) 340-2040. Tx. 31 651 epo nl. Fax: (+31-70) 340-3016	Authorized officer Sandra De Jong-van Dam
--	--

NOTES TO FORM PCT/ISA/220

These Notes are intended to give the basic instructions concerning the filing of amendments under article 19. The Notes are based on the requirements of the Patent Cooperation Treaty, the Regulations and the Administrative Instructions under that Treaty. In case of discrepancy between these Notes and those requirements, the latter are applicable. For more detailed information, see also the PCT Applicant's Guide, a publication of WIPO.

In these Notes, "Article", "Rule", and "Section" refer to the provisions of the PCT, the PCT Regulations and the PCT Administrative Instructions respectively.

INSTRUCTIONS CONCERNING AMENDMENTS UNDER ARTICLE 19

The applicant has, after having received the international search report, one opportunity to amend the claims of the international application. It should however be emphasized that, since all parts of the international application (claims, description and drawings) may be amended during the international preliminary examination procedure, there is usually no need to file amendments of the claims under Article 19 except where, e.g. the applicant wants the latter to be published for the purposes of provisional protection or has another reason for amending the claims before international publication. Furthermore, it should be emphasized that provisional protection is available in some States only.

What parts of the international application may be amended?

Under Article 19, only the claims may be amended.

During the international phase, the claims may also be amended (or further amended) under Article 34 before the International Preliminary Examining Authority. The description and drawings may only be amended under Article 34 before the International Examining Authority.

Upon entry into the national phase, all parts of the international application may be amended under Article 28 or, where applicable, Article 41.

When?

Within 2 months from the date of transmittal of the international search report or 16 months from the priority date, whichever time limit expires later. It should be noted, however, that the amendments will be considered as having been received on time if they are received by the International Bureau after the expiration of the applicable time limit but before the completion of the technical preparations for international publication (Rule 46.1).

Where not to file the amendments?

The amendments may only be filed with the International Bureau and not with the receiving Office or the International Searching Authority (Rule 46.2).

Where a demand for international preliminary examination has been/is filed, see below.

How?

Either by cancelling one or more entire claims, by adding one or more new claims or by amending the text of one or more of the claims as filed.

A replacement sheet must be submitted for each sheet of the claims which, on account of an amendment or amendments, differs from the sheet originally filed.

All the claims appearing on a replacement sheet must be numbered in Arabic numerals. Where a claim is cancelled, no renumbering of the other claims is required. In all cases where claims are renumbered, they must be renumbered consecutively (Administrative Instructions, Section 205(b)).

The amendments must be made in the language in which the international application is to be published.

What documents must/may accompany the amendments?

Letter (Section 205(b)):

The amendments must be submitted with a letter.

The letter will not be published with the international application and the amended claims. It should not be confused with the "Statement under Article 19(1)" (see below, under "Statement under Article 19(1)").

The letter must be in English or French, at the choice of the applicant. However, if the language of the international application is English, the letter must be in English; if the language of the international application is French, the letter must be in French.

NOTES TO FORM PCT/ISA/220 (c ntinued)

The letter must indicate the differences between the claims as filed and the claims as amended. It must, in particular, indicate, in connection with each claim appearing in the international application (it being understood that identical indications concerning several claims may be grouped), whether

- (i) the claim is unchanged;
- (ii) the claim is cancelled;
- (iii) the claim is new;
- (iv) the claim replaces one or more claims as filed;
- (v) the claim is the result of the division of a claim as filed.

The following examples illustrate the manner in which amendments must be explained in the accompanying letter:

1. [Where originally there were 48 claims and after amendment of some claims there are 51]:
"Claims 1 to 29, 31, 32, 34, 35, 37 to 48 replaced by amended claims bearing the same numbers; claims 30, 33 and 36 unchanged; new claims 49 to 51 added."
2. [Where originally there were 15 claims and after amendment of all claims there are 11]:
"Claims 1 to 15 replaced by amended claims 1 to 11."
3. [Where originally there were 14 claims and the amendments consist in cancelling some claims and in adding new claims]:
"Claims 1 to 6 and 14 unchanged; claims 7 to 13 cancelled; new claims 15, 16 and 17 added." or
"Claims 7 to 13 cancelled; new claims 15, 16 and 17 added; all other claims unchanged."
4. [Where various kinds of amendments are made]:
"Claims 1-10 unchanged; claims 11 to 13, 18 and 19 cancelled; claims 14, 15 and 16 replaced by amended claim 14; claim 17 subdivided into amended claims 15, 16 and 17; new claims 20 and 21 added."

"Statement under article 19(1)" (Rule 46.4)

The amendments may be accompanied by a statement explaining the amendments and indicating any impact that such amendments might have on the description and the drawings (which cannot be amended under Article 19(1)).

The statement will be published with the international application and the amended claims.

It must be in the language in which the international application is to be published.

It must be brief, not exceeding 500 words if in English or if translated into English.

It should not be confused with and does not replace the letter indicating the differences between the claims as filed and as amended. It must be filed on a separate sheet and must be identified as such by a heading, preferably by using the words "Statement under Article 19(1)."

It may not contain any disparaging comments on the international search report or the relevance of citations contained in that report. Reference to citations, relevant to a given claim, contained in the international search report may be made only in connection with an amendment of that claim.

Consequence if a demand for international preliminary examination has already been filed

If, at the time of filing any amendments under Article 19, a demand for international preliminary examination has already been submitted, the applicant must preferably, at the same time of filing the amendments with the International Bureau, also file a copy of such amendments with the International Preliminary Examining Authority (see Rule 62.2(a), first sentence).

Consequence with regard to translation of the international application for entry into the national phase

The applicant's attention is drawn to the fact that, where upon entry into the national phase, a translation of the claims as amended under Article 19 may have to be furnished to the designated/elected Offices, instead of, or in addition to, the translation of the claims as filed.

For further details on the requirements of each designated/elected Office, see Volume II of the PCT Applicant's Guide.

PATENT COOPERATION TREATY

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference 40750-5002W0	FOR FURTHER ACTION see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.	
International application No. PCT/US 99/ 17595	International filing date (day/month/year) 04/08/1999	(Earliest) Priority Date (day/month/year) 04/08/1998
Applicant LUDWIG INSTITUTE FOR CANCER RESEARCH et al.		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 6 sheets.

☒ It is also accompanied by a copy of each prior art document cited in this report.

1. Basis of the report

- a. With regard to the **language**, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.

☐ the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

- b. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international search was carried out on the basis of the sequence listing :

☒ contained in the international application in written form.

☒ filed together with the international application in computer readable form.

☐ furnished subsequently to this Authority in written form.

☐ furnished subsequently to this Authority in computer readable form.

☐ the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

☐ the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

2. ☒ **Certain claims were found unsearchable** (See Box I).

3. ☐ **Unity of invention is lacking** (see Box II).

4. With regard to the **title**,

☒ the text is approved as submitted by the applicant.

☐ the text has been established by this Authority to read as follows:

5. With regard to the **abstract**,

☒ the text is approved as submitted by the applicant.

☐ the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the **drawings** to be published with the abstract is Figure No. _____

☐ as suggested by the applicant.

☐ because the applicant failed to suggest a figure.

☐ because this figure better characterizes the invention.

☐ None of the figures.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 99/17595

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claims 10-11, as far as methods in vivo are concerned are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☒ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
See FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims 10-11 refer to modulating compounds, and claims 25-26 refer to binding partners of p70 S6K (beta) without giving a true technical characterization. Moreover, no such compounds are defined in the application. In consequence, the scope of said claims is ambiguous and vague, and their subject-matter is not sufficiently disclosed and supported (Art. 5 and 6 PCT). No search can be carried out for such purely speculative claims whose wording is, in fact, a mere recitation of the results to be achieved.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

International Classification I.
PCT/US 99/17595

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/54 C12N15/62 C12N9/12 C12N5/10 C07K16/40
G01N33/50 G01N33/566 C12Q1/68

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C07K G01N C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	GOUT I. ET AL.: "Molecular cloning and characterization of a novel p70 S6 kinase beta containing a proline-rich region" J. BIOL. CHEM., vol. 273, no. 46, 13 November 1998 (1998-11-13), pages 30061-30064, XP002124654 the whole document	1-36
P,X	SAITOH M. ET AL.: "Cloning and characterization of p70(S6 beta) defines a novel family of p70 S6 kinases" BIOCHEM. BIOPHYS. RES. COMMUN., vol. 253, no. 2, 18 December 1998 (1998-12-18), pages 471-476, XP002124655 the whole document	1-36

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance
"E" earlier document but published on or after the international filing date
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
"O" document referring to an oral disclosure, use, exhibition or other means
"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

20 December 1999

Date of mailing of the international search report

11/01/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Galli, I

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	WO 99 24463 A (INCYTE PHARMA INC ; MATHUR PREETE (US); REDDY ROOPA (US); AU YOUNG) 20 May 1999 (1999-05-20) compare nt 180-1450 of seq. ID 10 and nt 101-1370 of seq. ID 1 of present application ---	1-4
A	WO 98 18935 A (CIBA GEIGY AG ; THOMAS GEORGE (FR); KOZMA SARA (FR)) 7 May 1998 (1998-05-07) abstract claims 1-11 ---	1-36
A	WO 93 19752 A (DANA FARBER CANCER INST INC) 14 October 1993 (1993-10-14) abstract ---	1-36
A	MUKHOPADHYAY N.K. ET AL.: "An array of insulin-activated, proline-directed serine/threonine kinases phosphorylate the p70 S6 kinase" J. BIOL. CHEM., vol. 267, no. 5, 15 February 1995 (1995-02-15), pages 3325-3335, XP002124656 the whole document ---	1-36
A	WENG O.P. ET AL.: "Regulation of the p70 S6 kinase by phosphorylation in vivo" J. BIOL. CHEM., vol. 273, no. 26, 26 June 1998 (1998-06-26), pages 16621-16629, XP002124657 the whole document ---	1-36
A	ALESSI D.R. ET AL.: "3-Phosphoinositide-dependent protein kinase 1 (PDK1) phosphorylates and activates the p70 S6 kinase in vivo and in vitro" CURRENT BIOLOGY, vol. 8, 10 December 1997 (1997-12-10), pages 69-81, XP000857264 the whole document --- -/--	1-36

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>HAN J -W ET AL: "RAPAMYCIN, WORTMANNIN, AND THE METHYLXANTHINE SQ20006 INACTIVATE P70S6K BY INDUCING DEPHOSPHORYLATION OF THE SAME SUBSET OF SITES"</p> <p>JOURNAL OF BIOLOGICAL CHEMISTRY, US, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, vol. 270, no. 36, page 21396-21403</p> <p>XP002057557</p> <p>ISSN: 0021-9258</p> <p>the whole document</p>	1-36
A	<p>PEARSON R B ET AL: "THE PRINCIPAL TARGET OF RAPAMYCIN-INDUCED P70S6K INACTIVATION IS A NOVEL PHOSPHORYLATION SITE WITHIN A CONSERVED HYDROPHOBIC DOMAIN"</p> <p>EMBO JOURNAL, GB, OXFORD UNIVERSITY PRESS, SURREY, vol. 14, no. 21, page 5279-5287</p> <p>XP000561164</p> <p>ISSN: 0261-4189</p> <p>the whole document</p>	1-36
A	<p>DENNIS P B ET AL: "THE PRINCIPAL RAPAMYCIN-SENSITIVE P70S6K PHOSPHORYLATION SITES, T-229 AND T-389, ARE DIFFERENTIALLY REGULATED BY RAPAMYCIN-INSENSITIVE KINASE KINASES"</p> <p>MOLECULAR AND CELLULAR BIOLOGY, US, AMERICAN SOCIETY FOR MICROBIOLOGY, WASHINGTON, vol. 16, no. 11, page 6242-6251</p> <p>XP002057559</p> <p>ISSN: 0270-7306</p> <p>the whole document</p>	1-36
A	<p>WO 98 03662 A (CIBA GEIGY AG ; STEWART MARY (CH); THOMAS GEORGE (FR); KOZMA SARA ()</p> <p>29 January 1998 (1998-01-29)</p> <p>abstract</p> <p>claims 1-9</p>	1-36
A	<p>PROUD C G: "P70 S6 KINASE: AN ENIGMA WITH VARIATIONS"</p> <p>TIBS TRENDS IN BIOCHEMICAL SCIENCES, EN, ELSEVIER PUBLICATION, CAMBRIDGE, vol. 21, no. 5, page 181-185</p> <p>XP002057556</p> <p>ISSN: 0968-0004</p> <p>the whole document</p>	1-36

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 99/17595

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9924463 A	20-05-1999	US 5932445 A AU 1309599 A	03-08-1999 31-05-1999
WO 9818935 A	07-05-1998	AU 5314598 A EP 0942990 A	22-05-1998 22-09-1999
WO 9319752 A	14-10-1993	AU 3922493 A	08-11-1993
WO 9803662 A	29-01-1998	AU 4113897 A EP 0915982 A	10-02-1998 19-05-1999

RECEIVED

PATENT COOPERATION TREATY

RGA
MST
TFF

OCT 19 1999

From the INTERNATIONAL BUREAU

MORGAN, LEWIS & BOCKIUS LLP

PCT

NOTIFICATION CONCERNING
SUBMISSION OR TRANSMITTAL
OF PRIORITY DOCUMENT

(PCT Administrative Instructions, Section 411)

To:

ADLER, Reid, G.
Morgan, Lewis & Bockius LLP
1800 M Street, N.W.
Washington, DC 20036-5869
ÉTATS-UNIS D'AMÉRIQUE

Date of mailing (day/month/year) 28 September 1999 (28.09.99)	
Applicant's or agent's file reference 40750-5002WO	IMPORTANT NOTIFICATION
International application No. PCT/US99/17595	International filing date (day/month/year) 04 August 1999 (04.08.99)
International publication date (day/month/year) Not yet published	Priority date (day/month/year) 04 August 1998 (04.08.98)
Applicant LUDWIG INSTITUTE FOR CANCER RESEARCH et al	

1. The applicant is hereby notified of the date of receipt (except where the letters "NR" appear in the right-hand column) by the International Bureau of the priority document(s) relating to the earlier application(s) indicated below. Unless otherwise indicated by an asterisk appearing next to a date of receipt, or by the letters "NR", in the right-hand column, the priority document concerned was submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b).
2. This updates and replaces any previously issued notification concerning submission or transmittal of priority documents.
3. An asterisk(*) appearing next to a date of receipt, in the right-hand column, denotes a priority document submitted or transmitted to the International Bureau but not in compliance with Rule 17.1(a) or (b). In such a case, the attention of the applicant is directed to Rule 17.1(c) which provides that no designated Office may disregard the priority claim concerned before giving the applicant an opportunity, upon entry into the national phase, to furnish the priority document within a time limit which is reasonable under the circumstances.
4. The letters "NR" appearing in the right-hand column denote a priority document which was not received by the International Bureau or which the applicant did not request the receiving Office to prepare and transmit to the International Bureau, as provided by Rule 17.1(a) or (b), respectively. In such a case, the attention of the applicant is directed to Rule 17.1(c) which provides that no designated Office may disregard the priority claim concerned before giving the applicant an opportunity, upon entry into the national phase, to furnish the priority document within a time limit which is reasonable under the circumstances.

<u>Priority date</u>	<u>Priority application No.</u>	<u>Country or regional Office or PCT receiving Office</u>	<u>Date of receipt of priority document</u>
04 Augu 1998 (04.08.98)	60/095,268	US	24 Sept 1999 (24.09.99)

The International Bureau of WIPO
34, chemin des Colombettes
1211 Geneva 20, Switzerland

Facsimile No. (41-22) 740.14.35

Form PCT/IB/304 (July 1998)

Authorized officer

Carlos Naranjo

CSN

Telephone No. (41-22) 338.83.38

DOCKETED
By BB Date 10-20-99

002867940

RECEIVED

APR 25 2000

MORGAN, LEWIS & BOCKIUS LLP

PCT**PATENT COOPERATION TREATY**PCT/US99/17595
RGA
MST
TFD
FF

From the INTERNATIONAL BUREAU

To:

ADLER, Reid, G.
Morgan, Lewis & Bockius LLP
1800 M Street, N.W.
Washington, DC 20236-5869
ETATS-UNIS D'AMERIQUE**INFORMATION CONCERNING ELECTED
OFFICES NOTIFIED OF THEIR ELECTION**

(PCT Rule 61.3)

Date of mailing (day/month/year) 12 April 2000 (12.04.00)		IMPORTANT INFORMATION	
Applicant's or agent's file reference 40750-5002WO			
International application No. PCT/US99/17595	International filing date (day/month/year) 04 August 1999 (04.08.99)	Priority date (day/month/year) 04 August 1998 (04.08.98)	
Applicant LUDWIG INSTITUTE FOR CANCER RESEARCH et al			

1. The applicant is hereby informed that the International Bureau has, according to Article 31(7), notified each of the following Offices of its election:

EP : AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
National : AU, JP, US

2. The following Offices have waived the requirement for the notification of their election; the notification will be sent to them by the International Bureau only upon their request:

None

3. The applicant is reminded that he must enter the "national phase" before the expiration of 30 months from the priority date before each of the Offices listed above. This must be done by paying the national fee(s) and furnishing, if prescribed, a translation of the international application (Article 39(1)(a)), as well as, where applicable, by furnishing a translation of any annexes of the international preliminary examination report (Article 36(3)(b) and Rule 74.1).

Some offices have fixed time limits expiring later than the above-mentioned time limit. For detailed information about the applicable time limits and the acts to be performed upon entry into the national phase before a particular Office, see Volume II of the PCT Applicant's Guide.

The entry into the European regional phase is postponed until 31 months from the priority date for all States designated for the purposes of obtaining a European patent.

DOCKETEDBy *KJF*

Date

04/25/00

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Facsimile No. (41-22) 740.14.35	Authorized officer: Sean Taylor Telephone No. (41-22) 338.83.38
--	---

PATENT COOPERATION TREATY

PCT

REC'D 02 NOV 2000

WIPO

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference 40750-5002WO	FOR FURTHER ACTION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/US99/17595	International filing date (day/month/year) 04/08/1999	Priority date (day/month/year) 04/08/1998
International Patent Classification (IPC) or national classification and IPC C12N15/54		
Applicant LUDWIG INSTITUTE FOR CANCER RESEARCH et al.		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.



2. This REPORT consists of a total of 13 sheets, including this cover sheet.

- ☐ This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of sheets.

3. This report contains indications relating to the following items:

- I ☒ Basis of the report
- II ☒ Priority
- III ☒ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- IV ☒ Lack of unity of invention
- V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI ☒ Certain documents cited
- VII ☒ Certain defects in the international application
- VIII ☒ Certain observations on the international application

Date of submission of the demand 03/03/2000	Date of completion of this report 30.10.2000
Name and mailing address of the international preliminary examining authority:  European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465	Authorized officer Surdej, P Telephone No. +49 89 2399 7334 

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/US99/17595

I. Basis of the report

1. This report has been drawn on the basis of (*substitute sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to the report since they do not contain amendments.*):

Description, pages:

1-47 as originally filed

Claims, No.:

1-36 as originally filed

Drawings, sheets:

1/19-19/19 as originally filed

2. The amendments have resulted in the cancellation of:

- ☐ the description, pages:
- ☐ the claims, Nos.:
- ☐ the drawings, sheets:

3. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

4. Additional observations, if necessary:

see separate sheet

II. Priority

1. ☐ This report has been established as if no priority had been claimed due to the failure to furnish within the prescribed time limit the requested:
- ☐ copy of the earlier application whose priority has been claimed.
 - ☐ translation of the earlier application whose priority has been claimed.
2. ☒ This report has been established as if no priority had been claimed due to the fact that the priority claim has

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. PCT/US99/17595

been found invalid.

Thus for the purposes of this report, the international filing date indicated above is considered to be the relevant date.

3. Additional observations, if necessary:

see separate sheet

III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non-obvious), or to be industrially applicable have not been examined in respect of:

☐ the entire international application.

☒ claims Nos. 7, 10-11, 25-26.

because:

☒ the said international application, or the said claims Nos. 7, 10-11 relate to the following subject matter which does not require an international preliminary examination (*specify*):

see separate sheet

☐ the description, claims or drawings (*indicate particular elements below*) or said claims Nos. are so unclear that no meaningful opinion could be formed (*specify*):

☐ the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed.

☒ no international search report has been established for the said claims Nos. 10-11, 25-26.

IV. Lack of unity of invention

1. In response to the invitation to restrict or pay additional fees the applicant has:

☐ restricted the claims.

☐ paid additional fees.

☐ paid additional fees under protest.

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. PCT/US99/17595

☐ neither restricted nor paid additional fees.

2. ☒ This Authority found that the requirement of unity of invention is not complied and chose, according to Rule 68.1, not to invite the applicant to restrict or pay additional fees.

3. This Authority considers that the requirement of unity of invention in accordance with Rules 13.1, 13.2 and 13.3 is

☐ complied with.

☒ not complied with for the following reasons:

see separate sheet

4. Consequently, the following parts of the international application were the subject of international preliminary examination in establishing this report:

☒ all parts.

☐ the parts relating to claims Nos. .

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Yes:	Claims	2,6-9,17-24,28-36
	No:	Claims	1,3-5,12-16,27
Inventive step (IS)	Yes:	Claims	2,6-9,17-24,28-36
	No:	Claims	1,3-5,12-16,27
Industrial applicability (IA)	Yes:	Claims	1-6,8-9,12-24,27-36
	No:	Claims	

2. Citations and explanations

see separate sheet

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. PCT/US99/17595

VI. Certain documents cited

1. Certain published documents (Rule 70.10)

and / or

2. Non-written disclosures (Rule 70.9)

see separate sheet

VII. Certain defects in the international application

The following defects in the form or contents of the international application have been noted:

see separate sheet

VIII. Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

see separate sheet

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/US99/17595

Reference is made to the following documents:

- D1: GOUT I. ET AL.: 'Molecular cloning and characterization of a novel p70 S6 kinase beta containing a proline-rich region' J. BIOL. CHEM., vol. 273, no. 46, 13 November 1998 (1998-11-13), pages 30061-30064
- D2: SAITOH M. ET AL.: 'Cloning and characterization of p70(S6 beta) defines a novel family of p70 S6 kinases' BIOCHEM. BIOPHYS. RES. COMMUN., vol. 253, no. 2, 18 December 1998 (1998-12-18), pages 471-476
- D3: WO 99 24463 A (INCYTE PHARMA INC ;MATHUR PREETE (US); REDDY ROOPA (US); AU YOUNG) 20 May 1999 (1999-05-20)
- D4: WO 98 18935 A (CIBA GEIGY AG ;THOMAS GEORGE (FR); KOZMA SARA (FR)) 7 May 1998 (1998-05-07)
- D5: WO 93 19752 A (DANA FARBER CANCER INST INC) 14 October 1993 (1993-10-14)
- D6: MUKHOPADHYAY N.K. ET AL.: 'An array of insulin-activated, proline-directed serine/threonine kinases phosphorylate the p70 S6 kinase' J. BIOL. CHEM., vol. 267, no. 5, 15 February 1995 (1995-02-15), pages 3325-3335
- D7: WENG Q.P. ET AL.: 'Regulation of the p70 S6 kinase by phosphorylation in vivo' J. BIOL. CHEM., vol. 273, no. 26, 26 June 1998 (1998-06-26), pages 16621-16629
- D8: ALESSI D.R. ET AL.: '3-Phosphoinositide-dependent protein kinase 1 (PDK1) phosphorylates and activates the p70 S6 kinase in vivo and in vitro' CURRENT BIOLOGY, vol. 8, 10 December 1997 (1997-12-10), pages 69-81
- D9: HAN J -W ET AL: 'RAPAMYCIN, WORTMANNIN, AND THE METHYLXANTHINE SQ20006 INACTIVATE P70S6K BY INDUCING DEPHOSPHORYLATION OF THE SAME SUBSET OF SITES' JOURNAL OF BIOLOGICAL CHEMISTRY,US,AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, vol. 270, no. 36, page 21396-21403 ISSN: 0021-9258
- D10: PEARSON R B ET AL: 'THE PRINCIPAL TARGET OF RAPAMYCIN-INDUCED P70S6K INACTIVATION IS A NOVEL PHOSPHORYLATION SITE WITHIN A CONSERVED HYDROPHOBIC DOMAIN' EMBO JOURNAL,GB,OXFORD UNIVERSITY PRESS, SURREY, vol. 14, no. 21, page 5279-5287
- D11: DENNIS P B ET AL: 'THE PRINCIPAL RAPAMYCIN-SENSITIVE

P70S6K PHOSPHORYLATION SITES, T-229 AND T-389, ARE
DIFFERENTIALLY REGULATED BY RAPAMYCIN-INSENSITIVE KINASE
KINASES' MOLECULAR AND CELLULAR BIOLOGY,US,AMERICAN SOCIETY
FOR MICROBIOLOGY, WASHINGTON, vol. 16, no. 11, page 6242-6251

D12: WO 98 03662 A (CIBA GEIGY AG ;STEWART MARY (CH); THOMAS
GEORGE (FR); KOZMA SARA () 29 January 1998 (1998-01-29)

D13: PROUD C G: 'P70 S6 KINASE: AN ENIGMA WITH VARIATIONS'
TIBS TRENDS IN BIOCHEMICAL SCIENCES,EN,ELSEVIER PUBLICATION,
CAMBRIDGE, vol. 21, no. 5, page 181-185

D14: GROVES ET AL. 'Cloning and expression of two human p70 S6 kinase
polypeptides differing only at their amino termini' MOLECULAR AND CELLULAR
BIOLOGY,US,AMERICAN SOCIETY FOR MICROBIOLOGY, WASHINGTON, vol.
11, no. 11, page 5541-5550, D14 is not cited in the International Search Report,
but it is known to the applicant (see page 1, line 29)

Introduction

The application discloses a new S6 protein kinase, its sequence and structure,
methods to identify modulators of its phosphorylation, antibodies against it, fusion
proteins containing it, transformed cell with the gene encoding it, methods to
identified its substrates and its binding partners, its binding partners, methods to
determined its aberrant cellular level, and vectors containing it.

Re Item I

Basis of the report

1. The pages 1-11 of the listing of the sequences 1-8 filed with the international
application are taken into account for the establishment of this report.

Re Item II

Priority

2. The application draws priority from a document which has the date 4 August 1998
(P1).
The generation of activated mutants of p70beta^{S6k} referred to in claim 24 and part

of claim 35, described in the application, is not disclosed in the priority document P1. Therefore, the priority date of P1 cannot be acknowledged and only the filing date of the application will be considered for the subject matter of **claim 24 and part of claim 35**.

Since documents D1-D3 are published before the filing date of the application, they can be cited as prior art for the subject-matter not to be considered entitled to the priority date of P1.

Claims 1-9, 12-23, 27-34, part of 35 and 36 seem to be entitled to the priority date of the P1 document.

Re Item III

Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

3. No opinion is given on the subject-matter of **claims 10-11** and **claims 25-26** since no search report was established on said subject-matter.
4. For the assessment of the present **claims 7, 10-11** on the question whether they are industrially applicable, no unified criteria exist in the PCT Contracting States. The patentability can also be dependent upon the formulation of the claims. The EPO, for example, does not recognize as industrially applicable the subject-matter of claims to the use of a compound in medical treatment, but may allow, however, claims to a known compound for first use in medical treatment and the use of such a compound for the manufacture of a medicament for a new medical treatment.

Claims 7, 10-11 relate to subject-matter considered by this Authority to be covered by the provisions of Rule 67.1(iv) PCT. Consequently, no opinion will be formulated with respect to the industrial applicability of the subject-matter of these claims (Article 34(4)(a)(i) PCT).

Re Item IV

Lack of unity of invention

5. Document D1-D3 are published in the priority interval. The main part of the invention is disclosed in D1. The same protein (p70beta^{S6k}) was also identified in

D2. A protein with a sequence identical to part of p70beta^{S6k} was disclosed in D3. In particular, activated forms were described (see for example Fig. 3 in D1 and Fig. 4 in D2).

6. Therefore, the constitutive activated form of p70beta^{S6k}, which is referred to in claim 24 and part of 35, is not linked by a special technical feature to the subject-matter referred into claims 1-23, 25-34, part of 35 and 36 and they represent two separate inventions. The requisite unity of invention (Rule 13.1 PCT) therefore no longer exists inasmuch as a technical relationship involving a special technical feature in the sense of Rule 13.2 PCT does not exist.
7. Additional lack of unity seems to be present in the subject-matter referred to in claims 12-14, 27. These claims refer to antibodies recognising the protein p70beta^{S6k}.
Such antibodies were already disclosed in the prior art, as stated in the application, since an anti-phosphoserine antibody, commercially available before the priority date, recognises the p70beta^{S6k}.
Therefore, no special technical feature, in the sense of Rule 13.2 PCT, links the different antibodies recognising p70beta^{S6k} and each antibody may represent a separate invention. The claimed subject matter of claims 12-14, 27 seems not so linked as to form a single general inventive concept (Rule 13.1 PCT) and represents a group of separate inventions in regard to the subject-matter referred to in claims 1-11, 15-26, 28-36.
8. The term "stringent condition" used in claims 1 and 3 is not clearly defined in the description. Therefore, the scope of the said claims is not clear (Art. 5 and 6 PCT). As the conditions of hybridization are not defined, e.g. the isolated nucleic acid molecules p70alpha^{S6k}, which are largely disclosed in D4-D14 together with their activities, appear to fall into the scope of the said claims. Since claims 1 and 3 are not new, no special technical feature in the sense of Rule 13.2 PCT links claims 1, 3, 5 and 16, on one hand, and claims 2, 4, 6-15 and 17-36, on the other hand. They seem not so linked as to form a single general inventive concept (Rule 13.1 PCT).

Re Item V

Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

Novelty and inventive step (Art. 33.1-3)

9. Opinion on novelty and inventive step is given with the following proviso:
The term "p70beta^{S6k}" in claims 6-14, 17-31 and 35-36 is understood as referring to the protein with the sequence SEQ ID No.2 which appear to be new.
10. For reasons of clarity (see points 23 and 24): the second part of claim 2 "a protein having one or more conservative amino acid substitution in SEQ ID No.2" and the features "fragment" and "fusion protein" in claims 4, 15 and 17 are not taken into account for the reasoned statement on novelty and inventive step.
11. **Claims 1, 3 and 5** appear not to be new for the reason given in point 8.
12. **Claims 4 and 15** are not new because the proteins p70alpha^{S6k} and p70beta^{S6k} have 70% identity, therefore polypeptide fragments of p70alpha^{S6k}, as defined in the description, fall into the scope of the said claims.
13. **Claim 16** is not new. Said claim refers to cells transformed with nucleic acid molecules referred to in claims 1 and 3 which are not new (see point 8). Such transformed cells are already disclosed, for example, in D7 (page 16622, 2nd column, 4th paragraph), D8 (page 80, 2nd column), D9 (page 21397, 2nd column, 1st paragraph).
14. **Claims 12-14 and 27** are not new for the reasons given in point 7.
15. **Claims 2, 6-9, 17-24, 28-31 and 32-36** refer to an unknown protein having SEQ ID No.2. Therefore, said claims are new. The closest prior art document D14 discloses an isolated nucleic acid molecule having a sequence of a p70 S6 kinase. There are no indications of other member of the p70 S6 kinase family in the prior art and, as stated for example in D12 (page 29, 2nd paragraph) and in D13, it appears that p70^{S6k} is represented by a single gene in mammals. Thus,

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/US99/17595

said claims appear to involve an inventive step.

Re Item VI

Certain documents cited

Certain published documents (Rule 70.10)

Application No Patent No	Publication date (day/month/year)	Filing date (day/month/year)	Priority date (valid claim) (day/month/year)
D3: WO 99/24463	20/05/99	04/11/98	7/11/97

16. The applicants' attention is drawn to the fact that D3 will be considered as prior art in some PCT Contracting States. The EPO, for example, will consider D3 as prejudicial to the novelty of the subject-matter of the present application (Article 54(3) and (4) EPC) insofar as the same Designated Contracting States are concerned.

Re Item VII

Certain defects in the international application

17. The expression "incorporated by reference" (page 1, line 8; page 12, line 15, line 22, line 26; page 47, line 3) seems to imply that other subject matter is incorporated by reference, however the application should be self-explanatory (Art. 5 and 6, Rule 9.1 (iv) and Preliminary Examination Guidelines Ch. II-4.17 PCT).
18. Legibility of Figure 1 is somewhat lacking since the correspondance between identical bases cannot be clearly seen. The bands for p70beta^{s6k} cannot be clearly seen on Fig.4B (Art. 5 PCT).
19. In the legend of Figure 4A, it is not clear what are the different lanes (Art. 5 PCT).
20. It appears that the subject-matter of the last paragraph of page 19 is not related to the subject-matter of the invention (Rule 9.1 iv) and Art. 5 PCT).
21. The vague statement "spirit of the invention" on page 47, line 1 implies that the

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/US99/17595

subject-matter of the invention may be different from what is defined by the claims, thereby resulting in lack of clarity (Art. 6 PCT) when use to interpret them (see also the PCT Preliminary Examination Guidelines Ch. III-4.3a).

Re Item VIII

Certain observations on the international application

22. The term "conservative" used in claim 2 is defined on page 11, 4th paragraph of the description as referring to "alterations in the amino acid sequence that do not adversely affect the biological functions of the protein". However, it is mentioned in said paragraph that "conservative substitutions may irreversibly activate the protein" and it is not clear whether such changes do not adversely affect the biological function of the protein. Thus, the definition of conservative is not clear (Art. 5 and 6 PCT).
23. The term "fragment" used, for example, in claims 4, 15, 17 is not clear and any fragment seems to fall into the scope of such claims. The same observation applies for the term "fusion protein" (Art. 5 and 6 PCT).
24. The dependence of claim 13 is not clear since the said claim refers to a method in which no antibody are claimed. Thus, the scope of the claim is not clear (Art. 6 PCT).
25. The expression "a first" cellular extract in claims 19 and 21 is not clear since there is no reference to other extracts in the said claims (Art. 6 PCT).
26. In claim 8, it cannot be seen how the modulation of the phosphatase activity by an agent can be determined since the phosphatase seems not to be exposed to the agent. Therefore, the said claim lacks clarity and its scope is not clear (Art. 6 PCT).
27. The term "pcDNA3" employed in claim 34 and which appears to be a registered trade mark has no precise meaning as it is not internationally accepted as a standard descriptive term, thereby rendering the definition of the subject-matter of the said claim unclear (Article 6 PCT).

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/US99/17595

RGA
MST
TFP
FFFrom the
INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

PCT

To:

POCHE, Thomas F. et al
MORGAN, LEWIS & BOCKIUS LLP
1800 M Street, N.W.
Washington, D.C. 20036-5869
ETATS-UNIS D'AMERIQUE

RECEIVED

NOV 09 2000

MORGAN, LEWIS & BOCKIUS LLP

NOTIFICATION OF TRANSMITTAL OF
THE INTERNATIONAL PRELIMINARY
EXAMINATION REPORT

(PCT Rule 71.1)

Date of mailing
(day/month/year)

30.10.2000

Applicant's or agent's file reference
40750-5002WO

IMPORTANT NOTIFICATION

International application No.
PCT/US99/17595International filing date (day/month/year)
04/08/1999Priority date (day/month/year)
04/08/1998

Applicant

LUDWIG INSTITUTE FOR CANCER RESEARCH et al.

1. The applicant is hereby notified that this International Preliminary Examining Authority transmits herewith the international preliminary examination report and its annexes, if any, established on the international application.
2. A copy of the report and its annexes, if any, is being transmitted to the International Bureau for communication to all the elected Offices.
3. Where required by any of the elected Offices, the International Bureau will prepare an English translation of the report (but not of any annexes) and will transmit such translation to those Offices.

4. REMINDER

The applicant must enter the national phase before each elected Office by performing certain acts (filing translations and paying national fees) within 30 months from the priority date (or later in some Offices) (Article 39(1)) (see also the reminder sent by the International Bureau with Form PCT/IB/301).

Where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary examination report. It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned.

For further details on the applicable time limits and requirements of the elected Offices, see Volume II of the PCT Applicant's Guide.

DOCKETED

By GF Date 11/9/00

Name and mailing address of the IPEA/



European Patent Office
D-80298 Munich
Tel. +49 89 2399 - 0 Tx: 523656 epmu d
Fax: +49 89 2399 - 4465

Authorized officer

Emslander, S

Tel. +49 89 2399-8718



PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference 40750-5002WO	<div style="display: flex; justify-content: space-between;"> <div> FOR FURTHER ACTION </div> <div> See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416) </div> </div>	
International application No. PCT/US99/17595	International filing date (day/month/year) 04/08/1999	Priority date (day/month/year) 04/08/1998
International Patent Classification (IPC) or national classification and IPC C12N15/54		
Applicant LUDWIG INSTITUTE FOR CANCER RESEARCH et al.		
<p>1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.</p> <p>2. This REPORT consists of a total of 13 sheets, including this cover sheet.</p> <p><input type="checkbox"/> This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).</p> <p>These annexes consist of a total of sheets.</p>		
<p>3. This report contains indications relating to the following items:</p> <ul style="list-style-type: none"> I <input checked="" type="checkbox"/> Basis of the report II <input checked="" type="checkbox"/> Priority III <input checked="" type="checkbox"/> Non-establishment of opinion with regard to novelty, inventive step and industrial applicability IV <input checked="" type="checkbox"/> Lack of unity of invention V <input checked="" type="checkbox"/> Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement VI <input checked="" type="checkbox"/> Certain documents cited VII <input checked="" type="checkbox"/> Certain defects in the international application VIII <input checked="" type="checkbox"/> Certain observations on the international application 		
Date of submission of the demand 03/03/2000	Date of completion of this report 30.10.2000	
Name and mailing address of the international preliminary examining authority: <div style="display: flex; align-items: center;"> <div> European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465 </div> </div>	Authorized officer Surdej, P Telephone No. +49 89 2399 7334	



INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/US99/17595

I. Basis of the report

1. This report has been drawn on the basis of *(substitute sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to the report since they do not contain amendments.)*:

Description, pages:

1-47 as originally filed

Claims, No.:

1-36 as originally filed

Drawings, sheets:

1/19-19/19 as originally filed

2. The amendments have resulted in the cancellation of:

- ☐ the description, pages:
- ☐ the claims, Nos.:
- ☐ the drawings, sheets:

3. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

4. Additional observations, if necessary:

see separate sheet

II. Priority

1. ☐ This report has been established as if no priority had been claimed due to the failure to furnish within the prescribed time limit the requested:
- ☐ copy of the earlier application whose priority has been claimed.
 - ☐ translation of the earlier application whose priority has been claimed.
2. ☒ This report has been established as if no priority had been claimed due to the fact that the priority claim has

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. PCT/US99/17595

been found invalid.

Thus for the purposes of this report, the international filing date indicated above is considered to be the relevant date.

3. Additional observations, if necessary:

see separate sheet

III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non-obvious), or to be industrially applicable have not been examined in respect of:

- ☐ the entire international application.
- ☒ claims Nos. 7, 10-11, 25-26.

because:

- ☒ the said international application, or the said claims Nos. 7, 10-11 relate to the following subject matter which does not require an international preliminary examination (*specify*):

see separate sheet

- ☐ the description, claims or drawings (*indicate particular elements below*) or said claims Nos. are so unclear that no meaningful opinion could be formed (*specify*):
- ☐ the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed.
- ☒ no international search report has been established for the said claims Nos. 10-11, 25-26.

IV. Lack of unity of invention

1. In response to the invitation to restrict or pay additional fees the applicant has:

- ☐ restricted the claims.
- ☐ paid additional fees.
- ☐ paid additional fees under protest.

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. PCT/US99/17595

- ☐ neither restricted nor paid additional fees.
2. ☒ This Authority found that the requirement of unity of invention is not complied and chose, according to Rule 68.1, not to invite the applicant to restrict or pay additional fees.
3. This Authority considers that the requirement of unity of invention in accordance with Rules 13.1, 13.2 and 13.3 is
- ☐ complied with.
- ☒ not complied with for the following reasons:
- see separate sheet**
4. Consequently, the following parts of the international application were the subject of international preliminary examination in establishing this report:
- ☒ all parts.
- ☐ the parts relating to claims Nos. .

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Yes:	Claims	2,6-9,17-24,28-36
	No:	Claims	1,3-5,12-16,27
Inventive step (IS)	Yes:	Claims	2,6-9,17-24,28-36
	No:	Claims	1,3-5,12-16,27
Industrial applicability (IA)	Yes:	Claims	1-6,8-9,12-24,27-36
	No:	Claims	

2. Citations and explanations

see separate sheet

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. PCT/US99/17595

VI. Certain documents cited

1. Certain published documents (Rule 70.10)

and / or

2. Non-written disclosures (Rule 70.9)

see separate sheet

VII. Certain defects in the international application

The following defects in the form or contents of the international application have been noted:

see separate sheet

VIII. Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

see separate sheet

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/US99/17595

Reference is made to the following documents:

- D1: GOUT I. ET AL.: 'Molecular cloning and characterization of a novel p70 S6 kinase beta containing a proline-rich region' J. BIOL. CHEM., vol. 273, no. 46, 13 November 1998 (1998-11-13), pages 30061-30064
- D2: SAITOH M. ET AL.: 'Cloning and characterization of p70(S6 beta) defines a novel family of p70 S6 kinases' BIOCHEM. BIOPHYS. RES. COMMUN., vol. 253, no. 2, 18 December 1998 (1998-12-18), pages 471-476
- D3: WO 99 24463 A (INCYTE PHARMA INC ;MATHUR PREETE (US); REDDY ROOPA (US); AU YOUNG) 20 May 1999 (1999-05-20)
- D4: WO 98 18935 A (CIBA GEIGY AG ;THOMAS GEORGE (FR); KOZMA SARA (FR)) 7 May 1998 (1998-05-07)
- D5: WO 93 19752 A (DANA FARBER CANCER INST INC) 14 October 1993 (1993-10-14)
- D6: MUKHOPADHYAY N.K. ET AL.: 'An array of insulin-activated, proline-directed serine/threonine kinases phosphorylate the p70 S6 kinase' J. BIOL. CHEM., vol. 267, no. 5, 15 February 1995 (1995-02-15), pages 3325-3335
- D7: WENG Q.P. ET AL.: 'Regulation of the p70 S6 kinase by phosphorylation in vivo' J. BIOL. CHEM., vol. 273, no. 26, 26 June 1998 (1998-06-26), pages 16621-16629
- D8: ALESSI D.R. ET AL.: '3-Phosphoinositide-dependent protein kinase 1 (PDK1) phosphorylates and activates the p70 S6 kinase in vivo and in vitro' CURRENT BIOLOGY, vol. 8, 10 December 1997 (1997-12-10), pages 69-81
- D9: HAN J -W ET AL: 'RAPAMYCIN, WORTMANNIN, AND THE METHYLXANTHINE SQ20006 INACTIVATE P70S6K BY INDUCING DEPHOSPHORYLATION OF THE SAME SUBSET OF SITES' JOURNAL OF BIOLOGICAL CHEMISTRY,US,AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, vol. 270, no. 36, page 21396-21403 ISSN: 0021-9258
- D10: PEARSON R B ET AL: 'THE PRINCIPAL TARGET OF RAPAMYCIN-INDUCED P70S6K INACTIVATION IS A NOVEL PHOSPHORYLATION SITE WITHIN A CONSERVED HYDROPHOBIC DOMAIN' EMBO JOURNAL,GB,OXFORD UNIVERSITY PRESS, SURREY, vol. 14, no. 21, page 5279-5287
- D11: DENNIS P B ET AL: 'THE PRINCIPAL RAPAMYCIN-SENSITIVE

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/US99/17595

P70S6K PHOSPHORYLATION SITES, T-229 AND T-389, ARE
DIFFERENTIALLY REGULATED BY RAPAMYCIN-INSENSITIVE KINASE
KINASES' MOLECULAR AND CELLULAR BIOLOGY, US, AMERICAN SOCIETY
FOR MICROBIOLOGY, WASHINGTON, vol. 16, no. 11, page 6242-6251
D12: WO 98 03662 A (CIBA GEIGY AG ; STEWART MARY (CH); THOMAS
GEORGE (FR); KOZMA SARA () 29 January 1998 (1998-01-29)
D13: PROUD C G: 'P70 S6 KINASE: AN ENIGMA WITH VARIATIONS'
TIBS TRENDS IN BIOCHEMICAL SCIENCES, EN, ELSEVIER PUBLICATION,
CAMBRIDGE, vol. 21, no. 5, page 181-185
D14: GROVES ET AL. 'Cloning and expression of two human p70 S6 kinase
polypeptides differing only at their amino termini' MOLECULAR AND CELLULAR
BIOLOGY, US, AMERICAN SOCIETY FOR MICROBIOLOGY, WASHINGTON, vol.
11, no. 11, page 5541-5550, D14 is not cited in the International Search Report,
but it is known to the applicant (see page 1, line 29)

Introduction

The application discloses a new S6 protein kinase, its sequence and structure,
methods to identify modulators of its phosphorylation, antibodies against it, fusion
proteins containing it, transformed cell with the gene encoding it, methods to
identified its substrates and its binding partners, its binding partners, methods to
determined its aberrant cellular level, and vectors containing it.

Re Item I

Basis of the report

1. The pages 1-11 of the listing of the sequences 1-8 filed with the international
application are taken into account for the establishment of this report.

Re Item II

Priority

2. The application draws priority from a document which has the date 4 August 1998
(P1).
The generation of activated mutants of p70beta^{S6k} referred to in claim 24 and part

of claim 35, described in the application, is not disclosed in the priority document P1. Therefore, the priority date of P1 cannot be acknowledged and only the filing date of the application will be considered for the subject matter of **claim 24 and part of claim 35**.

Since documents D1-D3 are published before the filing date of the application, they can be cited as prior art for the subject-matter not to be considered entitled to the priority date of P1.

Claims 1-9, 12-23, 27-34, part of 35 and 36 seem to be entitled to the priority date of the P1 document.

Re Item III

Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

3. No opinion is given on the subject-matter of **claims 10-11** and **claims 25-26** since no search report was established on said subject-matter.
4. For the assessment of the present **claims 7, 10-11** on the question whether they are industrially applicable, no unified criteria exist in the PCT Contracting States. The patentability can also be dependent upon the formulation of the claims. The EPO, for example, does not recognize as industrially applicable the subject-matter of claims to the use of a compound in medical treatment, but may allow, however, claims to a known compound for first use in medical treatment and the use of such a compound for the manufacture of a medicament for a new medical treatment.

Claims 7, 10-11 relate to subject-matter considered by this Authority to be covered by the provisions of Rule 67.1(iv) PCT. Consequently, no opinion will be formulated with respect to the industrial applicability of the subject-matter of these claims (Article 34(4)(a)(i) PCT).

Re Item IV

Lack of unity of invention

5. Document D1-D3 are published in the priority interval. The main part of the invention is disclosed in D1. The same protein (p70beta^{S6k}) was also identified in

D2. A protein with a sequence identical to part of p70beta^{S6k} was disclosed in D3. In particular, activated forms were described (see for example Fig. 3 in D1 and Fig. 4 in D2).

6. Therefore, the constitutive activated form of p70beta^{S6k}, which is referred to in claim 24 and part of 35, is not linked by a special technical feature to the subject-matter referred into claims 1-23, 25-34, part of 35 and 36 and they represent two separate inventions. The requisite unity of invention (Rule 13.1 PCT) therefore no longer exists inasmuch as a technical relationship involving a special technical feature in the sense of Rule 13.2 PCT does not exist.

7. Additional lack of unity seems to be present in the subject-matter referred to in claims 12-14, 27. These claims refer to antibodies recognising the protein p70beta^{S6k}.

Such antibodies were already disclosed in the prior art, as stated in the application, since an anti-phosphoserine antibody, commercially available before the priority date, recognises the p70beta^{S6k}.

Therefore, no special technical feature, in the sense of Rule 13.2 PCT, links the different antibodies recognising p70beta^{S6k} and each antibody may represent a separate invention. The claimed subject matter of claims 12-14, 27 seems not so linked as to form a single general inventive concept (Rule 13.1 PCT) and represents a group of separate inventions in regard to the subject-matter referred to in claims 1-11, 15-26, 28-36.

8. The term "stringent condition" used in claims 1 and 3 is not clearly defined in the description. Therefore, the scope of the said claims is not clear (Art. 5 and 6 PCT). As the conditions of hybridization are not defined, e.g. the isolated nucleic acid molecules p70alpha^{S6k}, which are largely disclosed in D4-D14 together with their activities, appear to fall into the scope of the said claims. Since claims 1 and 3 are not new, no special technical feature in the sense of Rule 13.2 PCT links claims 1, 3, 5 and 16, on one hand, and claims 2, 4, 6-15 and 17-36, on the other hand. They seem not so linked as to form a single general inventive concept (Rule 13.1 PCT).

Re Item V

Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

Novelty and inventive step (Art. 33.1-3)

9. Opinion on novelty and inventive step is given with the following proviso:
The term "p70beta^{S6k}" in claims 6-14, 17-31 and 35-36 is understood as referring to the protein with the sequence SEQ ID No.2 which appear to be new.
10. For reasons of clarity (see points 23 and 24): the second part of claim 2 "a protein having one or more conservative amino acid substitution in SEQ ID No.2" and the features "fragment" and "fusion protein" in claims 4, 15 and 17 are not taken into account for the reasoned statement on novelty and inventive step.
11. **Claims 1, 3 and 5** appear not to be new for the reason given in point 8.
12. **Claims 4 and 15** are not new because the proteins p70alpha^{S6k} and p70beta^{S6k} have 70% identity, therefore polypeptide fragments of p70alpha^{S6k}, as defined in the description, fall into the scope of the said claims.
13. **Claim 16** is not new. Said claim refers to cells transformed with nucleic acid molecules referred to in claims 1 and 3 which are not new (see point 8). Such transformed cells are already disclosed, for example, in D7 (page 16622, 2nd column, 4th paragraph), D8 (page 80, 2nd column), D9 (page 21397, 2nd column, 1st paragraph).
14. **Claims 12-14 and 27** are not new for the reasons given in point 7.
15. **Claims 2, 6-9, 17-24, 28-31 and 32-36** refer to an unknown protein having SEQ ID No.2. Therefore, said claims are new. The closest prior art document D14 discloses an isolated nucleic acid molecule having a sequence of a p70 S6 kinase. There are no indications of other member of the p70 S6 kinase family in the prior art and, as stated for example in D12 (page 29, 2nd paragraph) and in D13, it appears that p70^{S6k} is represented by a single gene in mammals. Thus,

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/US99/17595

said claims appear to involve an inventive step.

Re Item VI

Certain documents cited

Certain published documents (Rule 70.10)

Application No Patent No	Publication date (day/month/year)	Filing date (day/month/year)	Priority date (valid claim) (day/month/year)
D3: WO 99/24463	20/05/99	04/11/98	7/11/97

16. The applicants' attention is drawn to the fact that D3 will be considered as prior art in some PCT Contracting States. The EPO, for example, will consider D3 as prejudicial to the novelty of the subject-matter of the present application (Article 54(3) and (4) EPC) insofar as the same Designated Contracting States are concerned.

Re Item VII

Certain defects in the international application

17. The expression "incorporated by reference" (page 1, line 8; page 12, line 15, line 22, line 26; page 47, line 3) seems to imply that other subject matter is incorporated by reference, however the application should be self-explanatory (Art. 5 and 6, Rule 9.1 (iv) and Preliminary Examination Guidelines Ch. II-4.17 PCT).
18. Legibility of Figure 1 is somewhat lacking since the correspondance between identical bases cannot be clearly seen. The bands for p70beta^{s6k} cannot be clearly seen on Fig.4B (Art. 5 PCT).
19. In the legend of Figure 4A, it is not clear what are the different lanes (Art. 5 PCT).
20. It appears that the subject-matter of the last paragraph of page 19 is not related to the subject-matter of the invention (Rule 9.1 iv) and Art. 5 PCT).
21. The vague statement "spirit of the invention" on page 47, line 1 implies that the

subject-matter of the invention may be different from what is defined by the claims, thereby resulting in lack of clarity (Art. 6 PCT) when use to interpret them (see also the PCT Preliminary Examination Guidelines Ch. III-4.3a).

Re Item VIII

Certain observations on the international application

22. The term "conservative" used in claim 2 is defined on page 11, 4th paragraph of the description as referring to "alterations in the amino acid sequence that do not adversely affect the biological functions of the protein". However, it is mentioned in said paragraph that "conservative substitutions may irreversibly activate the protein" and it is not clear whether such changes do not adversely affect the biological function of the protein. Thus, the definition of conservative is not clear (Art. 5 and 6 PCT).
23. The term "fragment" used, for example, in claims 4, 15, 17 is not clear and any fragment seems to fall into the scope of such claims. The same observation applies for the term "fusion protein" (Art. 5 and 6 PCT).
24. The dependence of claim 13 is not clear since the said claim refers to a method in which no antibody are claimed. Thus, the scope of the claim is not clear (Art. 6 PCT).
25. The expression "a first" cellular extract in claims 19 and 21 is not clear since there is no reference to other extracts in the said claims (Art. 6 PCT).
26. In claim 8, it cannot be seen how the modulation of the phosphatase activity by an agent can be determined since the phosphatase seems not to be exposed to the agent. Therefore, the said claim lacks clarity and its scope is not clear (Art. 6 PCT).
27. The term "pcDNA3" employed in claim 34 and which appears to be a registered trade mark has no precise meaning as it is not internationally accepted as a standard descriptive term, thereby rendering the definition of the subject-matter of the said claim unclear (Article 6 PCT).

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/US99/17595

M.H

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

ION



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C12N 15/54, 15/62, 9/12, 5/10, C07K 16/40, G01N 33/50, 33/566, C12Q 1/68		A1	(11) International Publication Number: WO 00/08173
			(43) International Publication Date: 17 February 2000 (17.02.00)
(21) International Application Number: PCT/US99/17595		(74) Agent: ADLER, Reid, G.; Morgan, Lewis & Bockius L.P., 1800 M Street, N.W., Washington, DC 20236-5869 (US).	
(22) International Filing Date: 4 August 1999 (04.08.99)			
(30) Priority Data: 60/095,268 4 August 1998 (04.08.98) US		(81) Designated States: AU, JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(71) Applicant (for all designated States except US): LUDWIG INSTITUTE FOR CANCER RESEARCH [US/US]; 34th floor, 1345 Avenue of the Americas, New York, NY 10105 (US).		Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(72) Inventors; and (75) Inventors/Applicants (for US only): GOUT, Ivan [-/US]; Ludwig Institute for Cancer Research, 34th floor, 1345 Avenue of the Americas, New York, NY 10105 (US). HARA, Kenta [-/US]; Ludwig Institute for Cancer Research, 34th floor, 1345 Avenue of the Americas, New York, NY 10105 (US). WATERFIELD, Mike [-/US]; Ludwig Institute for Cancer Research, 34th floor, 1345 Avenue of the Americas, New York, NY 10105 (US). YONEZAWA, Kazu [-/US]; Ludwig Institute for Cancer Research, 34th floor, 1345 Avenue of the Americas, New York, NY 10105 (US).			
(54) Title: IDENTIFICATION AND FUNCTIONAL CHARACTERIZATION OF A NOVEL RIBOSOMAL S6 PROTEIN KINASE			
(57) Abstract <p>A novel S6 kinase, p70^{βS6k}, is described, along with methods of making and using p70^{βS6k} and related nucleic acids. The invention also discloses methods of identifying agents which modulate the activity of p70^{βS6k} and/or its ligands.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

IDENTIFICATION AND FUNCTIONAL CHARACTERIZATION OF A NOVEL RIBOSOMAL S6 PROTEIN KINASE

5

This invention relates to United States Provisional Application Serial No. 60/095,268, filed August 4, 1988, which is incorporated by reference herein in its entirety.

10

FIELD OF THE INVENTION

The present invention relates to a novel S6 kinase (p70 β^{Sk6}), mutant variants thereof, methods of making and using this S6 kinase, and related nucleic acids and antibodies. The invention also relates to binding partners of the S6 kinase, methods of
15 identifying the binding partners and antibodies thereto.

BACKGROUND OF THE INVENTION

The 40S ribosomal protein S6 is a component of the 40S subunit of eukaryotic ribosomes. The ribosomes are part of the cellular machinery responsible for translation
20 of mRNA and protein synthesis. The S6 protein is phosphorylated in response to certain cellular signaling events such as hormone or growth factor induced cellular proliferation. p70 S6 kinase (p70 $S6^k$) is responsible for S6 phosphorylation and is believed to be the major physiological S6 kinase in mammalian cells (Proud, 1996 Trends Biochem. Sci. 21: 181-185).

25

1. p70 α S6 Kinase

A. Structure and Function

The first p70 S6 kinase identified was the alpha (α) form. The gene encoding the human p70 α S6 kinase (p70 $S6^k$) was isolated in 1991 (Grove *et al.*, 1991 Mol. Cell.

Biol. 11: 5541-5550). Other p70 α S6 kinase sequences have been described in *Mus musculus* (GenBank Accession No. SEG_AB015196S, AB015197, and AB015196), *Xenopus laevis* (GenBank Accession No. X66179), and rat (GenBank Accession No. M57428).

- 5 Two p70 α S6 kinase isoforms were identified: p70 α -I (GenBank Accession No. M60724) and p70 α -II (GenBank Accession No. M60725). The two p70 α S6 kinase isoforms differ only in their amino termini by 23 amino acid residues resulting in a 70 kD protein and a 85 kD protein. The isoforms are referred to in the literature as p70^{S6k}/p85^{S6k} or p70 α S6 kinase. Both isoforms share similar activity towards
- 10 ribosomal protein S6 *in vitro* but are expressed in different cells and tissues. The two isoforms are produced by two mRNA products and are not a result of post-translational modifications. They are serine/threonine kinases and are known to act on the substrate KKRNRRTLSVA (SEQ ID No. 7) (Pai *et al.*, 1994 Eur. J. Immunol. 24: 2364-8; and Leighton *et al.*, 1995 FEBS Letters 375: 289-93).
- 15 The p70 α S6 kinase plays an important role in the progression of cells from G1 to S phase of the cell cycle and in the initiation of protein synthesis. Recently, p70 α S6 kinase has been demonstrated to regulate the translation of a class of mRNAs containing an oligopyrimidine tract in their 5' untranslated region. This class of mRNAs, termed 5'TOP mRNAs, represent up to 20% of the a cell's total mRNA.
- 20 Many of the proteins encoded by 5'TOP mRNAs are translational apparatus proteins and cell-cycle progression proteins.

The p70 α S6 kinase has four identified interdependent domains: (1) a catalytic domain, (2) a kinase extension domain, (3) a pseudosubstrate autoinhibitory domain, and (4) the N-terminal domain. The catalytic domain is located in the middle of the

25 protein and is followed by the kinase extension domain, which is a unique feature for the PKA family. The pseudosubstrate autoinhibitory domain is also unique for the p70 α S6 kinase, not having been observed in any other known kinases. It possesses 5 phosphorylation sites which are responsible for the p70 α S6 kinase regulation. The N-terminal domain mediates the sensitivity for rapamycin, which strongly inhibits serum-

induced phosphorylation and activation of the p70 α S6 kinase. This domain may also mediate the interaction with a yet unknown phosphatase.

B. Regulators and Cascades

5 Growth factors, such as insulin, and mitogens are known to activate *in vivo* p70 α S6 kinase (Alessi *et al.*, 1998 Curr. Biol. 8: 69-81). Heat shock also activates p70 α S6 kinase (Lin *et al.*, 1997 J. Biol. Chem. 272: 31196-31202). Certain drugs have been identified that regulate p70 α S6 kinase activity including: rapamycin, wortmannin, Ro31-8220, GF109203X, LY294002, phenylephrine (PE), PD098059, SQ20006,
10 polymerized collagen, forskolin, interleukin-10 (IL-10), demethoxyviridin, phorbol 12-myristate 13-acetate (PMA), A23187, bombesin and antibodies which recognize the p70 α S6 kinase (Proud, 1996; Morreale *et al.*, 1997 FEBS Letters 417: 38-42; Kanda *et al.*, 1997 J. Biol. Chem. 272: 23347-23353; Boluyt *et al.*, 1997 Circ. Res. 81: 176-186; Coolican *et al.*, 1997 J. Biol. Chem. 272: 6653-6662; Koyama *et al.*, 1996 Cell 87: 1069-1078; Busca *et al.*, 1996 J. Biol. Chem. 271: 31824-31830; Crawley *et al.*, 1996
15 J. Biol. Chem. 271: 16357-16362; and Petritsch *et al.*, 1995 Eur. J. Biochem. 230: 431-8). The immunosuppressant rapamycin (Rap) is the most potent inhibitor of p70 α S6 kinase described (Pullen *et al.*, 1997 FEBS Letters 410: 78-82).

p70 α S6 kinase is an enzyme which lies downstream of phosphoinositide 3-
20 kinases (PI3-kinase). The mechanisms regulating the p70 α S6 kinase have not been fully elucidated. PI3-kinase has recently been shown to activate another phosphoinositide-dependent protein kinase, termed PDK-1. So far, only PDK-1 has been shown to phosphorylate p70 α S6 kinase *in vivo*, and this phosphorylation is essential for p70 α ^{S6k} activity towards ribosomal S6 protein. Wortmannin, a fungal
25 inhibitor which down-regulates the p70 α S6 kinase, is believed to act by inhibiting PI-3 kinase. In contrast, another fungal inhibitor, rapamycin, inhibits the p70 α S6 kinase by another cascade pathway involving the mammalian target of rapamycin (mTOR; also known as RAFT or FRAP) (Proud, 1996; Stewart *et al.*, 1994 BioEssays 16: 809-815). mTOR is a member of the PIK-related family of protein kinases (Pullen *et al.*, 1997).

Additional regulators of the p70 α S6 kinase include, but are not limited to protein kinase B (PKB), Cdc42, and Rac. The role of most of these proteins as p70 α S6 kinase regulators has yet to be fully elucidated.

5

SUMMARY OF THE INVENTION

The present invention is based on our discovery of a new gene which encodes a novel S6 kinase (p70 β ^{S6k}). The invention includes isolated nucleic acid molecules selected from the group consisting of an isolated nucleic acid molecule that encodes the
10 amino acid sequence of SEQ ID No.2, (*e.g.*, SEQ ID No.1) an isolated nucleic acid molecule that encodes a fragment of SEQ ID No.2, an isolated nucleic acid molecule which hybridizes to the complement of a nucleic acid molecule comprising SEQ ID No.1 under conditions of sufficient stringency to produce a clear signal and an isolated
15 nucleic acid molecule which hybridizes to the complement of a nucleic acid molecule that encodes the amino acid sequence of SEQ ID No.2 under conditions of sufficient stringency to produce a clear signal.

The present invention further includes the nucleic acid molecules operably linked to one or more expression control elements, including vectors comprising the isolated nucleic acid molecules. The invention further includes host cells transformed
20 to contain the nucleic acid molecules of the invention and methods for producing a protein comprising the step of culturing a host cell transformed with the nucleic acid molecule of the invention under conditions in which the protein is expressed.

The invention further provides an isolated polypeptide selected from the group consisting of an isolated polypeptide comprising the amino acid sequence of SEQ ID
25 No.2, an isolated polypeptide comprising a fragment of SEQ ID No.2, an isolated polypeptide comprising conservative amino acid substitutions of SEQ ID No.2 and naturally occurring amino acid sequence variants of SEQ ID No.2.

The invention further provides an isolated antibody that binds to a polypeptide of the invention, including monoclonal and polyclonal antibodies and fragments

thereof.

The invention further provides methods of identifying an agent which modulates the expression of a nucleic acid encoding the protein having the sequence of SEQ ID No.2 comprising the steps of: exposing cells which express the nucleic acid to
5 the agent; and determining whether the agent modulates expression of said nucleic acid, thereby identifying an agent which modulates the expression of a nucleic acid encoding the protein having the sequence of SEQ ID No.2.

The invention further provides methods of identifying an agent which modulates at least one activity of a protein comprising the sequence of SEQ ID No.2
10 comprising the steps of: exposing cells which express the protein to the agent; and determining whether the agent modulates at least one activity of said protein, thereby identifying an agent which modulates at least one activity of a protein comprising the sequence of SEQ ID No.2.

The invention further provides methods of identifying binding partners for a
15 protein comprising the sequence of SEQ ID No.2 or activated variants thereof, comprising for example, the steps of: exposing said protein to a potential binding partner; and determining if the potential binding partner binds to said protein, thereby identifying binding partners for a protein comprising the sequence of SEQ ID No.2. Exposing may be accomplished by expressing the protein in a cell.

20 The present invention further provides methods of modulating the expression of a nucleic acid encoding the protein having the sequence of SEQ ID No.2 comprising the step of: administering an effective amount of an agent which modulates the expression of a nucleic acid encoding the protein having the sequence of SEQ ID No.2. The invention also provides methods of modulating at least one activity of a protein
25 comprising the sequence of SEQ ID No.2 comprising the step of: administering an effective amount of an agent which modulates at least one activity of a protein comprising the sequence of SEQ ID No.2.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1. Nucleic acid sequence of p70 β^{S6k} (SEQ ID No.1) and comparison with p70 α^{S6k} (SEQ ID No. 3). Sequence analysis of cDNA encoding the p70 β S6 kinase. p70 β cDNA may encode two isoforms with the use of alternative start codon. The longer form may encode a protein of 495 amino acid residues and the shorter form,
 5 482 amino acids (aa). Alternative start codons and a stop codon are highlighted.

Figure 2A-2B. Amino Acid Sequence of p70 β^{S6k} (SEQ ID No.2) and comparison with p70 α^{S6k} (SEQ ID No. 4).

Figure 2A. Alignment of predicted protein sequences corresponding to the
 10 p70 α^{S6k} and p70 β S6 kinases. Identical amino acids are boxed.

Figure 2B. Comparative analysis of regulatory domains and phosphorylation sites between p70 α and β S6 kinases.

Figure 3A - 3B. Tissue Specific Expression of p70 β^{S6k} . Northern blot analysis
 15 of poly(A)+ RNA from human tissues (Figure 3A) and tumor cell lines (Figure 3B).

Figure 3A. Nylon membrane containing 2 μ g of gel-separated, pre-bound poly(A)+ RNA samples from various human tissues was hybridized with cDNA fragments of p70 α^{S6k} , p70 β^{S6k} or β -actin labeled by random priming. The upper, middle and lower panels are autoradiographs probed with p70 β^{S6k} , p70 α^{S6k} and β -actin,
 20 respectively. Each lane contains mRNA prepared from: heart (lane 1), brain (lane 2), placenta (lane 3), lung (lane 4), liver (lane 5), skeletal muscle (lane 6), kidney (lane 7), pancreas (lane 8), spleen (lane 9), thymus (lane 10), prostate (lane 11), testis (lane 12), ovary (lane 13), small intestine (lane 14), mucosal lining of the colon (lane 15), and peripheral blood leukocytes (lane 16).

25 **Figure 3B.** Nylon membrane containing 2 μ g of mRNA isolated from tumor cell lines was probed with the 3' cDNA fragment from p70 β^{S6k} , which was labeled by random-prime labeling. Specific binding was determined by autoradiography. Promyelocytic leukemia HL-60 (lane 1), HeLa cell S3 (lane 2, chronic myelogenous leukemia K562 (lane 3), lymphoblastic leukemia MOLT-4 (lane 4), Burkitt's

lymphoma Raji (lane 5), colorectal adenocarcinoma SW480 (lane 6), lung carcinoma (lane 7), and melanoma G361 (lane 8).

Figure 4A - 4B. Phosphorylation of the ribosomal protein S6 (Figure 4A) and its C-terminal synthetic peptide (Figure 4B) by p70 α^{S6k} and p70 β^{S6k} . Ribosomal S6 protein (purified ribosomal 40S subunits from liver) and synthetic peptides corresponding to the S6 protein C-terminus (*e.g.*, KEAKEKRQEIQIARRRLSSLRASTSKSESSQK-long form (SEQ ID No. 5) and RRRLSSLRASTSKSESSQK-(SEQ ID No. 6) short form) were used to measure the activity of the p70 α^{S6k} and p70 β^{S6k} . HEK293 cells were transfected with plasmids containing Flag-tag or EE-tag versions of p70 α^{S6k} or p70 β^{S6k} . Recombinant proteins were immunoprecipitated with anti-EE or anti-Flag antibodies and an *in vitro* kinase reaction performed in the presence of the ribosomal 40S subunits or synthetic peptides. After SDS-PAGE analysis, phosphorylation of the S6 protein and synthetic peptides was measured by PhosphorImager and expressed in arbitrary units (PI units).

Figure 5A - 5B. Stimulation of p70 β^{S6k} Activity by insulin, serum and TPA.

Figure 5A. CHO-IR cells were transfected with mock (lane1) or plasmids containing cDNAs of FLAG-tagged p70 α -I (lanes 2 and 3) or FLAG-tagged p70 β -II (lanes 4 to 7). After serum starvation for 16 hrs, cells were treated with the vehicle (lanes 2 and 4), 10⁻⁷ M insulin for 10 min (lanes 3 and 5), 15% serum for 10 min (lane 6) or 500 nM TPA for 30 min (lane7). After cell lysis and subsequent immunoprecipitation with anti-FLAG antibodies, immunoprecipitates were subjected to a p70 S6 kinase assay using 40S subunits as substrates. The reaction mixture was separated by SDS-PAGE, transferred onto PVDF membrane. The membrane was analyzed by autoradiography (upper panel) and then immunoblotted with anti-FLAG antibodies (lower panel). A representative of three experiments is shown. ³²P incorporation into S6 was quantified by Molecular Dynamics PhosphorImager™ and is expressed in arbitrary units (PI units).

Figure 5B. Stimulation of the p70 α^{S6k} and p70 β^{S6k} activity towards ribosomal S6 protein by PDGF in PAE-PDGF-R cells. PAE-PDGF-R cells were transfected with EE-tagged p70 α^{S6k} and p70 β^{S6k} plasmids using lipofectAMINE. After 24 hr, transfected cells were serum-starved for 16 hr and stimulated with 20 ng/ml PDGF BB (Calbiochem) for 20 min. Control cells were treated with the vehicle under the same conditions. After immunoprecipitation with anti-EE antibodies, an *in vitro* kinase reaction was carried out in the presence of 40S subunits, containing the S6 protein. Reaction mixtures were separated by SDS-PAGE and incorporation of ^{32}P into S6 protein was measured by PhosphorImager.

10

Figure 6A - 6B. Effects of rapamycin and wortmannin on p70 β^{S6k} and p70 α^{S6k} . Effects of rapamycin and wortmannin on S6 phosphorylation activity of p70 α -I or p70 β -II. HEK293 cells were transfected with mock cDNA or plasmids containing FLAG-tagged p70 α 1 or p70 β 2 isoforms. After 48 h of transfection, cells were treated with vehicle or indicated concentrations of rapamycin or wortmannin for 30 min. After immunoprecipitation with anti-FLAG antibodies, the kinase activity was determined by a p70 S6 kinase assay using 40S subunits as substrates. The proteins of the reaction mixture were separated by SDS-PAGE, transferred onto PVDF membrane and analyzed by autoradiography (Figures 6A and 6B, upper panels). Subsequent immunoblotting with anti-FLAG antibody confirmed the expression of p70 α -I (Figure 6A, lower panel) and p70 β -II (Figure 6B, lower panel). A representative of three experiments is shown. ^{32}P incorporation into S6 was quantified by PhosphorImager and is expressed in arbitrary units (PI units).

Figure 7. Interaction of the p70 β^{S6k} with different GST/SH3 fusion proteins. HEK293 cells were transiently transfected with EE-tag/p70 β^{S6k} . Two days later, cells were lysed and the lysates were immunoprecipitated with anti-EE antibodies. GST/SH3 fusion proteins (1.5 μ g each) were incubated with anti-EE tag immunoprecipitates. Specific interaction with p70 β^{S6k} was measured by anti-GST

immunoblotting. SH3 domains from different signaling and cytoskeletal proteins were expressed in bacteria as GST fusion proteins and purified nearly to homogeneity using glutathione-Sepharose beads. The GST/SH3 fusion proteins used are: GST (lane 1), p80 α subunit of the PI3-kinase (lane 2), GAP (lane 3), PLC γ (lane 4), spectrin (lane 5), crk (lane 6), n-grb2 (lane 7), c-grb2 (lane 8), grb2 full (lane 9), csk (lane 10), fgr (lane 11), fyn (lane 12), src (lane 13), ruk a (lane 14), ruk b (lane 15), ruk c (lane 16), p15 (lane 17), profilin (lane 18) and GST/GAP control (lane 19). "1" indicates instances of binding between p70 β^{S6k} and a SH3 containing fusion protein.

Figure 8. Immunoprecipitation and Western blot analysis of the p70 β -I and p70 β -II isoforms transiently over expressed in HEK293 cells with anti-p70 β^{S6k} antibodies. The lanes are the same for each panel: mock transfected (lane 1), Flag-p70 α -I transfected (lane 2), Flag-p70 β -I transfected (lane 3), and Flag-p70 β -II transfected (lane 4).

Figure 9. A model for the activation of p70 β^{S6k} Kinase. Schematic presentation of the p70 α^{S6k} structure, protein-protein interactions, activation levels and phosphorylation state.

Figure 10. p70 β^{S6k} mutations. Schematic presentation of substitution mutations engineered into p70 β^{S6k} , including a change of Threonine at amino acid 401 to Aspartic acid (T401D).

Figure 11. p70 β^{S6k} (T401D) activity. Activity of p70 β^{S6k} (T401D) variant as compared to wt p70 β^{S6k} under S6 Kinase and autophosphorylation assays.

Figure 12: p70 α^{S6k} (T412D) activity. Activity of p70 α^{S6k} (T412D) variant as compared to wt p70 α^{S6k} under S6 Kinase and autophosphorylation assays.

5 **DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT**

The terms "p70 α ", "p70 α^{S6k} " and "p70 α^{S6} kinase" are meant to include the two isoforms, p70 and p85, both of which phosphorylate the ribosomal protein S6. By "p70 α -1" and "p70 α -I" are meant the p85 isoform of the p70 α^{S6} kinase. By "p70 α -2" and "p70 α -II" are meant the p70 isoform of the p70 α^{S6} kinase.

10 The terms "p70 β ", "p70 β^{S6k} " and "p70 β^{S6} kinase" include the newly identified S6 kinase and all its isoforms.

I. General Description

The present invention is based in part on identifying a new gene that encodes a
15 novel S6 kinase (p70 β^{S6k}). This new gene and the protein that it encodes are members of the family of S6 kinases, of which the p70 α -I and -II (also referred to as p70 α -1 and p70 α -2) isoforms have already been reported.

The protein can serve as a target for agents that can be used to modulate the expression or activity of the protein. For example, agents may be identified which
20 modulate biological processes associated with ribosomal activity.

The present invention is further based on the development of methods for isolating binding partners that bind to the protein or its activated variants. Probes based on the protein are used as capture probes to isolate potential binding partners, such as other proteins. Dominant negative proteins, DNAs encoding these proteins, antibodies
25 to these proteins, peptide fragments of these proteins or mimics of these proteins may be introduced into cells to affect function. Additionally, these proteins provide a novel target for screening of synthetic small molecules and combinatorial or naturally occurring compound libraries to discover novel therapeutics to regulate ribosomal function.

II. Specific Embodiments

A. The Ribosome Associated Protein

The present invention provides isolated protein, allelic variants of the protein, and conservative amino acid substitutions of the protein, including substitutions that
5 activate the protein. As used herein, the protein or polypeptide refers to a protein that has the human amino acid sequence of depicted in SEQ ID No.2. The invention includes naturally occurring allelic variants and proteins that have a slightly different amino acid sequence than that specifically recited above. Allelic variants, though possessing a slightly different amino acid sequence than those recited above, will still
10 have the same or similar biological functions associated with the disclosed protein.

As used herein, the family of proteins related to the disclosed protein refer to proteins that have been isolated from organisms in addition to humans. The methods used to identify and isolate other members of the family of proteins related to the disclosed protein are described below.

15 The proteins of the present invention are preferably in isolated form. As used herein, a protein is said to be isolated when physical, mechanical or chemical methods are employed to remove the protein from cellular constituents that are normally associated with the protein. A skilled artisan can readily employ standard purification methods to obtain an isolated protein.

20 The proteins of the present invention further include conservative variants of the proteins herein described. As used herein, a conservative variant refers to alterations in the amino acid sequence that do not adversely affect the biological functions of the protein. A substitution, insertion or deletion is said to adversely affect the protein when the altered sequence prevents or disrupts a biological function associated with the
25 protein. For example, the overall charge, structure or hydrophobic/hydrophilic properties of the protein can be altered without adversely affecting a biological activity. Accordingly, the amino acid sequence can be altered, for example to render the peptide more hydrophobic or hydrophilic, without adversely affecting the biological activities of the protein. Conservative substitutions may irreversibly activate the protein.

Ordinarily, the allelic variants, the conservative substitution variants, the members of the protein family, will have an amino acid sequence having at least 71%-about 75% amino acid sequence identity with the human sequence set forth in SEQ ID No.2, more preferably at least 80%, even more preferably at least 90%, and most
5 preferably at least 95%. Identity or homology with respect to such sequences is defined herein as the percentage of amino acid residues in the candidate sequence that are identical with the known peptides, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent homology, and not considering any conservative substitutions as part of the sequence identity. N-terminal, C-terminal or
10 internal extensions, deletions, or insertions into the peptide sequence shall not be construed as affecting homology.

Homology or identity is determined by **BLAST (Basic Local Alignment Search Tool)** analysis using the algorithm employed by the programs **blastp**, **blastn**, **blastx**, **tblastn** and **tblastx** (Karlin , et al. Proc. Natl. Acad. Sci. USA 87: 2264-2268
15 (1990) and Altschul, S. F. J. Mol. Evol. 36: 290-300(1993), fully incorporated by reference) which are tailored for sequence similarity searching. The approach used by the **BLAST** program is to first consider similar segments between a query sequence and a database sequence, then to evaluate the statistical significance of all matches that are identified and finally to summarize only those matches which satisfy a preselected
20 threshold of significance. For a discussion of basic issues in similarity searching of sequence databases, see Altschul et al. (Nature Genetics 6: 119-129 (1994)) which is fully incorporated by reference. The search parameters for **histogram**, **descriptions**, **alignments**, **expect** (i.e., the statistical significance threshold for reporting matches against database sequences), **cutoff**, **matrix** and **filter** are at the default settings. The
25 default scoring matrix used by **blastp**, **blastx**, **tblastn**, and **tblastx** is the **BLOSUM62** matrix (Henikoff, et al. Proc. Natl. Acad. Sci. USA 89: 10915-10919 (1992), fully incorporated by reference). For **blastn**, the scoring matrix is set by the ratios of **M** (i.e., the reward score for a pair of matching residues) to **N** USA 87: 2264-2268 (1990) and (i.e., the penalty score for mismatching residues), wherein the default values for **M** and

N are 5 and -4, respectively.

Thus, the proteins of the present invention include molecules having the amino acid sequence disclosed in SEQ ID No.2; fragments thereof having a consecutive sequence of at least about 3, 5, 10 or 15 amino acid residues of the disclosed protein; amino acid sequence variants of such sequence wherein an amino acid residue has been inserted N- or C-terminal to, or within, the disclosed sequence; amino acid sequence variants of the disclosed sequence, or their fragments as defined above, that have been substituted by another residue. Contemplated variants further include those containing predetermined mutations by, *e.g.*, homologous recombination, site-directed or PCR mutagenesis, and the corresponding proteins of other animal species, including but not limited to rabbit, rat, murine, porcine, bovine, ovine, equine and non-human primate species, and the alleles or other naturally occurring variants of the family of proteins; and derivatives wherein the protein has been covalently modified by substitution, chemical, enzymatic, or other appropriate means with a moiety other than a naturally occurring amino acid (for example a detectable moiety such as an enzyme or radioisotope). Proteins of the invention may include fusion proteins comprising any of the foregoing.

As described below, members of the family of proteins can be used: 1) to identify agents which modulate at least one activity of the protein, including agents which may modulate phosphorylation mediated by the protein; 2) in methods of identifying binding partners for the protein, 3) as an antigen to raise polyclonal or monoclonal antibodies, and 4) as a therapeutic agent.

B. Nucleic Acid Molecules

The present invention further provides nucleic acid molecules that encode the protein having SEQ ID No.2 and the related proteins herein described, preferably in isolated form. As used herein, "nucleic acid" is defined as RNA or DNA that encodes a peptide as defined above, or is complementary to nucleic acid sequence encoding such peptides, or hybridizes to such nucleic acid and remains stably bound to it under

appropriate stringency conditions, or encodes a polypeptide sharing at least 75% sequence identity, preferably at least 80%, and more preferably at least 85%, with the peptide sequences. Specifically contemplated are genomic DNA, cDNA, mRNA and antisense molecules, as well as nucleic acids based on alternative backbone or including
5 alternative bases whether derived from natural sources or synthesized. Such hybridizing or complementary nucleic acids, however, are defined further as being novel and nonobvious over any prior art nucleic acid including that which encodes, hybridizes under appropriate stringency conditions, or is complementary to nucleic acid encoding a protein according to the present invention.

10 "Stringent conditions" are those that (1) employ low ionic strength and high temperature for washing, for example, 0.015 M NaCl, 0.0015 M sodium titrate, 0.1% SDS at 50°C; or (2) employ during hybridization a denaturing agent such as formamide, for example, 50% (vol/vol) formamide with 0.1% bovine serum albumin, 0.1% Ficoll, 0.1% polyvinylpyrrolidone, 50 mM sodium phosphate buffer at pH 6.5
15 with 750 mM NaCl, 75 mM sodium citrate at 42°C. Another example is use of 50% formamide, 5X SSC (0.75 M NaCl, 0.075 M sodium citrate), 50 mM sodium phosphate (pH 6.8), 0.1% sodium pyrophosphate, 5X Denhardt's solution, sonicated salmon sperm DNA (50 µg/ml), 0.1% SDS, and 10% dextran sulfate at 42°C, with washes at 42°C in 0.2X SSC and 0.1% SDS. A skilled artisan can readily determine and vary the
20 stringency conditions appropriately to obtain a clear and detectable hybridization signal.

As used herein, a nucleic acid molecule is said to be "isolated" when the nucleic acid molecule is substantially separated from contaminant nucleic acid encoding other polypeptides from the source of nucleic acid.

25 The present invention further provides fragments of the encoding nucleic acid molecule. As used herein, a fragment of an encoding nucleic acid molecule refers to a small portion of the entire protein encoding sequence. The size of the fragment will be determined by the intended use. For example, if the fragment is chosen so as to encode an active portion of the protein, the fragment will need to be large enough to encode the

functional region(s) of the protein. If the fragment is to be used as a nucleic acid probe or PCR primer, then the fragment length is chosen so as to obtain a relatively small number of false positives during probing/priming.

Fragments of the encoding nucleic acid molecules of the present invention (i.e.,
5 synthetic oligonucleotides) that are used as probes or specific primers for the polymerase chain reaction (PCR), or to synthesize gene sequences encoding proteins of the invention can easily be synthesized by chemical techniques, for example, the phosphotriester method of Matteucci, *et al.*, (*J. Am. Chem. Soc.* 103: 3185-3191, 1981) or using automated
10 synthesis methods. In addition, larger DNA segments can readily be prepared by well known methods, such as synthesis of a group of oligonucleotides that define various modular segments of the gene, followed by ligation of oligonucleotides to build the complete modified gene.

The encoding nucleic acid molecules of the present invention may further be modified so as to contain a detectable label for diagnostic and probe purposes. A
15 variety of such labels are known in the art and can readily be employed with the encoding molecules herein described. Suitable labels include, but are not limited to, biotin, radiolabeled nucleotides and the like. A skilled artisan can employ any of the art known labels to obtain a labeled encoding nucleic acid molecule.

Modifications to the primary structure itself by deletion, addition, or alteration of
20 the amino acids incorporated into the protein sequence during translation can be made without destroying the activity of the protein. Such substitutions or other alterations result in proteins having an amino acid sequence encoded by a nucleic acid falling within the contemplated scope of the present invention.

25 C. Isolation of Other Related Nucleic Acid Molecules

As described above, the identification of the human nucleic acid molecule having SEQ ID No.1 allows a skilled artisan to isolate nucleic acid molecules that encode other members of the p70 β^{S6k} family in addition to the human sequence herein described. Further, the presently disclosed nucleic acid molecules allow a skilled artisan to isolate

nucleic acid molecules that encode other members of the p70 β^{S6k} family of proteins in addition to the disclosed protein having SEQ ID No.2.

Essentially, a skilled artisan can readily use the amino acid sequence of SEQ ID No.2 to generate antibody probes to screen expression libraries prepared from
5 appropriate cells. Typically, polyclonal antiserum from mammals such as rabbits immunized with the purified protein (as described below) or monoclonal antibodies can be used to probe a mammalian cDNA or genomic expression library, such as λ gt11 library, to obtain the appropriate coding sequence for other members of the protein family. The cloned cDNA sequence can be expressed as a fusion protein, expressed directly using its
10 own control sequences, or expressed by constructions using control sequences appropriate to the particular host used for expression of the enzyme.

Alternatively, a portion of the coding sequence herein described can be synthesized and used as a probe to retrieve DNA encoding a member of the protein family from any mammalian organism. Oligomers containing approximately 18-20 or 21 nucleotides
15 (encoding about a 6-7 amino acid stretch) are prepared and used to screen genomic DNA or cDNA libraries to obtain hybridization under stringent conditions or conditions of sufficient stringency to eliminate an undue level of false positives.

Additionally, pairs of oligonucleotide primers can be prepared for use in a polymerase chain reaction (PCR) to selectively clone an encoding nucleic acid molecule.
20 A PCR denature/anneal/extend cycle for using such PCR primers is well known in the art and can readily be adapted for use in isolating other encoding nucleic acid molecules.

D. rDNA molecules Containing a Nucleic Acid Molecule

The present invention further provides recombinant DNA molecules (rDNAs) that
25 contain a coding sequence. As used herein, a rDNA molecule is a DNA molecule that has been subjected to molecular manipulation *in situ*. Methods for generating rDNA molecules are well known in the art, for example, see Sambrook *et al.*, (1989). In the preferred rDNA molecules, a coding DNA sequence is operably linked to expression control sequences and/or vector sequences.

The choice of vector and/or expression control sequences to which one of the protein family encoding sequences of the present invention is operably linked depends directly, as is well known in the art, on the functional properties desired, e.g., protein expression, and the host cell to be transformed. A vector contemplated by the present invention is at least capable of directing the replication or insertion into the host chromosome, and preferably also expression, of the structural gene included in the rDNA molecule.

Expression control elements that are used for regulating the expression of an operably linked protein encoding sequence are known in the art and include, but are not limited to, inducible promoters, constitutive promoters, secretion signals, and other regulatory elements. Preferably, the inducible promoter is readily controlled, such as being responsive to a nutrient in the host cell's medium.

In one embodiment, the vector containing a coding nucleic acid molecule will include a prokaryotic replicon, *i.e.*, a DNA sequence having the ability to direct autonomous replication and maintenance of the recombinant DNA molecule extrachromosomally in a prokaryotic host cell, such as a bacterial host cell, transformed therewith. Such replicons are well known in the art. In addition, vectors that include a prokaryotic replicon may also include a gene whose expression confers a detectable marker such as a drug resistance. Typical bacterial drug resistance genes are those that confer resistance to ampicillin or tetracycline.

Vectors that include a prokaryotic replicon can further include a prokaryotic or bacteriophage promoter capable of directing the expression (transcription and translation) of the coding gene sequences in a bacterial host cell, such as *E. coli*. A promoter is an expression control element formed by a DNA sequence that permits binding of RNA polymerase and transcription to occur. Promoter sequences compatible with bacterial hosts are typically provided in plasmid vectors containing convenient restriction sites for insertion of a DNA segment of the present invention. Typical of such vector plasmids are pUC8, pUC9, pBR322 and pBR329 available from Biorad Laboratories, (Richmond, CA), pPL and pKK223 available from Pharmacia, Piscataway, N.J.

Expression vectors compatible with eukaryotic cells, preferably those compatible with vertebrate cells, can also be used to form a rDNA molecules the contains a coding sequence. Eukaryotic cell expression vectors are well known in the art and are available from several commercial sources. Typically, such vectors are provided containing
5 convenient restriction sites for insertion of the desired DNA segment. Typical of such vectors are pSVL and pKSV-10 (Pharmacia), pBPV-1/pML2d (International Biotechnologies, Inc.), pTDT1 (ATCC, #31255), the vector pCDM8 described herein, and the like eukaryotic expression vectors.

Eukaryotic cell expression vectors used to construct the rDNA molecules of the
10 present invention may further include a selectable marker that is effective in an eukaryotic cell, preferably a drug resistance selection marker. A preferred drug resistance marker is the gene whose expression results in neomycin resistance, *i.e.*, the neomycin phosphotransferase (*neo*) gene (Southern *et al.*, J. Mol. Anal. Genet. 1: 327-341, 1982). Alternatively, the selectable marker can be present on a separate plasmid, and the two
15 vectors are introduced by co-transfection of the host cell, and selected by culturing in the appropriate drug for the selectable marker.

E. Host Cells Containing an Exogenously Supplied Coding Nucleic Acid Molecule

20 The present invention further provides host cells transformed with a nucleic acid molecule that encodes a protein of the present invention. The host cell can be either prokaryotic or eukaryotic. Eukaryotic cells useful for expression of a protein of the invention are not limited, so long as the cell line is compatible with cell culture methods and compatible with the propagation of the expression vector and expression of the gene
25 product. Preferred eukaryotic host cells include, but are not limited to, yeast, insect and mammalian cells, preferably vertebrate cells such as those from a mouse, rat, monkey or human cell line. Preferred eukaryotic host cells include Chinese hamster ovary (CHO) cells available from the ATCC as CCL61, NIH Swiss mouse embryo cells NIH/3T3 available from the ATCC as CRL 1658, baby hamster kidney cells (BHK), and the like eukaryotic

tissue culture cell lines.

Any prokaryotic host can be used to express a rDNA molecule encoding a protein of the invention. The preferred prokaryotic host is *E. coli*.

Transformation of appropriate cell hosts with a rDNA molecule of the present invention is accomplished by well known methods that typically depend on the type of vector used and host system employed. With regard to transformation of prokaryotic host cells, electroporation and salt treatment methods are typically employed, see, for example, Cohen *et al.*, Proc. Natl. Acad. Sci. USA 69: 2110, 1972; and Maniatis *et al.*, MOLECULAR CLONING, A LABORATORY MANUAL, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY (1982). With regard to transformation of vertebrate cells with vectors containing rDNAs, electroporation, cationic lipid or salt treatment methods are typically employed, see, for example, Graham *et al.*, Virology 52: 456, 1973; Wigler *et al.*, Proc. Natl. Acad. Sci. USA 76: 1373-76, 1979.

Successfully transformed cells, i.e., cells that contain a rDNA molecule of the present invention, can be identified by well known techniques including the selection for a selectable marker. For example, cells resulting from the introduction of an rDNA of the present invention can be cloned to produce single colonies. Cells from those colonies can be harvested, lysed and their DNA content examined for the presence of the rDNA using a method such as that described by Southern, J. Mol. Biol. 98:503, 1975, or Berent *et al.*, Biotech. 3: 208, 1985 or the proteins produced from the cell assayed via an immunological method.

Recombinant p70 β^{S6k} DNA can also be utilized to analyze the function of coding and non-coding sequences. For example, the 5' untranslated region of the p70 β^{S6k} clone contains a GA repeat (nucleotides 1-66 of P70 β^{S6k}), that may modulate the initiation of translation of its mRNA. This sequence can be utilized in an affinity matrix system to purify proteins obtained from cell lysates that associate with the p70 β^{S6k} GA sequence. Synthetic oligonucleotides would be coupled to the beads and probed with the lysates, as is commonly known in the art. Associated proteins could then be separated using, for example, a two dimensional SDS-PAGE system. Proteins thus isolated could be further

identified using mass spectroscopy or protein sequencing.

F. Production of Recombinant Proteins using a rDNA Molecule

The present invention further provides methods for producing a protein of the
5 invention using nucleic acid molecules herein described. In general terms, the production of a recombinant form of a protein typically involves the following steps:

First, a nucleic acid molecule is obtained that encodes a protein of the invention, such as the nucleic acid molecule depicted in SEQ ID No. 1, or particularly for the p70 β ^{S6k} nucleotides encoding the proline rich domain or the amino terminus of p70 β ^{S6k}. The
10 coding sequence is directly suitable for expression in any host, as it is not interrupted by introns. The sequence can be transfected into host cells such as eukaryotic cells or prokaryotic cells. Eukaryotic hosts include mammalian cells (*e.g.*, HEK293 cells, CHO cells and PAE-PDGF-R cells) as well as insect cells such as Sf9 cells using recombinant baculovirus. Alternatively, fragments encoding only portion of p70 β ^{S6k} can be expressed
15 alone or in the form of a fusion protein. For example, the C-terminal fragment of p70 β ^{S6k} containing the proline-rich domain, was expressed in bacteria as a GST- or His-tag fusion protein. These fusion proteins were then purified and used to generate polyclonal antibodies.

The nucleic acid molecule is then preferably placed in operable linkage with
20 suitable control sequences, as described above, to form an expression unit containing the protein open reading frame. The expression unit is used to transform a suitable host and the transformed host is cultured under conditions that allow the production of the recombinant protein. Optionally the recombinant protein is isolated from the medium or from the cells; recovery and purification of the protein may not be necessary in some instances where some
25 impurities may be tolerated.

Each of the foregoing steps can be done in a variety of ways. For example, the desired coding sequences may be obtained from genomic fragments and used directly in appropriate hosts. The construction of expression vectors that are operable in a variety of hosts is accomplished using appropriate replicons and control sequences, as set forth above.

The control sequences, expression vectors, and transformation methods are dependent on the type of host cell used to express the gene and were discussed in detail earlier. Suitable restriction sites can, if not normally available, be added to the ends of the coding sequence so as to provide an excisable gene to insert into these vectors. A skilled artisan can readily
5 adapt any host/expression system known in the art for use with the nucleic acid molecules of the invention to produce recombinant protein.

G. In Vitro Methods to Identify Binding Partners

Another embodiment of the present invention provides methods for use in
10 isolating and identifying binding partners of proteins of the invention. In detail, a protein of the invention is mixed with a potential binding partner or an extract or fraction of a cell under conditions that allow the association of potential binding partners with the protein of the invention. After mixing, peptides, polypeptides, proteins or other molecules that have become associated with a protein of the invention
15 are separated from the mixture. The binding partner that bound to the protein of the invention can then be removed and further analyzed. To identify and isolate a binding partner, the entire protein, for instance the entire disclosed protein of SEQ ID No.2 can be used. Alternatively, a fragment of the protein can be used.

As used herein, a cellular extract refers to a preparation or fraction which is
20 made from a lysed or disrupted cell.

A variety of methods can be used to obtain cell extracts. Cells can be disrupted using either physical or chemical disruption methods. Examples of physical disruption methods include, but are not limited to, sonication and mechanical shearing. Examples of chemical lysis methods include, but are not limited to, detergent lysis and enzyme
25 lysis. A skilled artisan can readily adapt methods for preparing cellular extracts in order to obtain extracts for use in the present methods.

Once an extract of a cell is prepared, the extract is mixed with the protein of the invention under conditions in which association of the protein with the binding partner can occur. A variety of conditions can be used, the most preferred being conditions that

closely resemble conditions found in the cytoplasm of a human cell. Features such as osmolarity, pH, temperature, and the concentration of cellular extract used, can be varied to optimize the association of the protein with the binding partner.

After mixing under appropriate conditions, the bound complex is separated from the mixture. A variety of techniques can be utilized to separate the mixture. For example, antibodies specific to a protein of the invention can be used to immunoprecipitate the binding partner complex. Alternatively, standard chemical separation techniques such as chromatography and density/sediment centrifugation can be used.

After removal of non-associated cellular constituents found in the extract, the binding partner can be dissociated from the complex using conventional methods. For example, dissociation can be accomplished by altering the salt concentration or pH of the mixture.

To aid in separating associated binding partner pairs from the mixed extract, the protein of the invention can be immobilized on a solid support. For example, the protein can be attached to a nitrocellulose matrix or acrylic beads. Attachment of the protein to a solid support aids in separating peptide/binding partner pairs from other constituents found in the extract. The identified binding partners can be either a single protein or a complex made up of two or more proteins.

Alternatively, the nucleic acid molecules of the invention can be used in a yeast two-hybrid system. The yeast two-hybrid system has been used to identify other protein partner pairs and can readily be adapted to employ the nucleic acid molecules herein described.

One preferred *in vitro* binding assay for p70 β^{S6k} would comprise a mixture of a polypeptide comprising at least the kinase domain of p70 β^{S6k} and one or more candidate binding targets or substrates. After incubating the mixture under appropriate conditions, one would determine whether p70 β^{S6k} or a polypeptide fragment thereof containing the kinase region either bound with the candidate substrate or phosphorylated the candidate substrate. For cell-free binding assays, one of the

components usually comprises or is coupled to a label. The label may provide for direct detection, such as radioactivity, luminescence, optical or electron density, *etc.*, or indirect detection such as an epitope tag, an enzyme, *etc.* A variety of methods may be employed to detect the label depending on the nature of the label and other assay components. For example, the label may be detected bound to the solid substrate or a portion of the bound complex containing the label may be separated from the solid substrate, and the label thereafter detected.

H. Methods to Identify Agents that Modulate the Expression a Nucleic Acid Encoding the S6 Kinase Protein.

Another embodiment of the present invention provides methods for identifying agents that modulate the expression of a nucleic acid encoding a protein of the invention such as a protein having the amino acid sequence of SEQ ID No.2. Such assays may utilize any available means of monitoring for changes in the expression level of the nucleic acids of the invention. As used herein, an agent is said to modulate the expression of a nucleic acid of the invention, for instance a nucleic acid encoding the protein having the sequence of SEQ ID No.2, if it is capable of up- or down-regulating expression of the nucleic acid in a cell.

In one assay format, cell lines that contain reporter gene fusions between the open reading frame defined by p70 β^{S6k} nucleotides 77-1,564 or 116-1,564 of SEQ ID No.1 and any assayable fusion partner may be prepared. Numerous assayable fusion partners are known and readily available including the firefly luciferase gene and the gene encoding chloramphenicol acetyltransferase (Alam *et al.*, 1990 Anal. Biochem. 188: 245-254). Cell lines containing the reporter gene fusions are then exposed to the agent to be tested under appropriate conditions and time. Differential expression of the reporter gene between samples exposed to the agent and control samples identifies agents which modulate the expression of a nucleic acid encoding the protein having the sequence of SEQ ID No.2.

Additional assay formats may be used to monitor the ability of the agent to

modulate the expression of a nucleic acid encoding a protein of the invention such as the protein having SEQ ID No.2. For instance, mRNA expression may be monitored directly by hybridization to the nucleic acids of the invention. Cell lines are exposed to the agent to be tested under appropriate conditions and time and total RNA or mRNA is
5 isolated by standard procedures such those disclosed in Sambrook *et al.* (MOLECULAR CLONING: A LABORATORY MANUAL, 2nd Ed. Cold Spring Harbor Laboratory Press, 1989).

Probes to detect differences in RNA expression levels between cells exposed to the agent and control cells may be prepared from the nucleic acids of the invention. It
10 is preferable, but not necessary, to design probes which hybridize only with target nucleic acids under conditions of high stringency. Only highly complementary nucleic acid hybrids form under conditions of high stringency. Accordingly, the stringency of the assay conditions determines the amount of complementarity which should exist between two nucleic acid strands in order to form a hybrid. Stringency should be
15 chosen to maximize the difference in stability between the probe:target hybrid and potential probe:non-target hybrids.

Probes may be designed from the nucleic acids of the invention through methods known in the art. For instance, the G+C content of the probe and the probe length can affect probe binding to its target sequence. Methods to optimize probe
20 specificity are commonly available in Sambrook *et al.* (1989) or Ausubel *et al.* (CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, Greene Publishing Co., NY, 1995).

Hybridization conditions are modified using known methods, such as those described by Sambrook *et al.* (1989) and Ausubel *et al.* (1995) as required for each probe. Hybridization of total cellular RNA or RNA enriched for polyA RNA can be
25 accomplished in any available format. For instance, total cellular RNA or RNA enriched for polyA RNA can be affixed to a solid support and the solid support exposed to at least one probe comprising at least one, or part of one of the sequences of the invention under conditions in which the probe will specifically hybridize. Alternatively, nucleic acid fragments comprising at least one, or part of one of the

sequences of the invention can be affixed to a solid support, such as a porous glass wafer. The glass wafer can then be exposed to total cellular RNA or polyA RNA from a sample under conditions in which the affixed sequences will specifically hybridize. Such glass wafers and hybridization methods are widely available, for example, those
5 disclosed by Beattie (WO 95/11755). By examining for the ability of a given probe to specifically hybridize to an RNA sample from an untreated cell population and from a cell population exposed to the agent, agents which up or down regulate the expression of a nucleic acid encoding the protein having the sequence of SEQ ID No.2 are identified.

10

I. Cell-Based Methods to Identify Binding Partners and Agents that Modulate at Least One Activity of the S6 Kinase Protein and Related Antibodies.

Another embodiment of the present invention provides methods for identifying agents that modulate at least one activity of a protein of the invention such as the
15 protein having the amino acid sequence of SEQ ID No.2. Such methods or assays may utilize any means of monitoring or detecting the desired activity.

In one format, the relative amounts of a protein of the invention between a cell population that has been exposed to the agent to be tested compared to an un-exposed control cell population may be assayed. In this format, probes such as specific
20 antibodies are used to monitor the differential expression of the protein in the different cell populations. Cell lines or populations are exposed to the agent to be tested under appropriate conditions and time. Cellular lysates may be prepared from the exposed cell line or population and a control, unexposed cell line or population. The cellular lysates are then analyzed with the probe.

25 For example, N- and C- terminal fragments of p70 β^{S6k} can be expressed in bacteria and used to search for proteins which bind to these fragments. Fusion proteins, such as His-tag or GST fusion to the N- or C-terminal regions of p70 β^{S6k} can be prepared for use as a p70 β^{S6k} fragment substrate. These fusion proteins can be coupled to Talon or Glutathione-Sepharose beads and then probed with cell lysates. Prior to

lysis, the cells may be treated with rapamycin or other drugs which may modulate p70 β^{S6k} or proteins that interact with p70 β^{S6k} . Lysate proteins binding to the fusion proteins can be resolved by SDS-PAGE, isolated and identified by protein sequencing or mass spectroscopy, as is known in the art. It is likely that signaling molecules
5 containing one or more SH3 domains may bind directly to the C-terminal region of p70 β^{S6k} . The N-terminal domain may have a p70 β^{S6k} -specific phosphatase as a binding partner.

Antibody probes are prepared by immunizing suitable mammalian hosts in appropriate immunization protocols using the peptides, polypeptides or proteins of the
10 invention, such as p70 β^{S6k} , variants and isolated binding partners, if they are of sufficient length, or, if desired, or if required to enhance immunogenicity, conjugated to suitable carriers. Methods for preparing immunogenic conjugates with carriers such as bovine serum albumin (BSA), keyhole limpet hemocyanin (KLH), or other carrier proteins are well known in the art. In some circumstances, direct conjugation using, for
15 example, carbodiimide reagents may be effective; in other instances linking reagents such as those supplied by Pierce Chemical Co., Rockford, IL, may be desirable to provide accessibility to the hapten. The hapten peptides can be extended at either the amino or carboxy terminus with a Cys residue or interspersed with cysteine residues, for example, to facilitate linking to a carrier. Administration of the immunogens is
20 conducted generally by injection over a suitable time period and with use of suitable adjuvants, as is generally understood in the art. During the immunization schedule, titers of antibodies are taken to determine adequacy of antibody formation.

Anti-peptide antibodies can be generated using synthetic peptides corresponding to, for example, the carboxy terminal 15 amino acids p70 β^{S6k} . Synthetic peptides can
25 be as small as 1-3 amino acids in length, but are preferably at least 4 or more amino acid residues long. The peptides are coupled to KLH using standard methods and can be immunized into animals such as rabbits. Polyclonal anti-p70 β^{S6k} peptide antibodies can then be purified, for example using Actigel beads containing the covalently bound peptide.

While the polyclonal antisera produced in this way may be satisfactory for some applications, for pharmaceutical compositions, use of monoclonal preparations is preferred. Immortalized cell lines which secrete the desired monoclonal antibodies may be prepared using the standard method of Kohler and Milstein or modifications which effect immortalization of lymphocytes or spleen cells, as is generally known. The immortalized cell lines secreting the desired antibodies are screened by immunoassay in which the antigen is the peptide hapten, polypeptide or protein. When the appropriate immortalized cell culture secreting the desired antibody is identified, the cells can be cultured either *in vitro* or by production in ascites fluid. Of particular interest, are monoclonal antibodies which recognize the proline-rich domain of p70 β^{S6k} .

The desired monoclonal antibodies are then recovered from the culture supernatant or from the ascites supernatant. Fragments of the monoclonals or the polyclonal antisera which contain the immunologically significant portion can be used as antagonists, as well as the intact antibodies. Use of immunologically reactive fragments, such as Fav, $_{sc}$ FV, Fab, Fab', or F(ab')₂ fragments is often preferable, especially in a therapeutic context, as these fragments are generally less immunogenic than the whole immunoglobulin. Antibodies may preferably also be human, humanized or chimeric variants of the foregoing. Such antibodies can be less immunogenic when administered to a subject. Methods of producing humanized or chimeric antibodies are well known in the art. The antibodies contemplated also include different isotypes and isotype subclasses (*e.g.*, IgG₁, IgG₂, IgM, to name a few). These antibodies can be prepared by raising them in vertebrates, in hybridoma cell lines or other cell lines, or by recombinant means. For references on how to prepare these antibodies, see E. Harlow and D. Lane, ANTIBODIES: A LABORATORY MANUAL (Cold Spring Harbor Press, Cold Spring Harbor, NY, 1988); Kohler and Milstein, (1976) E. J. Immunol. 6:511; Queen *et al.* U.S. Patent NO. 5,585,089; and Riechmann *et al.*, Nature 332:323 (1988).

The antibodies or fragments may also be produced, using current technology, by recombinant means. Regions that bind specifically to the desired regions of receptor

can also be produced in the context of chimeras with multiple species origin.

In an alternative format, a specific activity of a protein of the invention may be assayed, such as the ability of the protein to phosphorylate a substrate such as polypeptides of the S6 protein. For example, p70 β^{S6k} has been demonstrated to
5 phosphorylate the S6 protein and a synthetic peptide, RRLSSLRASTSKSESSQK (SEQ ID No. 8). The sequence comprising the synthetic peptide is located in the C-terminus of the S6 protein and is known to contain the five phosphorylation sites targeted by p70 α^{S6k} . Cell lines or populations are exposed under appropriate conditions to the agent to be tested. Agents which modulate the kinase activity of the protein of the invention
10 are identified by assaying the kinase activity of the protein from the exposed cell line or population and a control, unexposed cell line or population, thereby identifying agents which modulate the kinase activity of the protein. Polypeptides of the S6 protein, such as the above examples, are useful positive controls in identifying additional p70 β^{S6k} substrates.

15 Kinase assays to measure the ability of the agent to modulate the kinase activity of a protein of the invention are widely available such as the assays disclosed by Mishima *et al.* (1996) J. Biochem. 119: 906-913) and Michnoff *et al.* (1986) J. Biol. Chem. 261: 8320-8326. Alternative assay formats include actin-myosin motility assays such as those disclosed by Kohama *et al.* (1996) TIPS 17: 284-287 or Warrick *et al.*
20 (1987) Ann. Rev. Cell. Biol. 3: 379-421.

Agents that are assayed in the above method can be randomly selected or rationally selected or designed. As used herein, an agent is said to be randomly selected when the agent is chosen randomly without considering the specific sequences involved in the association of the a protein of the invention alone or with its associated
25 substrates, binding partners, etc. An example of randomly selected agents is the use a chemical library or a peptide combinatorial library, or a growth broth of an organism.

As used herein, an agent is said to be rationally selected or designed when the agent is chosen on a non-random basis which takes into account the sequence of the target site and/or its conformation in connection with the agent's action. As described

in the Examples, there are proposed binding sites for ATP/GTP and calmodulin as well as cAMP/cGMP kinase sites, TyrP sites and Ser/Thr kinase (catalytic) sites in the protein having SEQ ID No.2. Agents can be rationally selected or rationally designed by utilizing the peptide sequences that make up these sites. For example, a rationally
5 selected peptide agent can be a peptide whose amino acid sequence is identical to the ATP or calmodulin binding sites or domains.

The agents of the present invention can be, as examples, peptides, small molecules, vitamin derivatives, as well as carbohydrates. A skilled artisan can readily recognize that there is no limit as to the structural nature of the agents of the present
10 invention.

The peptide agents of the invention can be prepared using standard solid phase (or solution phase) peptide synthesis methods, as is known in the art. In addition, the DNA encoding these peptides may be synthesized using commercially available oligonucleotide synthesis instrumentation and produced recombinantly using standard
15 recombinant production systems. The production using solid phase peptide synthesis is necessitated if non-gene-encoded amino acids are to be included.

Another class of agents of the present invention are antibodies immunoreactive with critical positions of proteins of the invention. Antibody agents are obtained by immunization of suitable mammalian subjects with peptides, containing as antigenic
20 regions, those portions of the protein intended to be targeted by the antibodies.

J. Uses for Agents that Modulate at Least One Activity of the S6 Kinase Protein.

As provided in the Examples, the proteins and nucleic acids of the invention,
25 such as the protein having the amino acid sequence of SEQ ID No.2, are involved in ribosomal function. Agents that modulate or down-regulate the expression of the protein or agents such as agonists or antagonists of at least one activity of the protein may be used to modulate biological and pathologic processes associated with the protein's function and activity.

As used herein, a subject can be any mammal, so long as the mammal is in need of modulation of a pathological or biological process mediated by a protein of the invention. The term "mammal" is meant an individual belonging to the class Mammalia. The invention is particularly useful in the treatment of human subjects.

5 As used herein, a biological or pathological process mediated by a protein of the invention may include binding of substrates such as ATP, GTP or calmodulin or phosphorylation of a substrate, such as the S6 protein.

Pathological processes refer to a category of biological processes which produce a deleterious effect. For example, expression or up-regulation of expression of a
10 protein of the invention may be associated with certain diseases. As used herein, an agent is said to modulate a pathological process when the agent reduces the degree or severity of the process. For instance, a disease may be prevented or disease progression modulated by the administration of agents which reduce or modulate in some way the expression or at least one activity of a protein of the invention.

15 The agents of the present invention can be provided alone, or in combination with other agents that modulate a particular pathological process. As used herein, two agents are said to be administered in combination when the two agents are administered simultaneously or are administered independently in a fashion such that the agents will act at the same time.

20 The agents of the present invention can be administered via parenteral, subcutaneous, intravenous, intramuscular, intraperitoneal, transdermal, or buccal routes. Alternatively, or concurrently, administration may be by the oral route. The dosage administered will be dependent upon the age, health, and weight of the recipient, kind of concurrent treatment, if any, frequency of treatment, and the nature of the effect
25 desired.

The present invention further provides compositions containing one or more agents which modulate expression or at least one activity of a protein of the invention. While individual needs vary, determination of optimal ranges of effective amounts of each component is within the skill of the art. Typical dosages comprise about 0.1 to

100 $\mu\text{g/kg}$ body weight. The preferred dosages comprise about 0.1 to 10 $\mu\text{g/kg}$ body weight. The most preferred dosages comprise about 0.1 to 1 $\mu\text{g/kg}$ body weight. In tissue culture, optimal dosage ranges for drugs such as wortmannin and rapamycin range from about 500 pM to about 1000 nM. Less optimum ranges include about 10
5 pM to about 10 mg.

- In addition to the pharmacologically active agent, the compositions of the present invention may contain suitable pharmaceutically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically for delivery to the site of action.
- 10 Suitable formulations for parenteral administration include aqueous solutions of the active compounds in water-soluble form, for example, water-soluble salts. In addition, suspensions of the active compounds as appropriate oily injection suspensions may be administered. Suitable lipophilic solvents or vehicles include fatty oils, for example, sesame oil, or synthetic fatty acid esters, for example, ethyl oleate or triglycerides.
- 15 Aqueous injection suspensions may contain substances which increase the viscosity of the suspension include, for example, sodium carboxymethyl cellulose, sorbitol, and/or dextran. Optionally, the suspension may also contain stabilizers. Liposomes can also be used to encapsulate the agent for delivery into the cell.

- The pharmaceutical formulation for systemic administration according to the
20 invention may be formulated for enteral, parenteral or topical administration. Indeed, all three types of formulations may be used simultaneously to achieve systemic administration of the active ingredient.

- Suitable formulations for oral administration include hard or soft gelatin capsules, pills, tablets, including coated tablets, elixirs, suspensions, syrups or
25 inhalations and controlled release forms thereof.

In practicing the methods of this invention, the compounds of this invention may be used alone or in combination, or in combination with other therapeutic or diagnostic agents. In certain preferred embodiments, the compounds of this invention may be coadministered along with other compounds typically prescribed for these

conditions according to generally accepted medical practice. The compounds of this invention can be utilized *in vivo*, ordinarily in mammals, such as humans, sheep, horses, cattle, pigs, dogs, cats, rats and mice, or *in vitro*.

Without further description, it is believed that one of ordinary skill in the art can, using the preceding description and the following illustrative examples, make and utilize the compounds of the present invention and practice the claimed methods. The following working examples therefore, specifically point out preferred embodiments of the present invention, and are not to be construed as limiting in any way the remainder of the disclosure.

10

EXAMPLES

EXAMPLE 1

Amino Acid Sequence of p70 β ^{S6k} and comparison with p70 α ^{S6k}

Materials and Methods. Restriction enzymes and DNA modification enzymes were obtained from standard commercial sources and used according to manufacturer's recommendations. Oligonucleotides which were used for sequencing of p70 β ^{S6k} and various PCR fragments were synthesized by Genosys or Japan Bioservice, Inc. The pcDNA1 and pcDNA3 mammalian expression vectors were from Invitrogen. The pGEX-4T vector, glutathione-Sepharose-4B and HiTrapQ columns were purchased from Pharmacia. cDNA of rat p70 α -I was a gift from Dr. Joseph Avruch (Diabetes Unit, Massachusetts General Hospital). Rapamycin and PDGF BB were purchased from Calbiochem. Wortmannin was purchased from Sigma.

Cell cultures and Antibodies. A porcine aortic endothelial cell line (PAE-PDGF-R), stably expressing the human PDGF- β receptor, was maintained in HAM's F12 medium containing 10% fetal calf serum (FCS). CHO cells stably overexpressing human insulin receptors (CHO-IR cells) and HEK293 cells were maintained and cultured as described earlier (Hara *et al.*, 1998 J. Biol. Chem. 273: 14484-14494) in HAM's F12 medium or Dulbecco's modified Eagles minimal essential medium (DMEM) supplemented with 10% FCS, respectively. Anti-FLAG monoclonal M2

antibody was purchased from Eastman Kodak Corp. Anti-phosphopeptide antibodies against proline-directed site Ser434 of p70 α -I were purchased from New England Biolabs. Polyclonal antibodies raised against the C-terminal 104 amino acids fragment of p70 α ^{S6k} were from Dr. Joseph Avruch. A GST fusion protein containing amino acids 443-495 of p70 β ^{S6k} (p70 β C Ab) was used to raise polyclonal antibodies specific for p70 β ^{S6k}. Immunoreactive sera were affinity-purified on an Affigel matrix containing the GST/p70 β ^{S6k}-terminal fusion protein.

Fractionation of cell extracts. HEK293 cells were starved in DMEM medium for 16 h and then treated with 15% FCS for 10 min or 200 nM rapamycin for 30 min. After treatment, cells were lysed in ice-cold buffer A (20mM Tris/HCl pH 7.5, 20 mM NaCl, 1 mM EDTA, 5 mM EGTA, 20 mM β -glycerophosphate, 1 mM-DTT, 1 mM PMSF, 2 mg/ml aprotinin, 10 mg/ml leupeptin) and the lysates centrifuged at 4°C for 20 min at 10,000xg. Supernatants were filtered through a 0.45 μ M filter and then loaded onto a HighTrapQ Sepharose column (1.0 ml column volume) equilibrated in Buffer A. The column was washed extensively in buffer A and bound proteins eluted with a linear gradient of NaCl (20 - 500 mM). Aliquots of eluted proteins were subjected to SDS- PAGE and immunoblotted with anti-phosphopeptide antibodies directed against proline-directed site Ser-434 of p70 α ^{S6k} or anti-peptide antibodies against the carboxyl terminal end of p70 α ^{S6k}.

Construction and screening of a HEK293 Uni-ZAP library and DNA sequencing analysis. Total RNA was isolated from HEK293 cells as described (Hara *et al.*, 1998; Chomczynski *et al.*, 1987 Analytical Biochem. 162: 156-159), and poly(A)+ mRNA was selected by using Dynabeads mRNA purification kit (Dynal). An oligo(dT)-primed library was constructed in UNI-ZAP XR vector from 5 mg of HEK293 mRNA, using the Uni-ZAP cDNA synthesis kit (Stratagene). Packaging into phages was carried out by using Gigapack III Gold Packaging extracts (Stratagene). The cDNA encoding full length p70 β ^{S6k} kinase was isolated by screening 1x10⁶ primary phages from HEK293 Uni-ZAP library with a ³²P-labeled 0.65 Kb *EcoRI/NotI* fragment derived from the EST clone GenBank Accession No. AA410355 (Hillier *et al.*,

published on GenBank, 1997). Positive clones were confirmed, isolated in second-round screening and rescued as Bluescript plasmids by *in vivo* excision (Stratagene). PCR amplification and restriction mapping were used for primary characterization of isolated clones. Sequencing analysis of selected clones was performed on an Applied Biosystem 373A DNA automatic sequencer (PE Applied Biosystems).

Results. The $p70\alpha^{S6k}$ is activated by multiple phosphorylation within the pseudosubstrate and catalytic domains in response to extracellular stimuli, including serum, growth factors and hormones. Phosphospecific antibodies directed against phosphorylated sites of $p70\alpha^{S6k}$ have been recently developed: Phospho- $p70\alpha^{S6k}$ (Ser434) and Phospho- $p70\alpha^{S6k}$ (Thr444/Ser447). Both antibodies were shown to recognize specifically phosphorylated forms of $p70\alpha^{S6k}$, and this recognition was found to be sensitive to rapamycin. To compare the phosphorylation state and chromatographic behavior of $p70\alpha^{S6k}$ from cells stimulated with serum and treated with or without rapamycin, HEK293 cells were starved in DMEM medium for 16 h and then stimulated with 15% serum for 10 min prior treatment with or without 200 nM of rapamycin for 30 min. Cell extracts were fractionated using HighTrapQ Sepharose columns. Proteins were resolved on SDS-PAGE and immunoblotted with anti-phosphopeptide antibodies Ser434 and S444/T447 or antibodies specific for $p70\alpha^{S6k}$. In total lysates of serum stimulated HEK293 cells, this antibody recognizes specifically phosphorylated versions of $p70\alpha^{S6k}$ isoforms (p70 and p85). However, when cell lysates were fractionated and separated on SDS-PAGE, several additional bands appeared on the immunoblot together with the p70 and p85 isoforms of $p70\alpha^{S6k}$, including p190, p110, p90 and p60 (not shown). It is important to note that the recognition of these proteins by phosphospecific S434 antibodies was sensitive to rapamycin, indicating the specificity for the phosphorylated epitope. As expected, the anti-peptide antibodies specific for the $p70\alpha^{S6k}$ recognized 85-kDa and 70-kDa bands, which correspond to $p70\alpha$ -I and $p70\alpha$ -II, respectively. S434 is located in the autoinhibitory region of the $p70\alpha^{S6k}$, which is highly conserved among different species of $p70\alpha^{S6k}$, including *Drosophila* (Stewart *et al.*, 1996 Proc. Natl Acad. Sci. USA 93:

10791-10796; Watson *et al.*, 1996 Proc. Natl Acad. Sci. USA 93: 13694-13698). As phosphorylation of the S434 site is sensitive to rapamycin, it is possible to speculate that p190, p110, p90 and/or p60 may represent novel rapamycin-sensitive p70 α^{S6k} -related kinases.

5 *Molecular cloning of novel p70 α^{S6k} .* Peptide sequences which were used for raising anti-phosphopeptide antibodies S434 of p70 α -I were taken to search the expressed sequence tag (EST) databases. This search generated hundreds of EST clones that showed high degree of homology to the query sequence. Extensive analysis of these clones allowed us to isolate several clones which were highly homologous to
10 the 434 peptide, but did not match to cDNA clones from EMBL or Swissprot databases. Further characterization of these sequences indicated that two nearly identical clones (GenBank Accession Nos. AA284234 and AA410355) exhibited strong homology to the kinase extension domain of the protein kinase A (PKA) family of serine/threonine (S/T) kinases. Additionally, the homology in the kinase extension domain extended
15 into the putative autoinhibitory domain, which is unique for the p70 α^{S6k} (less than 75% identity between p70 α^{S6k} and the unknown potential S6 kinase). However, the homology with p70 α^{S6k} dropped significantly downstream of the kinase extension and autoinhibitory domains, suggesting that these clones encoded a novel kinase of this family. Based on these data, we decided to further characterize these clones. Both EST
20 clones were obtained from the UK HGMP Resource Center. Restriction mapping indicated that the GenBank Accession Nos. AA284234 and AA410355 clones contain short inserts of 0.6 kB and 0.65 kB respectively. Sequence analysis showed that these clones are identical to each other in an overlapping region and may encode a partial open reading frame (ORF), which shows very strong homology to the kinase extension
25 and autoinhibitory domains of the p70 α^{S6k} . These ESTs did not contain a full gene nor was there a protein coding sequence previously identified in these ESTs. Furthermore, four of the five proline-directed Ser/Thr phosphorylation sites located in an autoinhibitory pseudo-substrate domain of p70 α^{S6k} were conserved in the clones of p70 β^{S6k} . Immediately after the autoinhibitory pseudo-substrate domain, the homology

between $p70\alpha^{S6k}$ and $p70\beta^{S6k}$ was very low (12% identity). Taking in account these findings, we proceeded to clone the full length cDNA clone encoding this potentially novel kinase.

Since several rapamycin-sensitive bands were found in the HEK293 cells with the use of anti-Ser434 phosphospecific antibodies, a library from this cell line was created. We screened 10^6 primary clones from the Uni-Zap/HEK293 library with a full length insert from EST clone AA410355 and isolated 12 positive clones. Sequence analysis of rescued plasmids allowed us to identify one clone, which contained an open reading frame of 495 amino acids (Figure 2A). The C-terminus of this clone was found to be identical to the sequence of the EST clone AA410355, which was used for screening.

By analogy to $p70\alpha^{S6k}$, the novel cDNA, encoding $p70\beta^{S6k}$, could potentially encode two isoforms as a result of alternative start codons. If this is the case, the shorter isoform may utilize an ATG codon which is 13 amino acids (aa) downstream of the first methionine and may encode a protein of 482 amino acids. Two potential isoforms were termed $p70\beta$ -I (495 aa long) and $p70\beta$ -II (482 aa long). The presence of additional 13 aa at the N-terminus of $p70\beta$ -I isoform may determine its subcellular localization in the nucleus due to the presence of a putative nuclear localization sequence (RGRRRARG, amino acid numbers 3-9 of SEQ ID No. 2). The overall structure of $p70\beta^{S6k}$ is similar to that of $p70\alpha^{S6k}$. $p70\alpha^{S6k}$ and $p70\beta^{S6k}$ share 70% identity and 85% similarity on protein level. The $p70\beta^{S6k}$ kinase consists of the amino-terminal non-catalytic region, a catalytic domain, a kinase extension and a carboxyl-terminal non-catalytic tail, whose amino acid identity corresponds to domains of $p70\alpha^{S6k}$ is 40%, 83%, 80%, and 47%, respectively (Figure 2B). The strong argument that this clone encodes a novel p70 S6 kinase is the presence of the autoinhibitory pseudosubstrate domain, which is not present in any other known kinases.

$p70\alpha^{S6k}$ undergoes a multi-site phosphorylation in response to stimulation by insulin or mitogens. Such multiple phosphorylation sites are also well conserved in $p70\beta^{S6k}$ (Figure 2B). It also contains 3 sets of phosphorylation sites, similar to $p70\alpha^{S6k}$:

(i) a set of Ser/Thr-Pro motifs clustered in an autoinhibitory pseudosubstrate domain (Ser423, Ser430, Ser436, Ser441 in p70 β^{S6k} correspond to Ser 434, 441, and 447, Ser 452 in p70 α^{S6k} ; (ii) a second set includes Ser383 and Thr401 which is located in the kinase extension domain and corresponds to Ser394 and Thr412 in p70 α^{S6k} ; (iii) a third set consists of Thr251 which resides in the activation T-loop of kinase domain and corresponds to Thr252 in p70 α^{S6k} . The greatest difference between the p70 α^{S6k} and the p70 β^{S6k} sequences are in the amino-terminal non-catalytic region (40% identity and 60% similarity) and the carboxyl-terminal non-catalytic tail (47% identity and 66% similarity). p70 β^{S6k} also contains proline-rich sequences at the C-terminus, that may mediate the interaction with SH3-domain-containing molecules.

EXAMPLE 2

Tissue Specific Expression of p70 β^{S6k}

Materials and Methods. Northern blot analysis was performed using commercial nylon membranes pre-bound with 2 μ g of gel-separated poly(A)+ RNA samples obtained from various human tissues or tumor cell lines from Clontech. The following probes were used for the detection of p70 α^{S6k} and p70 β^{S6k} messages: (i) a 476-base pair (bp) *HindIII* fragment spanning 56 bp of 3' end coding region and 420 bp of 3' non-coding region of the human p70 α^{S6k} (EST clone, AA425599), (ii) a 650-bp fragment spanning 518 bp upstream of the stop codon and about 130 bp of non-coding region of the human p70 β^{S6k} (EST clone, AA410355). Human β -actin cDNA probe was used as a negative control (Clontech). These probes were labeled by Multiprime DNA labeling system (Amersham) and separated from unincorporated [γ^{32} P]dCTP by Nucletrap push columns (Stratagene). Northern blots were pre-hybridized with ExpressHyb solution and hybridized with labeled probes according to manufacturer's recommendations. After extensive washing with 2X SSC, 0.05% sodium dodecyl sulfate (SDS) at room temperature, and twice with 0.1X SSC, 0.1% SDS at 50°C, the localization of bound probes on membranes was identified by autoradiography or with the use of the PhosphorImager.

Results. In order to compare expression patterns of p70 α^{S6k} and p70 β^{S6k} in human tissues and cell lines, 3' prime coding and non-coding regions, which exhibit low level of homology between both the α and β S6 kinases, were used as probes. Northern blot analysis using poly(A)+ RNA isolated from human tissues revealed a single 2.2 kb transcript for p70 β^{S6k} , while p70 α^{S6k} probe specifically hybridized to 3.4 kb and 7.4 kb transcripts (Figure 3A). The expression pattern of p70 α^{S6k} and p70 β^{S6k} transcripts is remarkably similar, showing ubiquitous expression in all tissues. Highest expression levels were found in spleen, skeletal muscle and peripheral blood leukocytes, whereas brain, lung and kidney showed the lowest expression of transcripts for both S6 kinases. The only significant difference on the level of mRNA expression between p70 α^{S6k} and p70 β^{S6k} was found in liver. The expression of p70 β^{S6k} mRNA in liver is 2-3 times higher than that of p70 α^{S6k} . Liver possesses a high concentration of p70 α^{S6k} and was originally used by several groups to purify p70 α^{S6k} for biochemical studies and protein sequencing analysis (Banerjee *et al.*, 1990 Proc. Natl Acad. Sci. USA 87: 8550-8554; Kozma *et al.*, 1990 Proc. Natl Acad. Sci. USA 87: 7365-7369).

We also analyzed the expression of p70 β^{S6k} mRNA in tumor cell lines using the same probe as for the analysis of tissue distribution. A single transcript of the same size as in human tissues, 2.2 kb, was found to be highly expressed in HeLa and K562 cells, but was barely detectable in HL-60, MOLT-4 and melanoma G361 cell lines (Figure 3B).

EXAMPLE 3

Phosphorylation of the ribosomal protein S6 and its C-terminal synthetic peptide by p70 α^{S6k} and p70 β^{S6k}

Materials and Methods. Expression of GST/p70 β^{S6k} fusion protein in bacteria. A PCR-based strategy was used to make a bacterial expression plasmid for GST/p70 β^{S6k} fusion protein. A cDNA fragment encoding 443-495 amino acids of p70 β^{S6k} was amplified by PCR and cloned into the pGEX-4T expression vector (Pharmacia). This construct was transformed into *E. coli* XL1-Blue competent cells

(Stratagene) and the expression of the GST/p70 β^{S6k} fusion protein was induced by isopropyl β -D-thiogalactopyranoside (IPTG). The GST/p70 β^{S6k} fusion protein was purified by using glutathione-Sepharose-4B beads according to manufacturer's recommendation (Pharmacia). After SDS-PAGE analysis, affinity purified fusion
5 proteins were dialyzed against 20 mM (Tris pH 7.4), 150 mM NaCl, 50% Glycerol and stored at -20°C. This preparation of the GST/p70 β^{S6k} C-terminal fragment was used for the production of polyclonal antibodies specific for p70 β^{S6k} .

Construction of mammalian expression plasmids. The full length coding sequence, corresponding to the p70 β -I (I-495 amino acids) was amplified by PCR using
10 human cDNA clone N53 isolated from HEK293 library as a template and a panel of specific oligonucleotides. Amplified constructs were digested with appropriate enzymes, gel purified and cloned into the pcDNA1 vector in-frame with N-terminal FLAG epitope.

Amino-terminal EE-tagged p70 α -II and p70 β -II constructs were created by a
15 PCR-based cloning strategy. This was achieved by using specific oligonucleotides containing EE-tag sequence and appropriate restriction sites. The cDNA encoding full length human p70 β^{S6k} (clone 53) and rat p70 α^{S6k} were used as templates. The resulting PCR fragments were digested with restriction enzymes, gel purified and cloned into the pcDNA3 expression vector. The construction of the pMT2 FLAG p70 α -I was
20 described previously (Hara *et al.*, 1998). All constructs generated by a PCR-based approach were verified by sequencing. A Qiagen plasmid Midi kit was used to purify plasmid DNAs for transient transfections. The introduction of the FLAG-tag and the EE-tag sequences at the N-terminus of p70 α^{S6k} and p70 β^{S6k} allows the study of recombinant proteins via the use of specific antibodies.

25 **Results.** To test if the isolated p70 β^{S6k} cDNA would encode a functional kinase capable of phosphorylating ribosomal protein S6, a cDNA fragment encoding a short version of p70 β^{S6k} (p70 β -II) was subcloned into mammalian expression vector in frame with EE-tag or Flag-tag epitopes. These constructs were transfected into HEK293 cells using lipofectAMINE under conditions recommended by the manufacturer. The

expression of recombinant p70 β ^{S6k} was analyzed by immunoprecipitation or western blotting with EE-tag or Flag-tag antibodies. Both constructs express the protein of approximately 60kDa. The expression level of p70 β ^{S6k} was comparable to that of p70 α -I and p70 α -II isoforms, when expressed in HEK293 cells.

5 Anti-p70 β ^{S6k} polyclonal antibodies were generated using synthetic peptides corresponding to the carboxy terminal 15 amino acids of p70 β ^{S6k}. These peptides were coupled to KLH and then injected into rabbits using standard procedures. Immune sera was purified using Affigel beads containing covalently cross-linked carboxy terminal peptide.

10 To determine whether the putative p70 β ^{S6k} was indeed a novel ribosomal protein S6 kinase, the recombinant p70 β ^{S6k} was expressed in HEK293 cells, immunoprecipitated with anti-EE-tag antibodies and an *in vitro* kinase reaction performed in the presence of purified 40S ribosomal subunit. As shown in Figure 4A, p70 β ^{S6k} (p70 β -II isoform) phosphorylates the S6 protein *in vitro* nearly as efficiently as
15 p70 α ^{S6k}. We also tested the ability of p70 β ^{S6k} (p70 β -II isoform) to phosphorylate a synthetic peptide representing C-terminus of S6 protein, which contains all sites known to be phosphorylated by p70 α ^{S6k}. Figure 4B demonstrates that p70 β ^{S6k} (p70 β -II isoform) also phosphorylates this peptide but with slightly lower efficiency than observed with p70 α ^{S6k}. Therefore, p70 β ^{S6k} (p70 β -II isoform) may not phosphorylate
20 the same sites of the ribosomal protein S6 as does p70 α ^{S6k}.

The intrinsic activity of the p70 β ^{S6k} is significantly lower than p70 α ^{S6k}. The absence of one phosphorylation site in the autoinhibitory domain of p70 β ^{S6k} may be responsible for this decrease in intrinsic activity.

25

EXAMPLE 4

Stimulation of p70 β ^{S6k} Activity by insulin, serum and TPA

Materials and Methods. HEK293 cells or CHO-IR cells were transfected with plasmids containing p70 α ^{S6k} and p70 β ^{S6k} sequences using lipofectAMINE under conditions recommended by the manufacturer (Gibco-BRL). Two days later,

transfected cells were frozen in liquid nitrogen and stored until lysis. After cell extraction, the lysates were subjected to immunoprecipitation and/or immunoblot analysis. If cells were to be stimulated, they were starved in medium without FCS for 16 h and then stimulated with 10^{-7} M insulin for 10 min, 15% FCS for 10 min, 500 nM TPA for 30 min or vehicle alone. PAE-PDGF-R cells were transfected with appropriate plasmids using lipofectAMINE under conditions recommended by the manufacturer. After 24 h transfected cells were serum-starved for 16 h and stimulated with 20 ng/ml PDGF BB (Calbiochem) for 20 min. Control cells were treated with the vehicle under the same conditions.

Results. The effect of various extracellular stimuli on the $p70\beta^{S6k}$ activity was studied in different cell lines, transiently transfected with Flag-tagged or EE-tagged versions of $p70\beta^{S6k}$. The activation of $p70\beta^{S6k}$ ($p70\beta$ -II isoform) by insulin was analyzed in CHO-IR cells, which stably over expresses the insulin receptor. As shown in Figure 5A, treatment of CHO-IR cells with insulin induces $p70\beta^{S6k}$ ($p70\beta$ -II isoform) activity towards ribosomal S6 protein by 2.8 fold. In the same cell line and under the same conditions, the activity of $p70\alpha^{S6k}$ was activated 3.5 fold with insulin treatment (Figure 5A). Almost equal amounts of $p70\alpha^{S6k}$ and $p70\beta^{S6k}$ ($p70\beta$ -II isoform) were expressed in cells and used in an *in vitro* kinase assay after immunoprecipitation. In addition, both serum and TPA also stimulated $p70\beta^{S6k}$ ($p70\beta$ -II isoform) phosphorylation of the ribosomal protein S6 (Figure 5A).

Using PAE-PDGF-R cells, the activation of the $p70\alpha^{S6k}$ and $p70\beta^{S6k}$ ($p70\beta$ -II isoform) by PDGF was examined. This cell line stably over expresses the PDGF receptor, and the activation of $p70\alpha^{S6k}$ in response to PDGF was shown to be very efficient (Figure 5B). We found that PDGF stimulation of these cells leads to a rapid activation of recombinant $p70\beta^{S6k}$ ($p70\beta$ -II isoform).

These data indicate that $p70\beta^{S6k}$ is activated by a number of extracellular stimuli in a very similar way as $p70\alpha^{S6k}$. However, activation in the PAE-PDGF-R cells was 30 fold for $p70\beta^{S6k}$ and only 3.4 fold for $p70\alpha^{S6k}$.

EXAMPLE 5

Effects of rapamycin and wortmannin on p70 β ^{S6k} and p70 α ^{S6k}

Materials and Methods. Treatment of transfected cells with rapamycin or wortmannin was performed as follows: 48 h after transfection, the cells were treated with various concentrations of rapamycin or wortmannin for 30 min.

Results. These data in Examples 4 and 5 indicate that p70 β ^{S6k} is activated by a number of extracellular stimuli in a similar fashion to p70 α ^{S6k}. The two fungal inhibitors, wortmannin and rapamycin, specifically inhibit activation of p70 α ^{S6k} via PI3-kinase- and mTOR-dependent pathways respectively. Thus, the effects of both inhibitors on p70 β ^{S6k} activity were examined. After p70 α -I and p70 β -II were transiently expressed in HEK293 cells, cells were maintained in DMEM containing 10% FCS and then treated with various concentrations of rapamycin or wortmannin. We found that the activity of p70 α ^{S6k} and p70 β ^{S6k} were inhibited by rapamycin and wortmannin in a dose dependent manner (Figures 6A and B, upper panel). However, it appears that p70 β ^{S6k} is less sensitive to rapamycin and wortmannin, when compared with p70 α ^{S6k}. This difference is more obvious at lower concentration of inhibitors. In the presence of 20 nM rapamycin the inhibition of the p70 α ^{S6k} is 92%, while only 46% for p70 β ^{S6k}. Addition of 100 nM of wortmannin inhibits 86% of p70 α ^{S6k} activity and 62% of p70 β ^{S6k} activity. The inhibition of p70 β ^{S6k} by rapamycin and wortmannin is lower than that observed for p70 α ^{S6k} indicating different mechanisms of regulation exist for p70 β ^{S6k}.

EXAMPLE 6

Interaction of the p70 β ^{S6k} with different GST/SH3 fusion proteins

Materials and Methods. The EE-tag/p70 β ^{S6k} was transiently over expressed in HEK293 cells as described above. Transfected cells were lysed in buffer A (50 mM-Tris/HCl pH = 8.0, 1% NP-40, 120 mM NaCl, 20 mM NaF, 1 mM EDTA, 6 mM EGTA, 20 mM sodium β -glycerophosphate, 1 mM DTT, 1 mM PMSF, 10 μ g/ml leupeptin, 10 μ g/ml pepstatin and 2 μ g/ml aprotinin) two days after transfection. After

centrifugation at 12,000 rpm for 20 min, the supernatants were incubated for 2 hrs with Protein A beads pre-coupled with anti-EE antibodies. Beads were washed with lysis buffer before different GST/SH3 fusion proteins (1.5 mg each) were added to separate immunoprecipitation reactions. Two hours later, beads were washed extensively in lysis buffer, bound proteins separated on the SDS-PAGE and transferred to the PVDF membrane. Specific interaction of the GST/SH3 domains with pre-bound EE-tag/p70 β ^{S6k} was assessed by immunoblotting with the anti-GST antibodies.

Results. The C-terminus of the p70 β ^{S6k} contains proline-rich sequences which are not present in p70 α ^{S6k}. Src-homology region 3 domains (SH3 domain) are present in many signaling and cytoskeletal molecules and interact specifically with proline-rich sequences which form left-handed helices. Sequence analysis of the proline-rich region in p70 β ^{S6k} indicates the presence of several putative SH3 domain binding motifs. Therefore, the ability of p70 β ^{S6k} (p70 β -II isoform) to interact with a panel of SH3 domains was examined. In this experiment, the EE-tag/p70 β ^{S6k} was transiently over expressed in HEK293 cells and immunoprecipitated with anti-EE antibodies coupled to Protein G Sepharose. The resulting immunoprecipitates were incubated with different GST/SH3 domain fusion proteins. After extensive washing, specific interaction between p70 β ^{S6k} and SH3 domains was analyzed by SDS-PAGE and immunoblotting with anti-GST antibodies. As shown in Figure 7, several SH3 domains, including those of GAP, Src, Fgr exhibited specific interaction towards p70 β ^{S6k}.

EXAMPLE 7

Immunoprecipitation and Western blot analysis of transiently expressed p70 β -I and p70 β -II

Materials and Methods. Anti-p70 β ^{S6k} polyclonal antibodies were generated using a synthetic peptide corresponding to the C-terminal tail of p70 β ^{S6k}. The peptide was coupled to KLH, and rabbits were immunized using standard procedures. Immune sera harvested obtained from the immunized rabbits was purified using affinity chromatography on Affigel beads containing covalently cross-linked C-terminal

peptides of p70 β^{S6k} .

HEK293 cells were transfected with pcDNA1 along, pcDNA1/Flag-p70 α -I, pcDNA1/Flag-p70 β -I, or pcDNA1/Flag-p70 β -II. Two days after transfection with one of these plasmids, cell lysates were prepared. Proteins were immunoprecipitated using
5 the p70 β^{S6k} C-terminal affinity purified polyclonal antibodies or anti-Flag monoclonal antibodies. Immunoprecipitates were resolved on SDS PAGE and proteins transferred to PVDF membranes. The PVDF membranes were immunoblotted using anti-Flag monoclonal antibodies or p70 β^{S6k} C-terminal antibodies as indicated in Figure 8.

Results. The expression of both p70 β^{S6k} isoforms was analyzed in HEK293
10 cells using anti-p70 β^{S6k} C-terminus specific polyclonal antibodies. Both p70 β^{S6k} isoforms were found to be specifically immunoprecipitated with anti-p70 β^{S6k} antibodies, but not p70 α -I, as confirmed by anti-Flag and anti-p70 β^{S6k} immunoblotting. It was found that the p70 β -I isoform which encodes a 495 amino acid protein, is translated into a protein which migrates in a SDS-PAGE gel at approximately 70 kD.
15 The p70 β -II isoform, which is a truncated form of p70 β -I lacking 13 amino acids at the amino terminus of p70 β -II, migrates in a SDS-PAGE gel at approximately 60 kD.

EXAMPLE 8

Generation of activated variants of p70 β^{S6k} (T401D) and p70 α^{S6k} (T412D).

20 **Materials and Method.** Activated variants of p70 β^{S6k} and p70 α^{S6k} were made by site-directed mutagenesis. Oligonucleotide primers, specific to the site to be mutated and complimentary to opposite strands of p70 β^{S6k} and p70 α^{S6k} sequences were generated as recommended by manufacturer (Stratagene). Site-directed mutagenesis was carried out using pcDNA3/ Glu-tag-p70 β^{S6k} and pcDNA3/Glu-tag- p70 α^{S6k}
25 expression vector/plasmids as templates, according to the recommended protocol (Stratagene). All mutations were verified by DNA sequencing. Expression of mutated forms of both kinases was analyzed by immunoblotting with anti-Glu-tag antibodies. The activity of normal and mutated forms of both kinases was measured by in vitro S6 kinase assay. 40S ribosomal subunit was used as a substrate in this reaction.

Results. Studies on $p70\alpha^{S6k}$ demonstrate that this kinase is activated by multiple phosphorylations in response to growth factors or hormones (Fig. 9). A number of kinases that can phosphorylate $p70\alpha^{S6k}$ *in vitro* and *in vivo* have been identified, including cdc2, MAPK, SAPK, p38, TOR and PDK1. However, very little is known about the process of dephosphorylation, which is essential for the inactivation of the kinase.

We have generated an activated form of $p70\beta^{S6k}$ by substituting putative phosphorylation site Thr 401 with Aspartic acid (Asp) (" $p70\beta^{S6k}$ (T402D)") as shown in Fig 10. Transfection studies in HEK293 cells and S6 kinase assays indicated that $p70\beta^{S6k}$ (T401D) mutant is in an activated state in unstimulated cells, when compared with wild type kinase (3 times higher activity, as shown in Fig 11). We have also created an activated version of $p70\alpha^{S6k}$ (T412D), which showed a greater state of activation (18 fold activation, Fig. 12).

It will be apparent to the skilled artisan that activated variants of both kinases such as disclosed above can be used in the search for binding partners. Binding partners or molecules, such as phosphatases, are considered to form tighter and more stable complexes with such irreversibly activated kinases.

EXAMPLE 9

Identification of $p70\beta^{S6k}$ -binding partners.

Materials and Methods. HEK293 cells are transfected using lipofectAMINE (as recommended by manufacturer, Gibco-BRL) with pcDNA3 expression vectors encoding activated variants of $p70\beta^{S6k}$ (T401D) and $p70\alpha^{S6k}$ (T412D). Binding partners that preferentially associate with $p70\beta^{S6k}$ may be identified by comparing the profile of proteins precipitated from activated $p70\beta^{S6k}$ expressing cells to the profile of activated $p70\alpha^{S6k}$ expressing cells and/or negative control cells. Cells transfected with the pcDNA3 plasmid alone, may be used as a negative control in this experiment. Two days after transfection, cells are lysed in extraction buffer: 50 mM Tris/HCl (pH8.0); 120 mM NaCl; 20 mM NaF; 20 mM b-glycerophosphate; 1 mM EDTA, (pH 8.0); 6

mM EGTA; 1% NP-40; 1 mM DTT. The following protease and phosphatase inhibitors are added to the extraction buffer just before cell lysis: 5 mM Benzamidine; 1 mM PMSF; 1mg/ml of aprotinin; 0.125 mM NaVO₄; Pepstatin; and Leupeptin.

The resulting cell lysate is centrifuged at 14,000 rpm for 20 min at 4°C to
5 remove the insoluble fraction. If the lysate is not used immediately it is stored at -80°C until needed. The protein concentration of the samples is measured using a Coomassie Protein Assay reagent (Pierce) at 595 nm. An equal amount of supernatant from each sample is added to fresh 1.5 ml tubes and the volumes is equalized using lysis buffer. Affinity purified anti-Glu antibody is added to the supernatant and incubated on the
10 wheel for 1 hr at 4°C. Protein-G sepharose beads, pre-washed in lysis buffer, are used to bring down immune complexes.

After extensive washing in lysis buffer (4x), 2x sample buffer is added to the beads. Bound proteins are eluted from the beads by boiling and separated by SDS-PAGE electrophoresis. Separated proteins are silver stained and the pattern of
15 associated proteins is analyzed.

Results. The pattern of associated proteins are compared between activated variants of p70β^{S6k} and p70α^{S6k} kinases. Mutated variants of both kinases are transiently expressed in HEK293 cells as Glu-tag fusion proteins. The presence of a Glu-tag epitope at the N-terminus of p70β^{S6k} and p70α^{S6k} allows specific
20 immunoprecipitation of activated kinases from transfected cells. The skilled practitioner will recognize that the Glu-tag fusion is not necessary to the invention and that similar results could be obtained with antibodies specific to each or both of the activated variants in the absence of a fusion epitope.

The skilled practitioner will recognize that binding partners or polypeptides that
25 preferentially bind to activated P70β^{S6K} can be isolated by one or more standard techniques such as immunoprecipitation, hplc, fplc, column chromatography or preparative electrophoresis.

Although the present invention has been described in detail with reference to examples above, it is understood that various modifications can be made without

departing from the spirit of the invention. Accordingly, the invention is limited only by the following claims. All cited patents and publications referred to in this application are herein incorporated by reference in their entirety.

WHAT IS CLAIMED:

1. An isolated nucleic acid molecule selected from the group consisting of a nucleic acid molecule comprising the sequence of SEQ ID No.1 (the nucleotide sequence of the p70 β^{S6k}); and a nucleic acid molecule which encodes a p70 β^{S6k} and which hybridizes to a nucleic acid molecule having the sequence of SEQ ID No.1 under stringent conditions.

2. An isolated nucleic acid molecule which encodes a protein having SEQ ID No.2 (the p70 β^{S6k}) or a protein having one or more conservative amino acid substitutions in SEQ ID No.2.

3. An isolated nucleic acid molecule selected from the group consisting of a nucleic acid molecule comprising the sequence of SEQ ID No.1 (the nucleotide sequence of the p70 β^{S6k}); a nucleic acid molecule which encodes a p70 β^{S6k} and which hybridizes to a nucleic acid molecule having the sequence of SEQ ID No.1 under stringent conditions, and a nucleic acid molecule at least about 65% sequence identity with SEQ ID No.1.

4. An isolated nucleic acid molecule which encodes a protein having SEQ ID No.2 (the p70 β^{S6k}), a protein with at least 75% identity to SEQ ID No.2, or a polypeptide fragment of SEQ ID No.2.

5. An isolated polypeptide which phosphorylates a ribosomal S6 protein and is encoded by a nucleic acid molecule of claim 1 or claim 2.

6. A method of identifying an agent which modulates p70 β^{S6k} mediated phosphorylation of a ribosomal S6 subunit comprising the steps of:

exposing p70 β^{S6k} and a ribosomal S6 subunit to the agent; and

determining whether the agent modulates $p70\beta^{S6k}$ mediated phosphorylation of the ribosomal S6 subunit.

7. A method of modulating protein synthesis or cellular proliferation comprising the step of administering an agent which modulates $p70\beta^{S6k}$ phosphorylation of a ribosomal S6 subunit.

8. A method of identifying an agent that modulates a kinase or a phosphatase induced regulation of $p70\beta^{S6k}$ activity comprising the steps of:
exposing $p70\beta^{S6k}$ and the kinase which phosphorylates $p70\beta^{S6k}$ to an agent; and
determining whether the agent modulates the kinase or the phosphatase induced regulation of $p70\beta^{S6k}$ activity.

9. The method of claim 8, wherein the kinase which phosphorylates $p70\beta^{S6k}$ is PKC.

10. A method of modulating protein synthesis or cellular proliferation comprising the step of administering an agent which modulates the phosphorylation of $p70\beta^{S6k}$.

11. A method of modulating cell cycle comprising the step of administering an agent which regulates the ability $p70\beta^{S6k}$ to bind with a ligand.

12. An antibody or antibody fragment which specifically binds to an epitope of $p70\beta^{S6k}$.

13. The antibody of claim 11, wherein the antibody is selected from the group consisting of a monoclonal antibody, human antibody, chimeric antibody, and humanized antibody.

14. An antibody of claim 11 wherein the epitope is a proline rich epitope of a p70 β^{S6k} protein.
15. A fusion protein comprising SEQ ID No.2 or a polypeptide fragment thereof fused to a heterologous protein.
16. A cell transformed with a nucleic acid molecule of any of claims 1-3.
17. A method of identifying a substrate of p70 β^{S6k} comprising the steps of: exposing p70 β^{S6k} or a polypeptide fragment thereof to an agent; and determining whether p70 β^{S6k} binds to the agent.
18. A method of identifying a substrate of p70 β^{S6k} comprising the steps of: forming a mixture comprising p70 β^{S6k} and a candidate agent; incubating said mixture under conditions conducive to phosphorylation by p70 β^{S6k} ; and determining whether the candidate agent is phosphorylated.
19. A method of indentifying binding partners of p70 β^{S6K} comprising the step of incubating a first cellular extract with p70 β^{S6K} , activated variants of p70 β^{S6K} or a fusion protein of claim 15.
20. The method of claim 19 further comprising incubating a second cellular extract with p70 α^{S6K} , activated variants of p70 α^{S6K} or a fusion protein of p70 α^{S6K} and comparing the first and second cellular extracts.
21. A method of indentifying binding partners of p70 β^{S6K} comprising the step of isolating a first a first cellular extract from a cell containing p70 β^{S6K} , activated variants of p70 β^{S6K} or a fusion protein of claim 15.

22. The method of claim 19 further comprising isolating a second cellular extract from a cell containing p70 α^{S6K} , activated variants of p70 α^{S6K} or a fusion protein of p70 α^{S6K} and comparing the first and second cellular extracts.
23. An isolated polypeptide comprising an activated p70 β^{S6k} .
24. The isolated polypeptide of claim 23 further comprising a mutation of Threonine 401 to Aspartic acid.
25. An isolated polypeptide that preferentially binds to an activated p70 β^{S6K} of claim 23.
26. The isolated polypeptide of claim 25 that preferentially binds to an activated p70 β^{S6k} of claim 24.
27. An antibody or antibody fragment that specifically binds to the isolated polypeptide of claims 25 or 26.
28. A method of determining whether a cell expresses aberrant cellular levels of p70 β^{S6k} comprising:
 - (a) determining the level of p70 β^{S6k} in a normal cell type;
 - (b) determining the level of p70 β^{S6k} in a test cell;
 - (c) comparing the level of p70 β^{S6k} in the normal cell to the p70 β^{S6k} level in the test cell.
29. The method of claim 28 wherein the level of p70 β^{S6k} is determined by finding the level p70 β^{S6k} RNA in a cell.

30. The method of claim 28, wherein the level of $p70\beta^{S6k}$ is determined by finding the level of $p70\beta^{S6k}$ protein in a cell.
31. A method of determining whether a cell expresses aberrant cellular levels of a $p70\beta^{S6k}$ binding partner comprising:
 - (a) determining the level of said binding partner in a normal cell;
 - (b) determining the level of said binding partner in a test cell;
 - (c) comparing the level of said binding partner in the normal cell to the binding partner level in the test cell.
32. A vector comprising the isolated nucleic acid of claim 2, operably linked to a promotor or transcription.
33. The vector of claim 32, further comprising one or more enhancers or upstream activating sequences.
34. The vector of claim 32, wherein the vector comprises pcDNA3.
35. A vector which encodes an activated $p70\beta^{S6k}$ of claims 23 or 24.
36. A DNA vector comprising a nucleic acid encoding a $p70\beta^{S6k}$ or an activated $p70\beta^{S6k}$ fusion protein.

α 576 tagaaagagagggaataattatttgggaagacactgctgctgttttactttggca 627
 β 594 TGGAGCGAGAGGGCATCTTCTTGGGAAGATACGGCCCTGCTTCTACCTGGCT 643
 α 629 gaaatctccatggtgcttggggcatttacatcaaaaggggatcatctacag 677
 β 644 GAGATCACGCTGGCCCTGGGCCATCTCCACTCCAGGGCATCATCTACCG 693
 α 678 agacctgaagccggagaatatcatgcttaatcaccgaagtcagtgtgaac 727
 β 694 GGACCTCAAGCCCGAGAACATCATGCTCAGCAGCCAGGGCCACATCAAAC 743
 α 728 taacagacttttgactctatgcaagaatctattcatgatggaacagtcaca 777
 β 744 TGACCGACTTTGGACTCTGCAAGGAGTCTATCCATGAGGGCGCCGTCCT 793
 α 778 cacacatttttggaacaatagaatacatggccctgaaatcttgatgag 827
 β 794 CACACCTCTGCGGCACCACTGAGTACATGGCCCTGAGATTCTGGTGCG 843
 α 828 aagtggccacaatcgtgctgtggattgggtggagtttggggagcattaatgt 877
 β 844 CAGTGGCCACAACCGGGCTGTGACTGGTGGAGCCTGGGGGCCCTGATGT 893
 α 878 atgacatgctgactggagcacccttactggggagaatagaaagaaa 927
 β 894 ACGCATGCTCACTGGATCGCGCCCTTACCGCAGAGAACCGGAAGAAA 943
 α 928 acaattgacaaaatcctcaaatgtaaaactcaatttgccctccctacctcac 977
 β 944 ACCATGGATAAGATCATCAGGGGCAAGCTGGCACTGCCCCCTACCTCAC 993
 α 978 acaagaagccagagatctgcttaaaaagctgctgaaaagaaatgctgctt 1027
 β 994 CCCAGATGCCCGGGACCTTGTCAAAAAGTTTCTGAAACGGAATCCCAGCC 1043
 α 1028 ctgctctgggagctgggtcctggggacgctggagaagtccaagctcatcca 1077
 β 1044 AGCGGATTGGGGGTGGCCCGAGGGGATGCTGCTGATGTGCAGAGACATCCC 1093
 α 1078 ttttttagacacattaaatgggaagaactctggtctgaaaaggtggagcc 1127
 β 1094 TTTTTCGGCAGATGAATGGGACGACCTCTCTGGCCTGGCGTGTGGACCC 1143
 α 1128 cccctttaaaacctctgttgcaatctgaagaggatgtaagtcagtttgatt 1177
 β 1144 CCCCCCAGGCCCTGTCTGCAGTCAGAGGAGGACGTGAGCCAGTTTGATA 1193
 α 1173 ccaagttttacacgtcagacacctgtcgacagccagatgactcaactctc 1227
 β 1194 CCGGCTTCACACGGCAGACGCCGGTGGACASTCCTGATGACACAGCCCTC 1243
 α 1228 agtgaagtgccaatcagggtctttctgggttttacatatgtgggtccatc 1277
 β 1244 AGCGAGAGTGCCAACAGGCCCTTCTGGGCTTCACATACGTGGCGCCCTC 1293
 α 1278 tgtacttgaaagtgtgaaagaaaagttttcccttgaaacaaaaatccgat 1327
 β 1294 TGTCTTGGACAGCATCAAGGAGGCTTCTCTCTTCCAGCCCAAGCTGCGCT 1343
 α 1328 caccctgaagatttattggcagccacgaacacctgtcagccagtcaaa 1377
 β 1344 CACCCAGGCGCTCAACAGTAGCCCCGGGTCCCCGTACGCCCCCTCAAG 1393
 α 1378 ttttctctt...ggggatttctggggaagaggtgcttcggccagcacag 1423
 β 1394 TTTCTCCCCCTTTGAGGGGTTTCGGCCCCAGCCCCAGCCTGCCGGAGCCAC 1443

FIGURE 1 (cont'd)

3 / 19

α 1424 caaatcctcagacacctgtggaatacccaatggaaacaagtggcatagag 1473
 β 1444 GGAGCTACCTCTACCTCCACTCCTGCCACCGCCGCCGCCCTCGACCACCG 1493
 α 1474 cagaaggatgtgacaatgagtgagggaagcatcggcaccacttccaatacg 1523
 β 1494 CCCCTCTCCCCATCCGTCCCCCTCAGGGA...CCAAGAAGTCCAAGAGG 1540
 α 1524 acagccgaactcttgggccaatacaaaaaacaagcttttcccatgatctcca 1573
 β 1541 GGCCGTGGGCGTCCAGGGCGCTTAAAGCCGGGTGGGGGTGAGGGTAGCC 1590
 α 1574 aacggccagagcacctgcgtatgaaatctatcagagcaatgcttttaac 1623
 β 1591 CTGAGCCCTGTCCCTGCGGCTGTGAGAGCAGCAGGACCCTGGGCCAGTT 1640
 α 1624 gaatttaaggcaaaaagggtggagagggagatgtgtgagcatcctgcaagg 1673
 β 1641 CCAGAGACCTGGGGGTGTGTCTGGGGGTGGGGGTGTGAGTGCCTATGAAAG 1690
 α 1674 tgaaacaagactcaaaatgacagtttcagagagtcaatgtcattacatag 1723
 β 1691 TGTGTGTCTGCTGGGGCAGCTGTGCCCCCTGAATCATGGGCACGGAGGGC 1739
 α 1724 aacacttcggacac...aggaaaaataaacgtggatttttaaaaaatcaatc 1771
 β 1740 CGCCCCCACCACCCCGCGCTCAACTGCTCCCGTGAAGATTAAAGGGCTG 1789
 α 1772 aatggtgcataaaaaaaacttaaaagcaaaatagtattgctgaactcttagg 1821
 β 1790 AATCATGAAAAAAAAAAAAAAAAAAAAA..... 1816

→ p70d - extends

FIGURE 1 (cont'd)

P70a	:	MRRRRRRRDGFYPAPDFRDREAED	MAGVFD	IDLD	33																														
p70b	:	- - - - -	MARGRRARGAGAA	MAAVFDLDLE	23																														
P70a	34	QPE	DAGS	EDEL	EGGQLNESMDHGGVGPYE	LGM	56																												
p70b	24	TEE	EGSEG	EGEP	ELSPADACPLAELRAAGLE	-PV	55																												
P70a	67	EHC	EKFE	IS	ETSVN	RGPEK	IRPE	CFEL	LRV	LGK	99																								
p70b	56	GHY	EVEL	LT	ETSVN	VGPER	IRIG	PHCFEL	LRV	LGK	68																								
P70a	100	GGYGKVFQVRKVT	GANTGKI	-AMKVL	KKAM	IVR	132																												
p70b	89	GGYGKVFQVRKVG	TNLGKI	YAMKVL	RKAK	IVR	121																												
P70a	133	NAKDTAHT	KAERN	LE	EMKHP	PFIND	LIYA	FQTG	165																										
p70b	122	NAKDTAHT	TRAE	RN	LES	VKHP	FIVE	LA	YAFQTG	154																									
P70a	156	GKLYL	ILE	EY	ISGGEL	FMQL	EREG	FF	MEDT	ACFY	199																								
p70b	155	GKLYL	ILE	EC	ISGGEL	ETH	LE	REG	FL	EDT	ACFY	187																							
P70a	199	LAE	IS	MA	LGH	LHQ	KG	ITY	RD	LKPEN	MLNH	QGH	231																						
p70b	199	LAE	IT	LA	LGH	LES	QG	ITY	RD	LKPEN	MLSS	QGH	220																						
P70a	232	V	KL	TDF	GLCKES	IHD	GT	V	HT	FCGT	EXMA	PE	264																						
p70b	221	I	KL	TDF	GLCKES	IHEG	AV	HT	FCGT	EXMA	PE	253																							
P70a	265	L	M	R	S	G	H	N	R	A	V	D	W	S	L	G	A	L	M	Y	D	M	L	T	G	A	P	R	F	T	G	E	N	297	
p70b	254	L	V	R	S	G	H	N	R	A	V	D	W	S	L	G	A	L	M	Y	D	M	L	T	G	S	P	R	F	T	A	E	N	266	
P70a	296	R	K	K	T	I	D	K	T	L	K	C	K	L	N	L	P	P	Y	L	T	Q	E	A	R	D	L	L	K	K	L	L	K	R	330
p70b	287	R	K	K	T	M	D	K	T	I	R	G	K	L	A	L	P	P	Y	L	T	P	D	A	R	D	L	V	K	K	F	L	K	R	319
P70a	331	N	A	A	S	R	L	G	A	G	R	G	D	A	G	E	V	Q	A	H	P	F	F	R	I	N	W	E	E	L	A	R	363		
p70b	320	N	P	S	O	R	I	G	G	R	G	D	A	A	D	V	Q	R	H	P	F	F	R	H	M	N	W	D	D	L	L	A	W	352	
P70a	364	K	V	E	P	P	F	K	P	L	E	Q	S	E	E	D	V	S	Q	F	D	S	K	F	T	R	Q	T	R	V	D	S	P	D	396
p70b	353	R	V	D	P	P	F	R	P	C	E	Q	S	E	E	D	V	S	Q	F	D	T	R	F	T	R	Q	T	R	V	D	S	P	D	385
P70a	397	D	S	T	L	S	E	S	A	N	G	V	F	L	G	F	T	Y	V	A	P	S	V	L	E	S	V	K	E	K	F	S	F	E	429
p70b	386	D	T	A	L	S	E	S	A	N	G	A	F	L	G	F	T	Y	V	A	P	S	V	L	D	S	I	K	E	G	F	S	F	Q	413
P70a	430	P	K	I	R	S	P	R	R	F	I	G	S	P	R	T	P	M	S	P	V	K	F	S	P	-	G	D	F	W	-	G	R	G	460
p70b	419	P	K	L	R	S	P	R	R	L	N	S	S	P	R	V	P	V	S	P	L	K	F	S	P	F	E	G	F	R	P	S	P	S	451
P70a	461	A	S	A	S	T	A	N	P	Q	T	P	V	E	Y	P	M	E	T	S	G	I	E	Q	M	D	V	T	M	S	G	E	A	S	493
p70b	452	L	P	E	P	T	E	L	P	L	P	L	P	P	P	P	S	T	T	A	P	L	P	I	R	P	P	S	G	T	K	494			
P70a	494	A	P	L	P	I	R	Q	P	N	S	G	P	Y	K	K	Q	A	F	P	M	I	S	K	R	P	E	H	L	R	M	N	L	525	
p70b	485	K	S	K	R	G	R	G	R	P	G	R	495																						

FIGURE 2A




FIGURE 2B




FIGURE 3A

Expression pattern of the p70 β mRNAs in tumour cell lines




FIGURE 3B

- 1 Promyelocytic leukemia HL-60
- 2 HeLa cell S3
- 3 chronic myelogenous leukemia K562
- 4 Lymphoblastic leukemia MOLT-4
- 5 Burkitt's lymphoma Raji
- 6 colorectal adenocarcinoma SW480
- 7 Lung carcinoma A549
- 8 Melanoma G361

1 2 3 4 5 6 7



Autoradiography



-	-	I	-	I	S	T
-	-	α		β		

1 2 3 4 5 6 7



anti-Flag blot

FIGURE 4A

PHOSPHORYLATION OF THE RIBOSOMAL S6 PROTEIN
C-TERMINAL PEPTIDES BY p70 α AND β KINASES





FIGURE 4B

ACTIVATION THE p70 α and β KINASES
IN RESPONSE TO VARIOUS STIMULI *in vivo*



- 1 mock transfection
- 2 p70 α (starved and non treated)
- 3 p70 α (starved and insulin stimulated)
- 4 p70 β (starved and non treated)
- 5 p70 β (starved and insulin stimulated)
- 6 p70 β (starved and serum stimulated)
- 7 p70 β (starved and TPA stimulated)

FIGURE 5A

Activation of the p70S6 alpha and beta kinases by PDGF in transiently transfected PAE cells




FIGURE 5B




FIGURE 6A




FIGURE 6B

INTERACTION OF P70S6K β WITH
DIFFERENT GST/SH3 FUSION PROTEINS
IN VITRO





FIGURE 7

Immunoprecipitation and Western blot analysis of the p70 β I and β II transiently overexpressed in Hek 293 cells with anti-p70 antibodies.



1. mock transfection
2. Flag-p70 α I
3. Flag-p70 β I
4. Flag-p70 β II

FIGURE 8

Fig 12

Comparison between activity of P70 α wt and P70 α 412





Fig. 11

P70 β 401 activity



- S6 activity
- autophosphorylation

Fig 1C

p70 β Mutations





Fig. 9



SEQUENCE LISTING

<110> Ludwig Institute for Cancer Research

<110> Gout, Ivan
Hara, Kenta
Waterfield, Michael
Yonezawa, Kazu

<120> Identification and Functional Characterization of a
Novel Ribosomal S6 Protein Kinase

<130> 40750-5002

<140> Unassigned

<141> 1999-08-04

<150> 60/095,268

<151> 1998-08-04

<160> 8

<170> PatentIn Ver. 2.0

<210> 1

<211> 1816

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (77)..(1561)

<223> p70(beta) S6 Kinase gene

<400> 1

gagagagaga gagagagaga gagagagaga gagagagaga gagagagaga 60

gagagactcg tgccga atg gca cga ggc cga cgg gcc cgc ggg gcc ggc gcc 112
Met Ala Arg Gly Arg Arg Ala Arg Gly Ala Gly Ala
1 5 10

gcc atg gcg gcc gtg ttt gat ttg gat ttg gag acg gag gaa ggc agc 160
Ala Met Ala Ala Val Phe Asp Leu Asp Leu Glu Thr Glu Glu Gly Ser
15 20 25

gag ggc gag ggc gag cca gag ctc agc ccc gcg gac gca tgt ccc ctt 208
Glu Gly Glu Gly Glu Pro Glu Leu Ser Pro Ala Asp Ala Cys Pro Leu
30 35 40

gcc gag ttg agg gca gct ggc cta gag cct gtg gga cac tat gaa gag 256
Ala Glu Leu Arg Ala Ala Gly Leu Glu Pro Val Gly His Tyr Glu Glu
45 50 55 60

gtg gag ctg act gag acc agc gtg aac gtt ggc cca gag cgc atc ggg 304
Val Glu Leu Thr Glu Thr Ser Val Asn Val Gly Pro Glu Arg Ile Gly
65 70 75

ccc cac tgc ttt gag ctg ctg cgt gtg ctg ggc aag ggg ggc tat ggc	352
Pro His Cys Phe Glu Leu Leu Arg Val Leu Gly Lys Gly Gly Tyr Gly	
80 85 90	
aag gtg ttc cag gtg cga aag gtg caa ggc acc aac ttg ggc aaa ata	400
Lys Val Phe Gln Val Arg Lys Val Gln Gly Thr Asn Leu Gly Lys Ile	
95 100 105	
tat gcc atg aaa gtc cta agg aag gcc aaa att gtg cgc aat gcc aag	448
Tyr Ala Met Lys Val Leu Arg Lys Ala Lys Ile Val Arg Asn Ala Lys	
110 115 120	
gac aca gca cac aca cgg gct gag cgg aac att cta gag tca gtg aag	496
Asp Thr Ala His Thr Arg Ala Glu Arg Asn Ile Leu Glu Ser Val Lys	
125 130 135 140	
cac ccc ttt att gtg gaa ctg gcc tat gcc ttc cag act ggt ggc aaa	544
His Pro Phe Ile Val Glu Leu Ala Tyr Ala Phe Gln Thr Gly Gly Lys	
145 150 155	
ctc tac ctc atc ctt gag tgc ctc agt ggt ggc gag ctc ttc acg cat	592
Leu Tyr Leu Ile Leu Glu Cys Leu Ser Gly Gly Glu Leu Phe Thr His	
160 165 170	
ctg gag cga gag ggc atc ttc ctg gaa gat acg gcc tgc ttc tac ctg	640
Leu Glu Arg Glu Gly Ile Phe Leu Glu Asp Thr Ala Cys Phe Tyr Leu	
175 180 185	
gct gag atc acg ctg gcc ctg ggc cat ctc cac tcc cag ggc atc atc	688
Ala Glu Ile Thr Leu Ala Leu Gly His Leu His Ser Gln Gly Ile Ile	
190 195 200	
tac cgg gac ctc aag ccc gag aac atc atg ctc agc agc cag ggc cac	736
Tyr Arg Asp Leu Lys Pro Glu Asn Ile Met Leu Ser Ser Gln Gly His	
205 210 215 220	
atc aaa ctg acc gac ttt gga ctc tgc aag gag tct atc cat gag ggc	784
Ile Lys Leu Thr Asp Phe Gly Leu Cys Lys Glu Ser Ile His Glu Gly	
225 230 235	
gcc gtc act cac acc ttc tgc ggc acc att gag tac atg gcc cct gag	832
Ala Val Thr His Thr Phe Cys Gly Thr Ile Glu Tyr Met Ala Pro Glu	
240 245 250	
att ctg gtg cgc agt ggc cac aac cgg gct gtg gac tgg tgg agc ctg	880
Ile Leu Val Arg Ser Gly His Asn Arg Ala Val Asp Trp Trp Ser Leu	
255 260 265	
ggg gcc ctg atg tac gac atg ctc act gga tcg ccg ccc ttt acc gca	928
Gly Ala Leu Met Tyr Asp Met Leu Thr Gly Ser Pro Pro Phe Thr Ala	
270 275 280	
gag aac cgg aag aaa acc atg gat aag atc atc agg ggc aag ctg gca	976
Glu Asn Arg Lys Lys Thr Met Asp Lys Ile Ile Arg Gly Lys Leu Ala	
285 290 295 300	

ctg ccc ccc tac ctc acc cca gat gcc cgg gac ctt gtc aaa aag ttt	1024
Leu Pro Pro Tyr Leu Thr Pro Asp Ala Arg Asp Leu Val Lys Lys Phe	
305 310 315	
ctg aaa cgg aat ccc agc cag cgg att ggg ggt ggc cca ggg gat gct	1072
Leu Lys Arg Asn Pro Ser Gln Arg Ile Gly Gly Gly Pro Gly Asp Ala	
320 325 330	
gct gat gtg cag aga cat ccc ttt ttc cgg cac atg aat tgg gac gac	1120
Ala Asp Val Gln Arg His Pro Phe Phe Arg His Met Asn Trp Asp Asp	
335 340 345	
ctt ctg gcc tgg cgt gtg gac ccc cct ttc agg ccc tgt ctg cag tca	1168
Leu Leu Ala Trp Arg Val Asp Pro Pro Phe Arg Pro Cys Leu Gln Ser	
350 355 360	
gag gag gac gtg agc cag ttt gat acc cgc ttc aca cgg cag acg ccg	1216
Glu Glu Asp Val Ser Gln Phe Asp Thr Arg Phe Thr Arg Gln Thr Pro	
365 370 375 380	
gtg gac agt cct gat gac aca gcc ctc agc gag agt gcc aac cag gcc	1264
Val Asp Ser Pro Asp Asp Thr Ala Leu Ser Glu Ser Ala Asn Gln Ala	
385 390 395	
ttc ctg ggc ttc aca tac gtg gcg ccg tct gtc ctg gac agc atc aag	1312
Phe Leu Gly Phe Thr Tyr Val Ala Pro Ser Val Leu Asp Ser Ile Lys	
400 405 410	
gag ggc ttc tcc ttc cag ccc aag ctg cgc tca ccc agg cgc ctc aac	1360
Glu Gly Phe Ser Phe Gln Pro Lys Leu Arg Ser Pro Arg Arg Leu Asn	
415 420 425	
agt agc ccc cgg gtc ccc gtc agc ccc ctc aag ttc tcc cct ttt gag	1408
Ser Ser Pro Arg Val Pro Val Ser Pro Leu Lys Phe Ser Pro Phe Glu	
430 435 440	
ggg ttt cgg ccc agc ccc agc ctg ccg gag ccc acg gag cta cct cta	1456
Gly Phe Arg Pro Ser Pro Ser Leu Pro Glu Pro Thr Glu Leu Pro Leu	
445 450 455 460	
cct cca ctc ctg cca ccg ccg ccg ccc tcg acc acc gcc cct ctc ccc	1504
Pro Pro Leu Leu Pro Pro Pro Pro Ser Thr Thr Ala Pro Leu Pro	
465 470 475	
atc cgt ccc ccc tca ggg acc aag aag tcc aag agg ggc cgt ggg cgt	1552
Ile Arg Pro Pro Ser Gly Thr Lys Lys Ser Lys Arg Gly Arg Gly Arg	
480 485 490	
cca ggg cgc taggaagccg ggtgggggtg agggtagccc ttgagccctg	1601
Pro Gly Arg	
495	
tccctgcggc tgtgagagca gcaggaccct gggccagttc cagagacctg ggggtgtgtc	1661
tgggggtggg gtgtgagtgc gtatgaaagt gtgtgtctgc tggggcagct gtgccctga	1721

atcatgggca cggagggccg cccgccacac cccgcgtca actgctcccg tggaagatta 1781
 aagggtgaa tcatgaaaaa aaaaaaaaaa aaaaa 1816

<210> 2
 <211> 495
 <212> PRT
 <213> Homo sapiens

<220>
 <223> p70(beta) S6 Kinase protein

<400> 2
 Met Ala Arg Gly Arg Arg Ala Arg Gly Ala Gly Ala Ala Met Ala Ala
 1 5 10 15
 Val Phe Asp Leu Asp Leu Glu Thr Glu Glu Gly Ser Glu Gly Glu Gly
 20 25 30
 Glu Pro Glu Leu Ser Pro Ala Asp Ala Cys Pro Leu Ala Glu Leu Arg
 35 40 45
 Ala Ala Gly Leu Glu Pro Val Gly His Tyr Glu Glu Val Glu Leu Thr
 50 55 60
 Glu Thr Ser Val Asn Val Gly Pro Glu Arg Ile Gly Pro His Cys Phe
 65 70 75 80
 Glu Leu Leu Arg Val Leu Gly Lys Gly Gly Tyr Gly Lys Val Phe Gln
 85 90 95
 Val Arg Lys Val Gln Gly Thr Asn Leu Gly Lys Ile Tyr Ala Met Lys
 100 105 110
 Val Leu Arg Lys Ala Lys Ile Val Arg Asn Ala Lys Asp Thr Ala His
 115 120 125
 Thr Arg Ala Glu Arg Asn Ile Leu Glu Ser Val Lys His Pro Phe Ile
 130 135 140
 Val Glu Leu Ala Tyr Ala Phe Gln Thr Gly Gly Lys Leu Tyr Leu Ile
 145 150 155 160
 Leu Glu Cys Leu Ser Gly Gly Glu Leu Phe Thr His Leu Glu Arg Glu
 165 170 175
 Gly Ile Phe Leu Glu Asp Thr Ala Cys Phe Tyr Leu Ala Glu Ile Thr
 180 185 190
 Leu Ala Leu Gly His Leu His Ser Gln Gly Ile Ile Tyr Arg Asp Leu
 195 200 205
 Lys Pro Glu Asn Ile Met Leu Ser Ser Gln Gly His Ile Lys Leu Thr
 210 215 220

```

Asp Phe Gly Leu Cys Lys Glu Ser Ile His Glu Gly Ala Val Thr His
225                230                235                240

Thr Phe Cys Gly Thr Ile Glu Tyr Met Ala Pro Glu Ile Leu Val Arg
                245                250                255

Ser Gly His Asn Arg Ala Val Asp Trp Trp Ser Leu Gly Ala Leu Met
                260                265                270

Tyr Asp Met Leu Thr Gly Ser Pro Pro Phe Thr Ala Glu Asn Arg Lys
                275                280                285

Lys Thr Met Asp Lys Ile Ile Arg Gly Lys Leu Ala Leu Pro Pro Tyr
290                295                300

Leu Thr Pro Asp Ala Arg Asp Leu Val Lys Lys Phe Leu Lys Arg Asn
305                310                315                320

Pro Ser Gln Arg Ile Gly Gly Gly Pro Gly Asp Ala Ala Asp Val Gln
                325                330                335

Arg His Pro Phe Phe Arg His Met Asn Trp Asp Asp Leu Leu Ala Trp
                340                345                350

Arg Val Asp Pro Pro Phe Arg Pro Cys Leu Gln Ser Glu Glu Asp Val
                355                360                365

Ser Gln Phe Asp Thr Arg Phe Thr Arg Gln Thr Pro Val Asp Ser Pro
370                375                380

Asp Asp Thr Ala Leu Ser Glu Ser Ala Asn Gln Ala Phe Leu Gly Phe
385                390                395                400

Thr Tyr Val Ala Pro Ser Val Leu Asp Ser Ile Lys Glu Gly Phe Ser
                405                410                415

Phe Gln Pro Lys Leu Arg Ser Pro Arg Arg Leu Asn Ser Ser Pro Arg
                420                425                430

Val Pro Val Ser Pro Leu Lys Phe Ser Pro Phe Glu Gly Phe Arg Pro
                435                440                445

Ser Pro Ser Leu Pro Glu Pro Thr Glu Leu Pro Leu Pro Pro Leu Leu
450                455                460

Pro Pro Pro Pro Pro Ser Thr Thr Ala Pro Leu Pro Ile Arg Pro Pro
465                470                475                480

Ser Gly Thr Lys Lys Ser Lys Arg Gly Arg Gly Arg Pro Gly Arg
                485                490                495

```

```

<210> 3
<211> 2346
<212> DNA
<213> Homo sapiens

```

<220>

<221> CDS

<222> (28)..(1602)

<223> p70(alpha) S6 Kinase gene

<400> 3

gcacgaggct gcggcggggtc cgggccc atg agg cga cga agg agg cgg gac ggc 54

Met Arg Arg Arg Arg Arg Arg Asp Gly

1

5

ttt tac cca gcc ccg gac ttc cga gac agg gaa gct gag gac atg gca 102

Phe Tyr Pro Ala Pro Asp Phe Arg Asp Arg Glu Ala Glu Asp Met Ala

10

15

20

25

gga gtg ttt gac ata gac ctg gac cag cca gag gac gcg ggc tct gag 150

Gly Val Phe Asp Ile Asp Leu Asp Gln Pro Glu Asp Ala Gly Ser Glu

30

35

40

gat gag ctg gag gag ggg ggt cag tta aat gaa agc atg gac cat ggg 198

Asp Glu Leu Glu Glu Gly Gly Gln Leu Asn Glu Ser Met Asp His Gly

45

50

55

gga gtt gga cca tat gaa ctt ggc atg gaa cat tgt gag aaa ttt gaa 246

Gly Val Gly Pro Tyr Glu Leu Gly Met Glu His Cys Glu Lys Phe Glu

60

65

70

atc tca gaa act agt gtg aac aga ggg cca gaa aaa atc aga cca gaa 294

Ile Ser Glu Thr Ser Val Asn Arg Gly Pro Glu Lys Ile Arg Pro Glu

75

80

85

tgt ttt gag cta ctt cgg gta ctt ggt aaa ggg ggc tat gga aag gtt 342

Cys Phe Glu Leu Leu Arg Val Leu Gly Lys Gly Gly Tyr Gly Lys Val

90

95

100

105

ttt caa gta cga aaa gta aca gga gca aat act ggg aaa ata ttt gcc 390

Phe Gln Val Arg Lys Val Thr Gly Ala Asn Thr Gly Lys Ile Phe Ala

110

115

120

atg aag gtg ctt aaa aag gca atg ata gta aga aat gct aaa gat aca 438

Met Lys Val Leu Lys Lys Ala Met Ile Val Arg Asn Ala Lys Asp Thr

125

130

135

gct cat aca aaa gca gaa cgg aat att ctg gag gaa gta aag cat ccc 486

Ala His Thr Lys Ala Glu Arg Asn Ile Leu Glu Glu Val Lys His Pro

140

145

150

ttc atc gtg gat tta att tat gcc ttt cag act ggt gga aaa ctc tac 534

Phe Ile Val Asp Leu Ile Tyr Ala Phe Gln Thr Gly Gly Lys Leu Tyr

155

160

165

ctc atc ctt gag tat ctc agt gga gga gaa cta ttt atg cag tta gaa 582

Leu Ile Leu Glu Tyr Leu Ser Gly Gly Glu Leu Phe Met Gln Leu Glu

170

175

180

185

aga gag gga ata ttt atg gaa gac act gcc tgc ttt tac ttg gca gaa 630

Arg Glu Gly Ile Phe Met Glu Asp Thr Ala Cys Phe Tyr Leu Ala Glu

190										195										200									
atc	tcc	atg	gct	ttg	ggg	cat	tta	cat	caa	aag	ggg	atc	atc	tac	aga	678													
Ile	Ser	Met	Ala	Leu	Gly	His	Leu	His	Gln	Lys	Gly	Ile	Ile	Tyr	Arg														
205					210					215																			
gac	ctg	aag	ccg	gag	aat	atc	atg	ctt	aat	cac	caa	ggg	cat	gtg	aaa	726													
Asp	Leu	Lys	Pro	Glu	Asn	Ile	Met	Leu	Asn	His	Gln	Gly	His	Val	Lys														
220					225					230																			
cta	aca	gac	ttt	gga	cta	tgc	aaa	gaa	tct	att	cat	gat	gga	aca	gtc	774													
Leu	Thr	Asp	Phe	Gly	Leu	Cys	Lys	Glu	Ser	Ile	His	Asp	Gly	Thr	Val														
235					240					245																			
aca	cac	aca	ttt	tgt	gga	aca	ata	gaa	tac	atg	gcc	cct	gaa	atc	ttg	822													
Thr	His	Thr	Phe	Cys	Gly	Thr	Ile	Glu	Tyr	Met	Ala	Pro	Glu	Ile	Leu														
250					255					260					265														
atg	aga	agt	ggc	cac	aat	cgt	gct	gtg	gat	tgg	tgg	agt	ttg	gga	gca	870													
Met	Arg	Ser	Gly	His	Asn	Arg	Ala	Val	Asp	Trp	Trp	Ser	Leu	Gly	Ala														
270					275					280																			
tta	atg	tat	gac	atg	ctg	act	gga	gca	ccc	cca	ttc	act	ggg	gag	aat	918													
Leu	Met	Tyr	Asp	Met	Leu	Thr	Gly	Ala	Pro	Pro	Phe	Thr	Gly	Glu	Asn														
285					290					295																			
aga	aag	aaa	aca	att	gac	aaa	atc	ctc	aaa	tgt	aaa	ctc	aat	ttg	cct	966													
Arg	Lys	Lys	Thr	Ile	Asp	Lys	Ile	Leu	Lys	Cys	Lys	Leu	Asn	Leu	Pro														
300					305					310																			
ccc	tac	ctc	aca	caa	gaa	gcc	aga	gat	ctg	ctt	aaa	aag	ctg	ctg	aaa	1014													
Pro	Tyr	Leu	Thr	Gln	Glu	Ala	Arg	Asp	Leu	Leu	Lys	Lys	Leu	Leu	Lys														
315					320					325																			
aga	aat	gct	gct	tct	cgt	ctg	gga	gct	ggg	cct	ggg	gac	gct	gga	gaa	1062													
Arg	Asn	Ala	Ala	Ser	Arg	Leu	Gly	Ala	Gly	Pro	Gly	Asp	Ala	Gly	Glu														
330					335					340					345														
gtt	caa	gct	cat	cca	ttc	ttt	aga	cac	att	aac	tgg	gaa	gaa	ctt	ctg	1110													
Val	Gln	Ala	His	Pro	Phe	Phe	Arg	His	Ile	Asn	Trp	Glu	Glu	Leu	Leu														
350					355					360																			
gct	cga	aag	gtg	gag	ccc	ccc	ttt	aaa	cct	ctg	ttg	caa	tct	gaa	gag	1158													
Ala	Arg	Lys	Val	Glu	Pro	Pro	Phe	Lys	Pro	Leu	Leu	Gln	Ser	Glu	Glu														
365					370					375																			
gat	gta	agt	cag	ttt	gat	tcc	aag	ttt	aca	cgt	cag	aca	cct	gtc	gac	1206													
Asp	Val	Ser	Gln	Phe	Asp	Ser	Lys	Phe	Thr	Arg	Gln	Thr	Pro	Val	Asp														
380					385					390																			
agc	cca	gat	gac	tca	act	ctc	agt	gaa	agt	gcc	aat	cag	gtc	ttt	ctg	1254													
Ser	Pro	Asp	Asp	Ser	Thr	Leu	Ser	Glu	Ser	Ala	Asn	Gln	Val	Phe	Leu														
395					400					405																			
ggg	ttt	acat	tat	gtg	gct	cca	tct	gta	ctt	gaa	agt	gtg	aaa	gaa	aag	1302													
Gly	Phe	Thr	Tyr	Val	Ala	Pro	Ser	Val	Leu	Glu	Ser	Val	Lys	Glu	Lys														

```

410                               415                               420                               425
ttt tcc ttt gaa cca aaa atc cga tca cct cga aga ttt att ggc agc 1350
Phe Ser Phe Glu Pro Lys Ile Arg Ser Pro Arg Arg Phe Ile Gly Ser
                               430                               435                               440

cca cga aca cct gtc agc cca gtc aaa ttt tct cct ggg gat ttc tgg 1398
Pro Arg Thr Pro Val Ser Pro Val Lys Phe Ser Pro Gly Asp Phe Trp
                               445                               450                               455

gga aga ggt gct tcg gcc agc aca gca aat cct cag aca cct gtg gaa 1446
Gly Arg Gly Ala Ser Ala Ser Thr Ala Asn Pro Gln Thr Pro Val Glu
                               460                               465                               470

tac cca atg gaa aca agt ggc ata gag cag atg gat gtg aca atg agt 1494
Tyr Pro Met Glu Thr Ser Gly Ile Glu Gln Met Asp Val Thr Met Ser
                               475                               480                               485

ggg gaa gca tcg gca cca ctt cca ata cga cag ccg aac tct ggg cca 1542
Gly Glu Ala Ser Ala Pro Leu Pro Ile Arg Gln Pro Asn Ser Gly Pro
490                               495                               500                               505

tac aaa aaa caa gct ttt ccc atg atc tcc aaa cgg cca gag cac ctg 1590
Tyr Lys Lys Gln Ala Phe Pro Met Ile Ser Lys Arg Pro Glu His Leu
                               510                               515                               520

cgt atg aat cta tgacagagca atgcttttaa tgaatttaag gcaaaaagg 1642
Arg Met Asn Leu
                               525

ggagagggag atgtgtgagc atcctgcaag gtgaaacaag actcaaatg acagtttcag 1702

agagtcaatg tcattacata gaacacttcg gacacaggaa aaataaacgt ggatttttaa 1762

aatcaatca atggtgcaaa aaaaaactta aagcaaaata gtattgctga actcttaggc 1822

acatcaatta attgattcct cgcgacatct ttctcaacct tatcaaggat tttcatgttg 1882

atgactcgaa actgacagta ttaagggtag gatgttgctc tgaatcactg tgagtctgat 1942

gtgtgaagaa gggatatcct tcattaggca agtacaaatt gcctataata cttgcaacta 2002

aggacaaatt agcatgcaag cttggtcaaa cttttcccag gcaaaatggg aaggcaaaga 2062

caaaagaaac ttaccaattg atgttttacg tgcaaaacaac ctgaatcttt tttttatata 2122

aatatatatt tttcaaatag atttttgatt cagctcatta tgaaaaacat cccaaacttt 2182

aaaatgcgaa attattgggt ggtgtgaaga aagccagaca acttctgttt cttctcttgg 2242

tgaaataata aaatgcaaat gaatcattgt taacacagct gtggctcgtt tgagggattg 2302

gggtggacct ggggtttatt ttcagtaacc cagctgcgga gcct 2346

```

<210> 4

<211> 525

<212> PRT

<213> Homo sapiens

<220>

<223> p70(alpha) S6 Kinase protein

<400> 4

Met	Arg	Arg	Arg	Arg	Arg	Arg	Arg	Asp	Gly	Phe	Tyr	Pro	Ala	Pro	Asp	Phe
1					5					10					15	

Arg	Asp	Arg	Glu	Ala	Glu	Asp	Met	Ala	Gly	Val	Phe	Asp	Ile	Asp	Leu
			20					25					30		

Asp	Gln	Pro	Glu	Asp	Ala	Gly	Ser	Glu	Asp	Glu	Leu	Glu	Glu	Gly	Gly
		35					40					45			

Gln	Leu	Asn	Glu	Ser	Met	Asp	His	Gly	Gly	Val	Gly	Pro	Tyr	Glu	Leu
	50					55					60				

Gly	Met	Glu	His	Cys	Glu	Lys	Phe	Glu	Ile	Ser	Glu	Thr	Ser	Val	Asn
65					70					75					80

Arg	Gly	Pro	Glu	Lys	Ile	Arg	Pro	Glu	Cys	Phe	Glu	Leu	Leu	Arg	Val
				85					90					95	

Leu	Gly	Lys	Gly	Gly	Tyr	Gly	Lys	Val	Phe	Gln	Val	Arg	Lys	Val	Thr
		100					105						110		

Gly	Ala	Asn	Thr	Gly	Lys	Ile	Phe	Ala	Met	Lys	Val	Leu	Lys	Lys	Ala
		115					120					125			

Met	Ile	Val	Arg	Asn	Ala	Lys	Asp	Thr	Ala	His	Thr	Lys	Ala	Glu	Arg
	130					135					140				

Asn	Ile	Leu	Glu	Glu	Val	Lys	His	Pro	Phe	Ile	Val	Asp	Leu	Ile	Tyr
145					150					155					160

Ala	Phe	Gln	Thr	Gly	Gly	Lys	Leu	Tyr	Leu	Ile	Leu	Glu	Tyr	Leu	Ser
				165				170						175	

Gly	Gly	Glu	Leu	Phe	Met	Gln	Leu	Glu	Arg	Glu	Gly	Ile	Phe	Met	Glu
		180					185						190		

Asp	Thr	Ala	Cys	Phe	Tyr	Leu	Ala	Glu	Ile	Ser	Met	Ala	Leu	Gly	His
		195					200					205			

Leu	His	Gln	Lys	Gly	Ile	Ile	Tyr	Arg	Asp	Leu	Lys	Pro	Glu	Asn	Ile
	210						215				220				

Met	Leu	Asn	His	Gln	Gly	His	Val	Lys	Leu	Thr	Asp	Phe	Gly	Leu	Cys
225					230					235					240

Lys	Glu	Ser	Ile	His	Asp	Gly	Thr	Val	Thr	His	Thr	Phe	Cys	Gly	Thr
				245				250						255	

Ile Glu Tyr Met Ala Pro Glu Ile Leu Met Arg Ser Gly His Asn Arg
 260 265 270
 Ala Val Asp Trp Trp Ser Leu Gly Ala Leu Met Tyr Asp Met Leu Thr
 275 280 285
 Gly Ala Pro Pro Phe Thr Gly Glu Asn Arg Lys Lys Thr Ile Asp Lys
 290 295 300
 Ile Leu Lys Cys Lys Leu Asn Leu Pro Pro Tyr Leu Thr Gln Glu Ala
 305 310 315 320
 Arg Asp Leu Leu Lys Lys Leu Leu Lys Arg Asn Ala Ala Ser Arg Leu
 325 330 335
 Gly Ala Gly Pro Gly Asp Ala Gly Glu Val Gln Ala His Pro Phe Phe
 340 345 350
 Arg His Ile Asn Trp Glu Glu Leu Leu Ala Arg Lys Val Glu Pro Pro
 355 360 365
 Phe Lys Pro Leu Leu Gln Ser Glu Glu Asp Val Ser Gln Phe Asp Ser
 370 375 380
 Lys Phe Thr Arg Gln Thr Pro Val Asp Ser Pro Asp Asp Ser Thr Leu
 385 390 395 400
 Ser Glu Ser Ala Asn Gln Val Phe Leu Gly Phe Thr Tyr Val Ala Pro
 405 410 415
 Ser Val Leu Glu Ser Val Lys Glu Lys Phe Ser Phe Glu Pro Lys Ile
 420 425 430
 Arg Ser Pro Arg Arg Phe Ile Gly Ser Pro Arg Thr Pro Val Ser Pro
 435 440 445
 Val Lys Phe Ser Pro Gly Asp Phe Trp Gly Arg Gly Ala Ser Ala Ser
 450 455 460
 Thr Ala Asn Pro Gln Thr Pro Val Glu Tyr Pro Met Glu Thr Ser Gly
 465 470 475 480
 Ile Glu Gln Met Asp Val Thr Met Ser Gly Glu Ala Ser Ala Pro Leu
 485 490 495
 Pro Ile Arg Gln Pro Asn Ser Gly Pro Tyr Lys Lys Gln Ala Phe Pro
 500 505 510
 Met Ile Ser Lys Arg Pro Glu His Leu Arg Met Asn Leu
 515 520 525

<210> 5

<211> 31

<212> PRT

<213> Homo sapiens

<220>

<223> Sequence derived from C-terminus of ribosomal S6 protein

<400> 5

Lys Glu Ala Lys Glu Lys Arg Gln Glu Gln Ile Ala Arg Arg Arg Leu
1 5 10 15Ser Ser Leu Arg Ala Ser Thr Ser Lys Ser Glu Ser Ser Gln Lys
20 25 30

<210> 6

<211> 19

<212> PRT

<213> Homo sapiens

<220>

<223> Sequence derived from C-terminus of ribosomal S6 protein

<400> 6

Arg Arg Arg Leu Ser Ser Leu Arg Ala Ser Thr Ser Lys Ser Glu Ser
1 5 10 15

Ser Gln Lys

<210> 7

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
protease target substrate for p70(alpha) S6 Kinase
isoforms

<400> 7

Lys Lys Arg Asn Arg Thr Leu Ser Val Ala
1 5 10

<210> 8

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
protease target substrate for p70(beta) S6 Kinase
isoforms

<400> 8

Arg Arg Leu Ser Ser Leu Arg Ala Ser Thr Ser Lys Ser Glu Ser Ser
1 5 10 15

Gln Lys

INTERNATIONAL SEARCH REPORT

National Application No.

PCT/US 99/17595

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/54 C12N15/62 C12N9/12 C12N5/10 C07K16/40
G01N33/50 G01N33/566 C12Q1/68

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C07K G01N C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	GOUT I. ET AL.: "Molecular cloning and characterization of a novel p70 S6 kinase beta containing a proline-rich region" J. BIOL. CHEM., vol. 273, no. 46, 13 November 1998 (1998-11-13), pages 30061-30064, XP002124654 the whole document	1-36
P,X	SAITOH M. ET AL.: "Cloning and characterization of p70(S6 beta) defines a novel family of p70 S6 kinases" BIOCHEM. BIOPHYS. RES. COMMUN., vol. 253, no. 2, 18 December 1998 (1998-12-18), pages 471-476, XP002124655 the whole document	1-36



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
 "E" earlier document but published on or after the international filing date
 "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
 "O" document referring to an oral disclosure, use, exhibition or other means
 "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
 "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
 "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
 "&" document member of the same patent family

Date of the actual completion of the international search

20 December 1999

Date of mailing of the international search report

11/01/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax (+31-70) 340-3016

Authorized officer

Galli, I

INTERNATIONAL SEARCH REPORT

Sonal Application No

PCT/US 99/17595

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	WO 99 24463 A (INCYTE PHARMA INC ; MATHUR PREETE (US); REDDY ROOPA (US); AU YOUNG) 20 May 1999 (1999-05-20) compare nt 180-1450 of seq. ID 10 and nt 101-1370 of seq. ID 1 of present application	1-4
A	WO 98 18935 A (CIBA GEIGY AG ; THOMAS GEORGE (FR); KOZMA SARA (FR)) 7 May 1998 (1998-05-07) abstract claims 1-11	1-36
A	WO 93 19752 A (DANA FARBER CANCER INST INC) 14 October 1993 (1993-10-14) abstract	1-36
A	MUKHOPADHYAY N.K. ET AL.: "An array of insulin-activated, proline-directed serine/threonine kinases phosphorylate the p70 S6 kinase" J. BIOL. CHEM., vol. 267, no. 5, 15 February 1995 (1995-02-15), pages 3325-3335, XP002124656 the whole document	1-36
A	WENG Q.P. ET AL.: "Regulation of the p70 S6 kinase by phosphorylation in vivo" J. BIOL. CHEM., vol. 273, no. 26, 26 June 1998 (1998-06-26), pages 16621-16629, XP002124657 the whole document	1-36
A	ALESSI D.R. ET AL.: "3-Phosphoinositide-dependent protein kinase 1 (PDK1) phosphorylates and activates the p70 S6 kinase in vivo and in vitro" CURRENT BIOLOGY, vol. 8, 10 December 1997 (1997-12-10), pages 69-81, XP000857264 the whole document	1-36
	— -/-	

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>HAN J -W ET AL: "RAPAMYCIN, WORTMANNIN, AND THE METHYLXANTHINE SQ20006 INACTIVATE P70S6K BY INDUCING DEPHOSPHORYLATION OF THE SAME SUBSET OF SITES"</p> <p>JOURNAL OF BIOLOGICAL CHEMISTRY,US,AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, vol. 270, no. 36, page 21396-21403 XP002057557 ISSN: 0021-9258 the whole document</p>	1-36
A	<p>PEARSON R B ET AL: "THE PRINCIPAL TARGET OF RAPAMYCIN-INDUCED P70S6K INACTIVATION IS A NOVEL PHOSPHORYLATION SITE WITHIN A CONSERVED HYDROPHOBIC DOMAIN"</p> <p>EMBO JOURNAL,GB,OXFORD UNIVERSITY PRESS, SURREY, vol. 14, no. 21, page 5279-5287 XP000561164 ISSN: 0261-4189 the whole document</p>	1-36
A	<p>DENNIS P B ET AL: "THE PRINCIPAL RAPAMYCIN-SENSITIVE P70S6K PHOSPHORYLATION SITES, T-229 AND T-389, ARE DIFFERENTIALLY REGULATED BY RAPAMYCIN-INSENSITIVE KINASE KINASES"</p> <p>MOLECULAR AND CELLULAR BIOLOGY,US,AMERICAN SOCIETY FOR MICROBIOLOGY, WASHINGTON, vol. 16, no. 11, page 6242-6251 XP002057559 ISSN: 0270-7306 the whole document</p>	1-36
A	<p>WO 98 03662 A (CIBA GEIGY AG ;STEWART MARY (CH); THOMAS GEORGE (FR); KOZMA SARA () 29 January 1998 (1998-01-29) abstract claims 1-9</p>	1-36
A	<p>PROUD C G: "P70 S6 KINASE: AN ENIGMA WITH VARIATIONS"</p> <p>TIBS TRENDS IN BIOCHEMICAL SCIENCES,EN,ELSEVIER PUBLICATION, CAMBRIDGE, vol. 21, no. 5, page 181-185 XP002057556 ISSN: 0968-0004 the whole document</p>	1-36

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 99/17595

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claims 10-11, as far as methods in vivo are concerned are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☒ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
See FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims 10-11 refer to modulating compounds, and claims 25-26 refer to binding partners of p70 S6K (beta) without giving a true technical characterization. Moreover, no such compounds are defined in the application. In consequence, the scope of said claims is ambiguous and vague, and their subject-matter is not sufficiently disclosed and supported (Art. 5 and 6 PCT). No search can be carried out for such purely speculative claims whose wording is, in fact, a mere recitation of the results to be achieved.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 99/17595

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
W0 9924463	A	20-05-1999	US	5932445 A	03-08-1999
			AU	1309599 A	31-05-1999
W0 9818935	A	07-05-1998	AU	5314598 A	22-05-1998
			EP	0942990 A	22-09-1999
W0 9319752	A	14-10-1993	AU	3922493 A	08-11-1993
W0 9803662	A	29-01-1998	AU	4113897 A	10-02-1998
			EP	0915982 A	19-05-1999



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C12N 15/54, 15/62, 9/12, 5/10, C07K 16/40, G01N 33/50, 33/566, C12Q 1/68	A1	(11) International Publication Number: WO 00/08173 (43) International Publication Date: 17 February 2000 (17.02.00)
(21) International Application Number: PCT/US99/17595 (22) International Filing Date: 4 August 1999 (04.08.99) (30) Priority Data: 60/095,268 4 August 1998 (04.08.98) US (71) Applicant (for all designated States except US): LUDWIG INSTITUTE FOR CANCER RESEARCH [US/US]; 34th floor, 1345 Avenue of the Americas, New York, NY 10105 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): GOUT, Ivan [-/US]; Ludwig Institute for Cancer Research, 34th floor, 1345 Avenue of the Americas, New York, NY 10105 (US). HARA, Kenta [-/US]; Ludwig Institute for Cancer Research, 34th floor, 1345 Avenue of the Americas, New York, NY 10105 (US). WATERFIELD, Mike [-/US]; Ludwig Institute for Cancer Research, 34th floor, 1345 Avenue of the Americas, New York, NY 10105 (US). YONEZAWA, Kazu [-/US]; Ludwig Institute for Cancer Research, 34th floor, 1345 Avenue of the Americas, New York, NY 10105 (US).		(74) Agent: ADLER, Reid, G.; Morgan, Lewis & Bockius LLP, 1800 M Street, N.W., Washington, DC 20236-5869 (US). (81) Designated States: AU, JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: IDENTIFICATION AND FUNCTIONAL CHARACTERIZATION OF A NOVEL RIBOSOMAL S6 PROTEIN KINASE (57) Abstract <p>A novel S6 kinase, p70^{βS6k}, is described, along with methods of making and using p70^{βS6k} and related nucleic acids. The invention also discloses methods of identifying agents which modulate the activity of p70^{βS6k} and/or its ligands.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Larvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

IDENTIFICATION AND FUNCTIONAL CHARACTERIZATION OF A NOVEL RIBOSOMAL S6 PROTEIN KINASE

5

This invention relates to United States Provisional Application Serial No. 60/095,268, filed August 4, 1988, which is incorporated by reference herein in its entirety.

10

FIELD OF THE INVENTION

The present invention relates to a novel S6 kinase ($p70^{\beta^{Sk6}}$), mutant variants thereof, methods of making and using this S6 kinase, and related nucleic acids and antibodies. The invention also relates to binding partners of the S6 kinase, methods of
15 identifying the binding partners and antibodies thereto.

BACKGROUND OF THE INVENTION

The 40S ribosomal protein S6 is a component of the 40S subunit of eukaryotic ribosomes. The ribosomes are part of the cellular machinery responsible for translation
20 of mRNA and protein synthesis. The S6 protein is phosphorylated in response to certain cellular signaling events such as hormone or growth factor induced cellular proliferation. $p70$ S6 kinase ($p70^{S6k}$) is responsible for S6 phosphorylation and is believed to be the major physiological S6 kinase in mammalian cells (Proud, 1996 Trends Biochem. Sci. 21: 181-185).

25

1. $p70^{\alpha}$ S6 Kinase

A. Structure and Function

The first $p70$ S6 kinase identified was the alpha (α) form. The gene encoding the human $p70^{\alpha}$ S6 kinase ($p70^{S6k}$) was isolated in 1991 (Grove *et al.*, 1991 Mol. Cell.

Biol. 11: 5541-5550). Other p70 α S6 kinase sequences have been described in *Mus musculus* (GenBank Accession No. SEG_AB015196S, AB015197, and AB015196), *Xenopus laevis* (GenBank Accession No. X66179), and rat (GenBank Accession No. M57428).

- 5 Two p70 α S6 kinase isoforms were identified: p70 α -I (GenBank Accession No. M60724) and p70 α -II (GenBank Accession No. M60725). The two p70 α S6 kinase isoforms differ only in their amino termini by 23 amino acid residues resulting in a 70 kD protein and a 85 kD protein. The isoforms are referred to in the literature as p70^{S6k}/p85^{S6k} or p70 α S6 kinase. Both isoforms share similar activity towards
- 10 ribosomal protein S6 *in vitro* but are expressed in different cells and tissues. The two isoforms are produced by two mRNA products and are not a result of post-translational modifications. They are serine/threonine kinases and are known to act on the substrate KKRNRTLVA (SEQ ID No. 7) (Pai *et al.*, 1994 Eur. J. Immunol. 24: 2364-8; and Leighton *et al.*, 1995 FEBS Letters 375: 289-93).
- 15 The p70 α S6 kinase plays an important role in the progression of cells from G1 to S phase of the cell cycle and in the initiation of protein synthesis. Recently, p70 α S6 kinase has been demonstrated to regulate the translation of a class of mRNAs containing an oligopyrimidine tract in their 5' untranslated region. This class of mRNAs, termed 5'TOP mRNAs, represent up to 20% of the a cell's total mRNA.
- 20 Many of the proteins encoded by 5'TOP mRNAs are translational apparatus proteins and cell-cycle progression proteins.

The p70 α S6 kinase has four identified interdependent domains: (1) a catalytic domain, (2) a kinase extension domain, (3) a pseudosubstrate autoinhibitory domain, and (4) the N-terminal domain. The catalytic domain is located in the middle of the

25 protein and is followed by the kinase extension domain, which is a unique feature for the PKA family. The pseudosubstrate autoinhibitory domain is also unique for the p70 α S6 kinase, not having been observed in any other known kinases. It possesses 5 phosphorylation sites which are responsible for the p70 α S6 kinase regulation. The N-terminal domain mediates the sensitivity for rapamycin, which strongly inhibits serum-

induced phosphorylation and activation of the p70 α S6 kinase. This domain may also mediate the interaction with a yet unknown phosphatase.

B. Regulators and Cascades

5 Growth factors, such as insulin, and mitogens are known to activate *in vivo* p70 α S6 kinase (Alessi *et al.*, 1998 Curr. Biol. 8: 69-81). Heat shock also activates p70 α S6 kinase (Lin *et al.*, 1997 J. Biol. Chem. 272: 31196-31202). Certain drugs have been identified that regulate p70 α S6 kinase activity including: rapamycin, wortmannin, Ro31-8220, GF109203X, LY294002, phenylephrine (PE), PD098059, SQ20006,
10 polymerized collagen, forskolin, interleukin-10 (IL-10), demethoxyviridin, phorbol 12-myristate 13-acetate (PMA), A23187, bombesin and antibodies which recognize the p70 α S6 kinase (Proud, 1996; Morreale *et al.*, 1997 FEBS Letters 417: 38-42; Kanda *et al.*, 1997 J. Biol. Chem. 272: 23347-23353; Boluyt *et al.*, 1997 Circ. Res. 81: 176-186; Coolican *et al.*, 1997 J. Biol. Chem. 272: 6653-6662; Koyama *et al.*, 1996 Cell 87: 1069-1078; Busca *et al.*, 1996 J. Biol. Chem. 271: 31824-31830; Crawley *et al.*, 1996
15 J. Biol. Chem. 271: 16357-16362; and Petritsch *et al.*, 1995 Eur. J. Biochem. 230: 431-8). The immunosuppressant rapamycin (Rap) is the most potent inhibitor of p70 α S6 kinase described (Pullen *et al.*, 1997 FEBS Letters 410: 78-82).

p70 α S6 kinase is an enzyme which lies downstream of phosphoinositide 3-
20 kinases (PI3-kinase). The mechanisms regulating the p70 α S6 kinase have not been fully elucidated. PI3-kinase has recently been shown to activate another phosphoinositide-dependent protein kinase, termed PDK-1. So far, only PDK-1 has been shown to phosphorylate p70 α S6 kinase *in vivo*, and this phosphorylation is essential for p70 α ^{S6k} activity towards ribosomal S6 protein. Wortmannin, a fungal
25 inhibitor which down-regulates the p70 α S6 kinase, is believed to act by inhibiting PI-3 kinase. In contrast, another fungal inhibitor, rapamycin, inhibits the p70 α S6 kinase by another cascade pathway involving the mammalian target of rapamycin (mTOR; also known as RAFT or FRAP) (Proud, 1996; Stewart *et al.*, 1994 BioEssays 16: 809-815). mTOR is a member of the PIK-related family of protein kinases (Pullen *et al.*, 1997).

Additional regulators of the p70 α S6 kinase include, but are not limited to protein kinase B (PKB), Cdc42, and Rac. The role of most of these proteins as p70 α S6 kinase regulators has yet to be fully elucidated.

5

SUMMARY OF THE INVENTION

The present invention is based on our discovery of a new gene which encodes a novel S6 kinase (p70 β ^{S6k}). The invention includes isolated nucleic acid molecules selected from the group consisting of an isolated nucleic acid molecule that encodes the
10 amino acid sequence of SEQ ID No.2, (*e.g.*, SEQ ID No.1) an isolated nucleic acid molecule that encodes a fragment of SEQ ID No.2, an isolated nucleic acid molecule which hybridizes to the complement of a nucleic acid molecule comprising SEQ ID No.1 under conditions of sufficient stringency to produce a clear signal and an isolated nucleic acid molecule which hybridizes to the complement of a nucleic acid molecule
15 that encodes the amino acid sequence of SEQ ID No.2 under conditions of sufficient stringency to produce a clear signal.

The present invention further includes the nucleic acid molecules operably linked to one or more expression control elements, including vectors comprising the isolated nucleic acid molecules. The invention further includes host cells transformed
20 to contain the nucleic acid molecules of the invention and methods for producing a protein comprising the step of culturing a host cell transformed with the nucleic acid molecule of the invention under conditions in which the protein is expressed.

The invention further provides an isolated polypeptide selected from the group consisting of an isolated polypeptide comprising the amino acid sequence of SEQ ID
25 No.2, an isolated polypeptide comprising a fragment of SEQ ID No.2, an isolated polypeptide comprising conservative amino acid substitutions of SEQ ID No.2 and naturally occurring amino acid sequence variants of SEQ ID No.2.

The invention further provides an isolated antibody that binds to a polypeptide of the invention, including monoclonal and polyclonal antibodies and fragments

thereof.

The invention further provides methods of identifying an agent which modulates the expression of a nucleic acid encoding the protein having the sequence of SEQ ID No.2 comprising the steps of: exposing cells which express the nucleic acid to
5 the agent; and determining whether the agent modulates expression of said nucleic acid, thereby identifying an agent which modulates the expression of a nucleic acid encoding the protein having the sequence of SEQ ID No.2.

The invention further provides methods of identifying an agent which modulates at least one activity of a protein comprising the sequence of SEQ ID No.2
10 comprising the steps of: exposing cells which express the protein to the agent; and determining whether the agent modulates at least one activity of said protein, thereby identifying an agent which modulates at least one activity of a protein comprising the sequence of SEQ ID No.2.

The invention further provides methods of identifying binding partners for a
15 protein comprising the sequence of SEQ ID No.2 or activated variants thereof, comprising for example, the steps of: exposing said protein to a potential binding partner; and determining if the potential binding partner binds to said protein, thereby identifying binding partners for a protein comprising the sequence of SEQ ID No.2. Exposing may be accomplished by expressing the protein in a cell.

20 The present invention further provides methods of modulating the expression of a nucleic acid encoding the protein having the sequence of SEQ ID No.2 comprising the step of: administering an effective amount of an agent which modulates the expression of a nucleic acid encoding the protein having the sequence of SEQ ID No.2. The invention also provides methods of modulating at least one activity of a protein
25 comprising the sequence of SEQ ID No.2 comprising the step of: administering an effective amount of an agent which modulates at least one activity of a protein comprising the sequence of SEQ ID No.2.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1. Nucleic acid sequence of p70 β^{S6k} (SEQ ID No.1) and comparison with p70 α^{S6k} (SEQ ID No. 3). Sequence analysis of cDNA encoding the p70 β S6 kinase. p70 β cDNA may encode two isoforms with the use of alternative start codon. The longer form may encode a protein of 495 amino acid residues and the shorter form, 5 482 amino acids (aa). Alternative start codons and a stop codon are highlighted.

Figure 2A-2B. Amino Acid Sequence of p70 β^{S6k} (SEQ ID No.2) and comparison with p70 α^{S6k} (SEQ ID No. 4).

Figure 2A. Alignment of predicted protein sequences corresponding to the 10 p70 α^{S6k} and p70 β S6 kinases. Identical amino acids are boxed.

Figure 2B. Comparative analysis of regulatory domains and phosphorylation sites between p70 α and β S6 kinases.

Figure 3A - 3B. Tissue Specific Expression of p70 β^{S6k} . Northern blot analysis 15 of poly(A)+ RNA from human tissues (Figure 3A) and tumor cell lines (Figure 3B).

Figure 3A. Nylon membrane containing 2 μ g of gel-separated, pre-bound poly(A)+ RNA samples from various human tissues was hybridized with cDNA fragments of p70 α^{S6k} , p70 β^{S6k} or β -actin labeled by random priming. The upper, middle and lower panels are autoradiographs probed with p70 β^{S6k} , p70 α^{S6k} and β -actin, 20 respectively. Each lane contains mRNA prepared from: heart (lane 1), brain (lane 2), placenta (lane 3), lung (lane 4), liver (lane 5), skeletal muscle (lane 6), kidney (lane 7), pancreas (lane 8), spleen (lane 9), thymus (lane 10), prostate (lane 11), testis (lane 12), ovary (lane 13), small intestine (lane 14), mucosal lining of the colon (lane 15), and peripheral blood leukocytes (lane 16).

25 Figure 3B. Nylon membrane containing 2 μ g of mRNA isolated from tumor cell lines was probed with the 3' cDNA fragment from p70 β^{S6k} , which was labeled by random-prime labeling. Specific binding was determined by autoradiography. Promyelocytic leukemia HL-60 (lane 1), HeLa cell S3 (lane 2, chronic myelogenous leukemia K562 (lane 3), lymphoblastic leukemia MOLT-4 (lane 4), Burkitt's

lymphoma Raji (lane 5), colorectal adenocarcinoma SW480 (lane 6), lung carcinoma (lane 7), and melanoma G361 (lane 8).

Figure 4A - 4B. Phosphorylation of the ribosomal protein S6 (Figure 4A) and its C-terminal synthetic peptide (Figure 4B) by p70 α^{S6k} and p70 β^{S6k} . Ribosomal S6 protein (purified ribosomal 40S subunits from liver) and synthetic peptides corresponding to the S6 protein C-terminus (*e.g.*, KEAKEKRQEIQIARRRLSSLRASTSKSESSQK-long form (SEQ ID No. 5) and RRLSSLRASTSKSESSQK-(SEQ ID No. 6) short form) were used to measure the activity of the p70 α^{S6k} and p70 β^{S6k} . HEK293 cells were transfected with plasmids containing Flag-tag or EE-tag versions of p70 α^{S6k} or p70 β^{S6k} . Recombinant proteins were immunoprecipitated with anti-EE or anti-Flag antibodies and an *in vitro* kinase reaction performed in the presence of the ribosomal 40S subunits or synthetic peptides. After SDS-PAGE analysis, phosphorylation of the S6 protein and synthetic peptides was measured by PhosphoImager and expressed in arbitrary units (PI units).

Figure 5A - 5B. Stimulation of p70 β^{S6k} Activity by insulin, serum and TPA. Figure 5A. CHO-IR cells were transfected with mock (lane1) or plasmids containing cDNAs of FLAG-tagged p70 α -I (lanes 2 and 3) or FLAG-tagged p70 β -II (lanes 4 to 7). After serum starvation for 16 hrs, cells were treated with the vehicle (lanes 2 and 4), 10⁻⁷ M insulin for 10 min (lanes 3 and 5), 15% serum for 10 min (lane 6) or 500 nM TPA for 30 min (lane7). After cell lysis and subsequent immunoprecipitation with anti-FLAG antibodies, immunoprecipitates were subjected to a p70 S6 kinase assay using 40S subunits as substrates. The reaction mixture was separated by SDS-PAGE, transferred onto PVDF membrane. The membrane was analyzed by autoradiography (upper panel) and then immunoblotted with anti-FLAG antibodies (lower panel). A representative of three experiments is shown. ³²P incorporation into S6 was quantified by Molecular Dynamics PhosphorImager™ and is expressed in arbitrary units (PI units).

Figure 5B. Stimulation of the p70 α^{S6k} and p70 β^{S6k} activity towards ribosomal S6 protein by PDGF in PAE-PDGF-R cells. PAE-PDGF-R cells were transfected with EE-tagged p70 α^{S6k} and p70 β^{S6k} plasmids using lipofectAMINE. After 24 hr, transfected cells were serum-starved for 16 hr and stimulated with 20 ng/ml PDGF BB (Calbiochem) for 20 min. Control cells were treated with the vehicle under the same conditions. After immunoprecipitation with anti-EE antibodies, an *in vitro* kinase reaction was carried out in the presence of 40S subunits, containing the S6 protein. Reaction mixtures were separated by SDS-PAGE and incorporation of ^{32}P into S6 protein was measured by PhosphorImager.

10

Figure 6A - 6B. Effects of rapamycin and wortmannin on p70 β^{S6k} and p70 α^{S6k} . Effects of rapamycin and wortmannin on S6 phosphorylation activity of p70 α -I or p70 β -II. HEK293 cells were transfected with mock cDNA or plasmids containing FLAG-tagged p70 α 1 or p70 β 2 isoforms. After 48 h of transfection, cells were treated with vehicle or indicated concentrations of rapamycin or wortmannin for 30 min. After immunoprecipitation with anti-FLAG antibodies, the kinase activity was determined by a p70 S6 kinase assay using 40S subunits as substrates. The proteins of the reaction mixture were separated by SDS-PAGE, transferred onto PVDF membrane and analyzed by autoradiography (Figures 6A and 6B, upper panels). Subsequent immunoblotting with anti-FLAG antibody confirmed the expression of p70 α -I (Figure 6A, lower panel) and p70 β -II (Figure 6B, lower panel). A representative of three experiments is shown. ^{32}P incorporation into S6 was quantified by PhosphorImager and is expressed in arbitrary units (PI units).

20

Figure 7. Interaction of the p70 β^{S6k} with different GST/SH3 fusion proteins. HEK293 cells were transiently transfected with EE-tag/p70 β^{S6k} . Two days later, cells were lysed and the lysates were immunoprecipitated with anti-EE antibodies. GST/SH3 fusion proteins (1.5 μg each) were incubated with anti-EE tag immunoprecipitates. Specific interaction with p70 β^{S6k} was measured by anti-GST

25

immunoblotting. SH3 domains from different signaling and cytoskeletal proteins were expressed in bacteria as GST fusion proteins and purified nearly to homogeneity using glutathione-Sepharose beads. The GST/SH3 fusion proteins used are: GST (lane 1), p80 α subunit of the PI3-kinase (lane 2), GAP (lane 3), PLC γ (lane 4), spectrin (lane 5), crk (lane 6), n-grb2 (lane 7), c-grb2 (lane 8), grb2 full (lane 9), csk (lane 10), fgr (lane 11), fyn (lane 12), src (lane 13), ruk a (lane 14), ruk b (lane 15), ruk c (lane 16), p15 (lane 17), profilin (lane 18) and GST/GAP control (lane 19). "+" indicates instances of binding between p70 β^{S6k} and a SH3 containing fusion protein.

Figure 8. Immunoprecipitation and Western blot analysis of the p70 β -I and p70 β -II isoforms transiently over expressed in HEK293 cells with anti-p70 β^{S6k} antibodies. The lanes are the same for each panel: mock transfected (lane 1), Flag-p70 α -I transfected (lane 2), Flag-p70 β -I transfected (lane 3), and Flag-p70 β -II transfected (lane 4).

Figure 9. A model for the activation of p70 β^{S6k} Kinase. Schematic presentation of the p70 α^{S6k} structure, protein-protein interactions, activation levels and phosphorylation state.

Figure 10. p70 β^{S6k} mutations. Schematic presentation of substitution mutations engineered into p70 β^{S6k} , including a change of Threonine at amino acid 401 to Aspartic acid (T401D).

Figure 11. p70 β^{S6k} (T401D) activity. Activity of p70 β^{S6k} (T401D) variant as compared to wt p70 β^{S6k} under S6 Kinase and autophosphorylation assays.

Figure 12: p70 α^{S6k} (T412D) activity. Activity of p70 α^{S6k} (T412D) variant as compared to wt p70 α^{S6k} under S6 Kinase and autophosphorylation assays.

5 **DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT**

The terms "p70 α ", "p70 α^{S6k} " and "p70 α^{S6} kinase" are meant to include the two isoforms, p70 and p85, both of which phosphorylate the ribosomal protein S6. By "p70 α -1" and "p70 α -I" are meant the p85 isoform of the p70 α^{S6} kinase. By "p70 α -2" and "p70 α -II" are meant the p70 isoform of the p70 α^{S6} kinase.

10 The terms "p70 β ", "p70 β^{S6k} " and "p70 β^{S6} kinase" include the newly identified S6 kinase and all its isoforms.

I. General Description

The present invention is based in part on identifying a new gene that encodes a
15 novel S6 kinase (p70 β^{S6k}). This new gene and the protein that it encodes are members of the family of S6 kinases, of which the p70 α -I and -II (also referred to as p70 α -1 and p70 α -2) isoforms have already been reported.

The protein can serve as a target for agents that can be used to modulate the expression or activity of the protein. For example, agents may be identified which
20 modulate biological processes associated with ribosomal activity.

The present invention is further based on the development of methods for isolating binding partners that bind to the protein or its activated variants. Probes based on the protein are used as capture probes to isolate potential binding partners, such as other proteins. Dominant negative proteins, DNAs encoding these proteins, antibodies
25 to these proteins, peptide fragments of these proteins or mimics of these proteins may be introduced into cells to affect function. Additionally, these proteins provide a novel target for screening of synthetic small molecules and combinatorial or naturally occurring compound libraries to discover novel therapeutics to regulate ribosomal function.

II. Specific Embodiments

A. The Ribosome Associated Protein

The present invention provides isolated protein, allelic variants of the protein, and conservative amino acid substitutions of the protein, including substitutions that
5 activate the protein. As used herein, the protein or polypeptide refers to a protein that has the human amino acid sequence of depicted in SEQ ID No.2. The invention includes naturally occurring allelic variants and proteins that have a slightly different amino acid sequence than that specifically recited above. Allelic variants, though possessing a slightly different amino acid sequence than those recited above, will still
10 have the same or similar biological functions associated with the disclosed protein.

As used herein, the family of proteins related to the disclosed protein refer to proteins that have been isolated from organisms in addition to humans. The methods used to identify and isolate other members of the family of proteins related to the disclosed protein are described below.

15 The proteins of the present invention are preferably in isolated form. As used herein, a protein is said to be isolated when physical, mechanical or chemical methods are employed to remove the protein from cellular constituents that are normally associated with the protein. A skilled artisan can readily employ standard purification methods to obtain an isolated protein.

20 The proteins of the present invention further include conservative variants of the proteins herein described. As used herein, a conservative variant refers to alterations in the amino acid sequence that do not adversely affect the biological functions of the protein. A substitution, insertion or deletion is said to adversely affect the protein when the altered sequence prevents or disrupts a biological function associated with the
25 protein. For example, the overall charge, structure or hydrophobic/hydrophilic properties of the protein can be altered without adversely affecting a biological activity. Accordingly, the amino acid sequence can be altered, for example to render the peptide more hydrophobic or hydrophilic, without adversely affecting the biological activities of the protein. Conservative substitutions may irreversibly activate the protein.

Ordinarily, the allelic variants, the conservative substitution variants, the members of the protein family, will have an amino acid sequence having at least 71%-about 75% amino acid sequence identity with the human sequence set forth in SEQ ID No.2, more preferably at least 80%, even more preferably at least 90%, and most
5 preferably at least 95%. Identity or homology with respect to such sequences is defined herein as the percentage of amino acid residues in the candidate sequence that are identical with the known peptides, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent homology, and not considering any conservative substitutions as part of the sequence identity. N-terminal, C-terminal or
10 internal extensions, deletions, or insertions into the peptide sequence shall not be construed as affecting homology.

Homology or identity is determined by **BLAST** (Basic Local Alignment Search Tool) analysis using the algorithm employed by the programs **blastp**, **blastn**, **blastx**, **tblastn** and **tblastx** (Karlin , et al. Proc. Natl. Acad. Sci. USA 87: 2264-2268
15 (1990) and Altschul, S. F. J. Mol. Evol. 36: 290-300(1993), fully incorporated by reference) which are tailored for sequence similarity searching. The approach used by the **BLAST** program is to first consider similar segments between a query sequence and a database sequence, then to evaluate the statistical significance of all matches that are identified and finally to summarize only those matches which satisfy a preselected
20 threshold of significance. For a discussion of basic issues in similarity searching of sequence databases, see Altschul et al. (Nature Genetics 6: 119-129 (1994)) which is fully incorporated by reference. The search parameters for **histogram**, **descriptions**, **alignments**, **expect** (i.e., the statistical significance threshold for reporting matches against database sequences), **cutoff**, **matrix** and **filter** are at the default settings. The
25 default scoring matrix used by **blastp**, **blastx**, **tblastn**, and **tblastx** is the **BLOSUM62** matrix (Henikoff, et al. Proc. Natl. Acad. Sci. USA 89: 10915-10919 (1992), fully incorporated by reference). For **blastn**, the scoring matrix is set by the ratios of **M** (i.e., the reward score for a pair of matching residues) to **N** USA 87: 2264-2268 (1990) and (i.e., the penalty score for mismatching residues), wherein the default values for **M** and

N are 5 and -4, respectively.

Thus, the proteins of the present invention include molecules having the amino acid sequence disclosed in SEQ ID No.2; fragments thereof having a consecutive sequence of at least about 3, 5, 10 or 15 amino acid residues of the disclosed protein; amino acid sequence variants of such sequence wherein an amino acid residue has been inserted N- or C-terminal to, or within, the disclosed sequence; amino acid sequence variants of the disclosed sequence, or their fragments as defined above, that have been substituted by another residue. Contemplated variants further include those containing predetermined mutations by, *e.g.*, homologous recombination, site-directed or PCR mutagenesis, and the corresponding proteins of other animal species, including but not limited to rabbit, rat, murine, porcine, bovine, ovine, equine and non-human primate species, and the alleles or other naturally occurring variants of the family of proteins; and derivatives wherein the protein has been covalently modified by substitution, chemical, enzymatic, or other appropriate means with a moiety other than a naturally occurring amino acid (for example a detectable moiety such as an enzyme or radioisotope). Proteins of the invention may include fusion proteins comprising any of the foregoing.

As described below, members of the family of proteins can be used: 1) to identify agents which modulate at least one activity of the protein, including agents which may modulate phosphorylation mediated by the protein; 2) in methods of identifying binding partners for the protein, 3) as an antigen to raise polyclonal or monoclonal antibodies, and 4) as a therapeutic agent.

B. Nucleic Acid Molecules

The present invention further provides nucleic acid molecules that encode the protein having SEQ ID No.2 and the related proteins herein described, preferably in isolated form. As used herein, "nucleic acid" is defined as RNA or DNA that encodes a peptide as defined above, or is complementary to nucleic acid sequence encoding such peptides, or hybridizes to such nucleic acid and remains stably bound to it under

appropriate stringency conditions, or encodes a polypeptide sharing at least 75% sequence identity, preferably at least 80%, and more preferably at least 85%, with the peptide sequences. Specifically contemplated are genomic DNA, cDNA, mRNA and antisense molecules, as well as nucleic acids based on alternative backbone or including
5 alternative bases whether derived from natural sources or synthesized. Such hybridizing or complementary nucleic acids, however, are defined further as being novel and nonobvious over any prior art nucleic acid including that which encodes, hybridizes under appropriate stringency conditions, or is complementary to nucleic acid encoding a protein according to the present invention.

10 "Stringent conditions" are those that (1) employ low ionic strength and high temperature for washing, for example, 0.015 M NaCl, 0.0015 M sodium titrate, 0.1% SDS at 50°C; or (2) employ during hybridization a denaturing agent such as formamide, for example, 50% (vol/vol) formamide with 0.1% bovine serum albumin, 0.1% Ficoll, 0.1% polyvinylpyrrolidone, 50 mM sodium phosphate buffer at pH 6.5
15 with 750 mM NaCl, 75 mM sodium citrate at 42°C. Another example is use of 50% formamide, 5X SSC (0.75 M NaCl, 0.075 M sodium citrate), 50 mM sodium phosphate (pH 6.8), 0.1% sodium pyrophosphate, 5X Denhardt's solution, sonicated salmon sperm DNA (50 µg/ml), 0.1% SDS, and 10% dextran sulfate at 42°C, with washes at 42°C in 0.2X SSC and 0.1% SDS. A skilled artisan can readily determine and vary the
20 stringency conditions appropriately to obtain a clear and detectable hybridization signal.

As used herein, a nucleic acid molecule is said to be "isolated" when the nucleic acid molecule is substantially separated from contaminant nucleic acid encoding other polypeptides from the source of nucleic acid.

25 The present invention further provides fragments of the encoding nucleic acid molecule. As used herein, a fragment of an encoding nucleic acid molecule refers to a small portion of the entire protein encoding sequence. The size of the fragment will be determined by the intended use. For example, if the fragment is chosen so as to encode an active portion of the protein, the fragment will need to be large enough to encode the

functional region(s) of the protein. If the fragment is to be used as a nucleic acid probe or PCR primer, then the fragment length is chosen so as to obtain a relatively small number of false positives during probing/priming.

Fragments of the encoding nucleic acid molecules of the present invention (i.e.,
5 synthetic oligonucleotides) that are used as probes or specific primers for the polymerase chain reaction (PCR), or to synthesize gene sequences encoding proteins of the invention can easily be synthesized by chemical techniques, for example, the phosphotriester method of Matteucci, *et al.*, (J. Am. Chem. Soc. 103: 3185-3191, 1981) or using automated
10 synthesis methods. In addition, larger DNA segments can readily be prepared by well known methods, such as synthesis of a group of oligonucleotides that define various modular segments of the gene, followed by ligation of oligonucleotides to build the complete modified gene.

The encoding nucleic acid molecules of the present invention may further be modified so as to contain a detectable label for diagnostic and probe purposes. A
15 variety of such labels are known in the art and can readily be employed with the encoding molecules herein described. Suitable labels include, but are not limited to, biotin, radiolabeled nucleotides and the like. A skilled artisan can employ any of the art known labels to obtain a labeled encoding nucleic acid molecule.

Modifications to the primary structure itself by deletion, addition, or alteration of
20 the amino acids incorporated into the protein sequence during translation can be made without destroying the activity of the protein. Such substitutions or other alterations result in proteins having an amino acid sequence encoded by a nucleic acid falling within the contemplated scope of the present invention.

25 C. Isolation of Other Related Nucleic Acid Molecules

As described above, the identification of the human nucleic acid molecule having SEQ ID No.1 allows a skilled artisan to isolate nucleic acid molecules that encode other members of the p70 β^{S6k} family in addition to the human sequence herein described. Further, the presently disclosed nucleic acid molecules allow a skilled artisan to isolate

nucleic acid molecules that encode other members of the p70 β^{S6k} family of proteins in addition to the disclosed protein having SEQ ID No.2.

Essentially, a skilled artisan can readily use the amino acid sequence of SEQ ID No.2 to generate antibody probes to screen expression libraries prepared from
5 appropriate cells. Typically, polyclonal antiserum from mammals such as rabbits immunized with the purified protein (as described below) or monoclonal antibodies can be used to probe a mammalian cDNA or genomic expression library, such as λ gt11 library, to obtain the appropriate coding sequence for other members of the protein family. The cloned cDNA sequence can be expressed as a fusion protein, expressed directly using its
10 own control sequences, or expressed by constructions using control sequences appropriate to the particular host used for expression of the enzyme.

Alternatively, a portion of the coding sequence herein described can be synthesized and used as a probe to retrieve DNA encoding a member of the protein family from any mammalian organism. Oligomers containing approximately 18-20 or 21 nucleotides
15 (encoding about a 6-7 amino acid stretch) are prepared and used to screen genomic DNA or cDNA libraries to obtain hybridization under stringent conditions or conditions of sufficient stringency to eliminate an undue level of false positives.

Additionally, pairs of oligonucleotide primers can be prepared for use in a polymerase chain reaction (PCR) to selectively clone an encoding nucleic acid molecule.
20 A PCR denature/anneal/extend cycle for using such PCR primers is well known in the art and can readily be adapted for use in isolating other encoding nucleic acid molecules.

D. rDNA molecules Containing a Nucleic Acid Molecule

The present invention further provides recombinant DNA molecules (rDNAs) that
25 contain a coding sequence. As used herein, a rDNA molecule is a DNA molecule that has been subjected to molecular manipulation *in situ*. Methods for generating rDNA molecules are well known in the art, for example, see Sambrook *et al.*, (1989). In the preferred rDNA molecules, a coding DNA sequence is operably linked to expression control sequences and/or vector sequences.

The choice of vector and/or expression control sequences to which one of the protein family encoding sequences of the present invention is operably linked depends directly, as is well known in the art, on the functional properties desired, e.g., protein expression, and the host cell to be transformed. A vector contemplated by the present invention is at least capable of directing the replication or insertion into the host chromosome, and preferably also expression, of the structural gene included in the rDNA molecule.

Expression control elements that are used for regulating the expression of an operably linked protein encoding sequence are known in the art and include, but are not limited to, inducible promoters, constitutive promoters, secretion signals, and other regulatory elements. Preferably, the inducible promoter is readily controlled, such as being responsive to a nutrient in the host cell's medium.

In one embodiment, the vector containing a coding nucleic acid molecule will include a prokaryotic replicon, *i.e.*, a DNA sequence having the ability to direct autonomous replication and maintenance of the recombinant DNA molecule extrachromosomally in a prokaryotic host cell, such as a bacterial host cell, transformed therewith. Such replicons are well known in the art. In addition, vectors that include a prokaryotic replicon may also include a gene whose expression confers a detectable marker such as a drug resistance. Typical bacterial drug resistance genes are those that confer resistance to ampicillin or tetracycline.

Vectors that include a prokaryotic replicon can further include a prokaryotic or bacteriophage promoter capable of directing the expression (transcription and translation) of the coding gene sequences in a bacterial host cell, such as *E. coli*. A promoter is an expression control element formed by a DNA sequence that permits binding of RNA polymerase and transcription to occur. Promoter sequences compatible with bacterial hosts are typically provided in plasmid vectors containing convenient restriction sites for insertion of a DNA segment of the present invention. Typical of such vector plasmids are pUC8, pUC9, pBR322 and pBR329 available from Biorad Laboratories, (Richmond, CA), pPL and pKK223 available from Pharmacia, Piscataway, N.J.

Expression vectors compatible with eukaryotic cells, preferably those compatible with vertebrate cells, can also be used to form a rDNA molecules the contains a coding sequence. Eukaryotic cell expression vectors are well known in the art and are available from several commercial sources. Typically, such vectors are provided containing
5 convenient restriction sites for insertion of the desired DNA segment. Typical of such vectors are pSVL and pKSV-10 (Pharmacia), pBPV-1/pML2d (International Biotechnologies, Inc.), pTDT1 (ATCC, #31255), the vector pCDM8 described herein, and the like eukaryotic expression vectors.

Eukaryotic cell expression vectors used to construct the rDNA molecules of the
10 present invention may further include a selectable marker that is effective in an eukaryotic cell, preferably a drug resistance selection marker. A preferred drug resistance marker is the gene whose expression results in neomycin resistance, *i.e.*, the neomycin phosphotransferase (*neo*) gene (Southern *et al.*, J. Mol. Anal. Genet 1: 327-341, 1982). Alternatively, the selectable marker can be present on a separate plasmid, and the two
15 vectors are introduced by co-transfection of the host cell, and selected by culturing in the appropriate drug for the selectable marker.

E. Host Cells Containing an Exogenously Supplied Coding Nucleic Acid Molecule

20 The present invention further provides host cells transformed with a nucleic acid molecule that encodes a protein of the present invention. The host cell can be either prokaryotic or eukaryotic. Eukaryotic cells useful for expression of a protein of the invention are not limited, so long as the cell line is compatible with cell culture methods and compatible with the propagation of the expression vector and expression of the gene
25 product. Preferred eukaryotic host cells include, but are not limited to, yeast, insect and mammalian cells, preferably vertebrate cells such as those from a mouse, rat, monkey or human cell line. Preferred eukaryotic host cells include Chinese hamster ovary (CHO) cells available from the ATCC as CCL61, NIH Swiss mouse embryo cells NIH/3T3 available from the ATCC as CRL 1658, baby hamster kidney cells (BHK), and the like eukaryotic

tissue culture cell lines.

Any prokaryotic host can be used to express a rDNA molecule encoding a protein of the invention. The preferred prokaryotic host is *E. coli*.

Transformation of appropriate cell hosts with a rDNA molecule of the present invention is accomplished by well known methods that typically depend on the type of vector used and host system employed. With regard to transformation of prokaryotic host cells, electroporation and salt treatment methods are typically employed, see, for example, Cohen *et al.*, Proc. Natl. Acad. Sci. USA 69: 2110, 1972; and Maniatis *et al.*, MOLECULAR CLONING, A LABORATORY MANUAL, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY (1982). With regard to transformation of vertebrate cells with vectors containing rDNAs, electroporation, cationic lipid or salt treatment methods are typically employed, see, for example, Graham *et al.*, Virology 52: 456, 1973; Wigler *et al.*, Proc. Natl. Acad. Sci. USA 76: 1373-76, 1979.

Successfully transformed cells, i.e., cells that contain a rDNA molecule of the present invention, can be identified by well known techniques including the selection for a selectable marker. For example, cells resulting from the introduction of an rDNA of the present invention can be cloned to produce single colonies. Cells from those colonies can be harvested, lysed and their DNA content examined for the presence of the rDNA using a method such as that described by Southern, J. Mol. Biol. 98:503, 1975, or Berent *et al.*, Biotech. 3: 208, 1985 or the proteins produced from the cell assayed via an immunological method.

Recombinant p70 β^{S6k} DNA can also be utilized to analyze the function of coding and non-coding sequences. For example, the 5' untranslated region of the p70 β^{S6k} clone contains a GA repeat (nucleotides 1-66 of P70 β^{S6k}), that may modulate the initiation of translation of its mRNA. This sequence can be utilized in an affinity matrix system to purify proteins obtained from cell lysates that associate with the p70 β^{S6k} GA sequence. Synthetic oligonucleotides would be coupled to the beads and probed with the lysates, as is commonly known in the art. Associated proteins could then be separated using, for example, a two dimensional SDS-PAGE system. Proteins thus isolated could be further

identified using mass spectroscopy or protein sequencing.

F. Production of Recombinant Proteins using a rDNA Molecule

The present invention further provides methods for producing a protein of the
5 invention using nucleic acid molecules herein described. In general terms, the production of a recombinant form of a protein typically involves the following steps:

First, a nucleic acid molecule is obtained that encodes a protein of the invention, such as the nucleic acid molecule depicted in SEQ ID No. 1, or particularly for the $p70\beta^{S6k}$ nucleotides encoding the proline rich domain or the amino terminus of $p70\beta^{S6k}$. The
10 coding sequence is directly suitable for expression in any host, as it is not interrupted by introns. The sequence can be transfected into host cells such as eukaryotic cells or prokaryotic cells. Eukaryotic hosts include mammalian cells (*e.g.*, HEK293 cells, CHO cells and PAE-PDGF-R cells) as well as insect cells such as Sf9 cells using recombinant baculovirus. Alternatively, fragments encoding only portion of $p70\beta^{S6k}$ can be expressed
15 alone or in the form of a fusion protein. For example, the C-terminal fragment of $p70\beta^{S6k}$ containing the proline-rich domain, was expressed in bacteria as a GST- or His-tag fusion protein. These fusion proteins were then purified and used to generate polyclonal antibodies.

The nucleic acid molecule is then preferably placed in operable linkage with
20 suitable control sequences, as described above, to form an expression unit containing the protein open reading frame. The expression unit is used to transform a suitable host and the transformed host is cultured under conditions that allow the production of the recombinant protein. Optionally the recombinant protein is isolated from the medium or from the cells; recovery and purification of the protein may not be necessary in some instances where some
25 impurities may be tolerated.

Each of the foregoing steps can be done in a variety of ways. For example, the desired coding sequences may be obtained from genomic fragments and used directly in appropriate hosts. The construction of expression vectors that are operable in a variety of hosts is accomplished using appropriate replicons and control sequences, as set forth above.

The control sequences, expression vectors, and transformation methods are dependent on the type of host cell used to express the gene and were discussed in detail earlier. Suitable restriction sites can, if not normally available, be added to the ends of the coding sequence so as to provide an excisable gene to insert into these vectors. A skilled artisan can readily
5 adapt any host/expression system known in the art for use with the nucleic acid molecules of the invention to produce recombinant protein.

G. In Vitro Methods to Identify Binding Partners

Another embodiment of the present invention provides methods for use in
10 isolating and identifying binding partners of proteins of the invention. In detail, a protein of the invention is mixed with a potential binding partner or an extract or fraction of a cell under conditions that allow the association of potential binding partners with the protein of the invention. After mixing, peptides, polypeptides, proteins or other molecules that have become associated with a protein of the invention
15 are separated from the mixture. The binding partner that bound to the protein of the invention can then be removed and further analyzed. To identify and isolate a binding partner, the entire protein, for instance the entire disclosed protein of SEQ ID No.2 can be used. Alternatively, a fragment of the protein can be used.

As used herein, a cellular extract refers to a preparation or fraction which is
20 made from a lysed or disrupted cell.

A variety of methods can be used to obtain cell extracts. Cells can be disrupted using either physical or chemical disruption methods. Examples of physical disruption methods include, but are not limited to, sonication and mechanical shearing. Examples of chemical lysis methods include, but are not limited to, detergent lysis and enzyme
25 lysis. A skilled artisan can readily adapt methods for preparing cellular extracts in order to obtain extracts for use in the present methods.

Once an extract of a cell is prepared, the extract is mixed with the protein of the invention under conditions in which association of the protein with the binding partner can occur. A variety of conditions can be used, the most preferred being conditions that

closely resemble conditions found in the cytoplasm of a human cell. Features such as osmolarity, pH, temperature, and the concentration of cellular extract used, can be varied to optimize the association of the protein with the binding partner.

After mixing under appropriate conditions, the bound complex is separated from the mixture. A variety of techniques can be utilized to separate the mixture. For example, antibodies specific to a protein of the invention can be used to immunoprecipitate the binding partner complex. Alternatively, standard chemical separation techniques such as chromatography and density/sediment centrifugation can be used.

After removal of non-associated cellular constituents found in the extract, the binding partner can be dissociated from the complex using conventional methods. For example, dissociation can be accomplished by altering the salt concentration or pH of the mixture.

To aid in separating associated binding partner pairs from the mixed extract, the protein of the invention can be immobilized on a solid support. For example, the protein can be attached to a nitrocellulose matrix or acrylic beads. Attachment of the protein to a solid support aids in separating peptide/binding partner pairs from other constituents found in the extract. The identified binding partners can be either a single protein or a complex made up of two or more proteins.

Alternatively, the nucleic acid molecules of the invention can be used in a yeast two-hybrid system. The yeast two-hybrid system has been used to identify other protein partner pairs and can readily be adapted to employ the nucleic acid molecules herein described.

One preferred *in vitro* binding assay for p70 β^{S6k} would comprise a mixture of a polypeptide comprising at least the kinase domain of p70 β^{S6k} and one or more candidate binding targets or substrates. After incubating the mixture under appropriate conditions, one would determine whether p70 β^{S6k} or a polypeptide fragment thereof containing the kinase region either bound with the candidate substrate or phosphorylated the candidate substrate. For cell-free binding assays, one of the

components usually comprises or is coupled to a label. The label may provide for direct detection, such as radioactivity, luminescence, optical or electron density, *etc.*, or indirect detection such as an epitope tag, an enzyme, *etc.* A variety of methods may be employed to detect the label depending on the nature of the label and other assay components. For example, the label may be detected bound to the solid substrate or a portion of the bound complex containing the label may be separated from the solid substrate, and the label thereafter detected.

H. Methods to Identify Agents that Modulate the Expression a Nucleic Acid Encoding the S6 Kinase Protein.

Another embodiment of the present invention provides methods for identifying agents that modulate the expression of a nucleic acid encoding a protein of the invention such as a protein having the amino acid sequence of SEQ ID No.2. Such assays may utilize any available means of monitoring for changes in the expression level of the nucleic acids of the invention. As used herein, an agent is said to modulate the expression of a nucleic acid of the invention, for instance a nucleic acid encoding the protein having the sequence of SEQ ID No.2, if it is capable of up- or down-regulating expression of the nucleic acid in a cell.

In one assay format, cell lines that contain reporter gene fusions between the open reading frame defined by p70 β^{S6k} nucleotides 77-1,564 or 116-1,564 of SEQ ID No.1 and any assayable fusion partner may be prepared. Numerous assayable fusion partners are known and readily available including the firefly luciferase gene and the gene encoding chloramphenicol acetyltransferase (Alam *et al.*, 1990 Anal. Biochem. 188: 245-254). Cell lines containing the reporter gene fusions are then exposed to the agent to be tested under appropriate conditions and time. Differential expression of the reporter gene between samples exposed to the agent and control samples identifies agents which modulate the expression of a nucleic acid encoding the protein having the sequence of SEQ ID No.2.

Additional assay formats may be used to monitor the ability of the agent to

modulate the expression of a nucleic acid encoding a protein of the invention such as the protein having SEQ ID No.2. For instance, mRNA expression may be monitored directly by hybridization to the nucleic acids of the invention. Cell lines are exposed to the agent to be tested under appropriate conditions and time and total RNA or mRNA is
5 isolated by standard procedures such those disclosed in Sambrook *et al.* (MOLECULAR CLONING: A LABORATORY MANUAL, 2nd Ed. Cold Spring Harbor Laboratory Press, 1989).

Probes to detect differences in RNA expression levels between cells exposed to the agent and control cells may be prepared from the nucleic acids of the invention. It
10 is preferable, but not necessary, to design probes which hybridize only with target nucleic acids under conditions of high stringency. Only highly complementary nucleic acid hybrids form under conditions of high stringency. Accordingly, the stringency of the assay conditions determines the amount of complementarity which should exist between two nucleic acid strands in order to form a hybrid. Stringency should be
15 chosen to maximize the difference in stability between the probe:target hybrid and potential probe:non-target hybrids.

Probes may be designed from the nucleic acids of the invention through methods known in the art. For instance, the G+C content of the probe and the probe length can affect probe binding to its target sequence. Methods to optimize probe
20 specificity are commonly available in Sambrook *et al.* (1989) or Ausubel *et al.* (CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, Greene Publishing Co., NY, 1995).

Hybridization conditions are modified using known methods, such as those described by Sambrook *et al.* (1989) and Ausubel *et al.* (1995) as required for each probe. Hybridization of total cellular RNA or RNA enriched for polyA RNA can be
25 accomplished in any available format. For instance, total cellular RNA or RNA enriched for polyA RNA can be affixed to a solid support and the solid support exposed to at least one probe comprising at least one, or part of one of the sequences of the invention under conditions in which the probe will specifically hybridize. Alternatively, nucleic acid fragments comprising at least one, or part of one of the

sequences of the invention can be affixed to a solid support, such as a porous glass wafer. The glass wafer can then be exposed to total cellular RNA or polyA RNA from a sample under conditions in which the affixed sequences will specifically hybridize. Such glass wafers and hybridization methods are widely available, for example, those
5 disclosed by Beattie (WO 95/11755). By examining for the ability of a given probe to specifically hybridize to an RNA sample from an untreated cell population and from a cell population exposed to the agent, agents which up or down regulate the expression of a nucleic acid encoding the protein having the sequence of SEQ ID No.2 are identified.

10

I. Cell-Based Methods to Identify Binding Partners and Agents that Modulate at Least One Activity of the S6 Kinase Protein and Related Antibodies.

Another embodiment of the present invention provides methods for identifying agents that modulate at least one activity of a protein of the invention such as the
15 protein having the amino acid sequence of SEQ ID No.2. Such methods or assays may utilize any means of monitoring or detecting the desired activity.

In one format, the relative amounts of a protein of the invention between a cell population that has been exposed to the agent to be tested compared to an un-exposed control cell population may be assayed. In this format, probes such as specific
20 antibodies are used to monitor the differential expression of the protein in the different cell populations. Cell lines or populations are exposed to the agent to be tested under appropriate conditions and time. Cellular lysates may be prepared from the exposed cell line or population and a control, unexposed cell line or population. The cellular lysates are then analyzed with the probe.

25 For example, N- and C- terminal fragments of p70 β^{S6k} can be expressed in bacteria and used to search for proteins which bind to these fragments. Fusion proteins, such as His-tag or GST fusion to the N- or C-terminal regions of p70 β^{S6k} can be prepared for use as a p70 β^{S6k} fragment substrate. These fusion proteins can be coupled to Talon or Glutathione-Sepharose beads and then probed with cell lysates. Prior to

lysis, the cells may be treated with rapamycin or other drugs which may modulate p70 β^{S6k} or proteins that interact with p70 β^{S6k} . Lysate proteins binding to the fusion proteins can be resolved by SDS-PAGE, isolated and identified by protein sequencing or mass spectroscopy, as is known in the art. It is likely that signaling molecules
5 containing one or more SH3 domains may bind directly to the C-terminal region of p70 β^{S6k} . The N-terminal domain may have a p70 β^{S6k} -specific phosphatase as a binding partner.

Antibody probes are prepared by immunizing suitable mammalian hosts in appropriate immunization protocols using the peptides, polypeptides or proteins of the
10 invention, such as p70 β^{S6k} , variants and isolated binding partners, if they are of sufficient length, or, if desired, or if required to enhance immunogenicity, conjugated to suitable carriers. Methods for preparing immunogenic conjugates with carriers such as bovine serum albumin (BSA), keyhole limpet hemocyanin (KLH), or other carrier proteins are well known in the art. In some circumstances, direct conjugation using, for
15 example, carbodiimide reagents may be effective; in other instances linking reagents such as those supplied by Pierce Chemical Co., Rockford, IL, may be desirable to provide accessibility to the hapten. The hapten peptides can be extended at either the amino or carboxy terminus with a Cys residue or interspersed with cysteine residues, for example, to facilitate linking to a carrier. Administration of the immunogens is
20 conducted generally by injection over a suitable time period and with use of suitable adjuvants, as is generally understood in the art. During the immunization schedule, titers of antibodies are taken to determine adequacy of antibody formation.

Anti-peptide antibodies can be generated using synthetic peptides corresponding to, for example, the carboxy terminal 15 amino acids p70 β^{S6k} . Synthetic peptides can
25 be as small as 1-3 amino acids in length, but are preferably at least 4 or more amino acid residues long. The peptides are coupled to KLH using standard methods and can be immunized into animals such as rabbits. Polyclonal anti-p70 β^{S6k} peptide antibodies can then be purified, for example using Actigel beads containing the covalently bound peptide.

While the polyclonal antisera produced in this way may be satisfactory for some applications, for pharmaceutical compositions, use of monoclonal preparations is preferred. Immortalized cell lines which secrete the desired monoclonal antibodies may be prepared using the standard method of Kohler and Milstein or modifications which effect immortalization of lymphocytes or spleen cells, as is generally known. The immortalized cell lines secreting the desired antibodies are screened by immunoassay in which the antigen is the peptide hapten, polypeptide or protein. When the appropriate immortalized cell culture secreting the desired antibody is identified, the cells can be cultured either *in vitro* or by production in ascites fluid. Of particular interest, are monoclonal antibodies which recognize the proline-rich domain of p70 β^{S6k} .

The desired monoclonal antibodies are then recovered from the culture supernatant or from the ascites supernatant. Fragments of the monoclonals or the polyclonal antisera which contain the immunologically significant portion can be used as antagonists, as well as the intact antibodies. Use of immunologically reactive fragments, such as Fav, FV , Fab, Fab', or F(ab')_2 fragments is often preferable, especially in a therapeutic context, as these fragments are generally less immunogenic than the whole immunoglobulin. Antibodies may preferably also be human, humanized or chimeric variants of the foregoing. Such antibodies can be less immunogenic when administered to a subject. Methods of producing humanized or chimeric antibodies are well known in the art. The antibodies contemplated also include different isotypes and isotype subclasses (*e.g.*, IgG₁, IgG₂, IgM, to name a few). These antibodies can be prepared by raising them in vertebrates, in hybridoma cell lines or other cell lines, or by recombinant means. For references on how to prepare these antibodies, see E. Harlow and D. Lane, *ANTIBODIES: A LABORATORY MANUAL* (Cold Spring Harbor Press, Cold Spring Harbor, NY, 1988); Kohler and Milstein, (1976) *E. J. Immunol.* 6:511; Queen *et al.* U.S. Patent NO. 5,585,089; and Riechmann *et al.*, *Nature* 332:323 (1988).

The antibodies or fragments may also be produced, using current technology, by recombinant means. Regions that bind specifically to the desired regions of receptor

can also be produced in the context of chimeras with multiple species origin.

In an alternative format, a specific activity of a protein of the invention may be assayed, such as the ability of the protein to phosphorylate a substrate such as polypeptides of the S6 protein. For example, p70 β^{S6k} has been demonstrated to
5 phosphorylate the S6 protein and a synthetic peptide, RRLSSLRASTSKSESSQK (SEQ ID No. 8). The sequence comprising the synthetic peptide is located in the C-terminus of the S6 protein and is known to contain the five phosphorylation sites targeted by p70 α^{S6k} . Cell lines or populations are exposed under appropriate conditions to the agent to be tested. Agents which modulate the kinase activity of the protein of the invention
10 are identified by assaying the kinase activity of the protein from the exposed cell line or population and a control, unexposed cell line or population, thereby identifying agents which modulate the kinase activity of the protein. Polypeptides of the S6 protein, such as the above examples, are useful positive controls in identifying additional p70 β^{S6k} substrates.

15 Kinase assays to measure the ability of the agent to modulate the kinase activity of a protein of the invention are widely available such as the assays disclosed by Mishima *et al.* (1996) J. Biochem. 119: 906-913) and Michnoff *et al.* (1986) J. Biol. Chem. 261: 8320-8326. Alternative assay formats include actin-myosin motility assays such as those disclosed by Kohama *et al.* (1996) TIPS 17: 284-287 or Warrick *et al.*
20 (1987) Ann. Rev. Cell. Biol. 3: 379-421.

Agents that are assayed in the above method can be randomly selected or rationally selected or designed. As used herein, an agent is said to be randomly selected when the agent is chosen randomly without considering the specific sequences involved in the association of the a protein of the invention alone or with its associated
25 substrates, binding partners, etc. An example of randomly selected agents is the use a chemical library or a peptide combinatorial library, or a growth broth of an organism.

As used herein, an agent is said to be rationally selected or designed when the agent is chosen on a non-random basis which takes into account the sequence of the target site and/or its conformation in connection with the agent's action. As described

in the Examples, there are proposed binding sites for ATP/GTP and calmodulin as well as cAMP/cGMP kinase sites, TyrP sites and Ser/Thr kinase (catalytic) sites in the protein having SEQ ID No.2. Agents can be rationally selected or rationally designed by utilizing the peptide sequences that make up these sites. For example, a rationally
5 selected peptide agent can be a peptide whose amino acid sequence is identical to the ATP or calmodulin binding sites or domains.

The agents of the present invention can be, as examples, peptides, small molecules, vitamin derivatives, as well as carbohydrates. A skilled artisan can readily recognize that there is no limit as to the structural nature of the agents of the present
10 invention.

The peptide agents of the invention can be prepared using standard solid phase (or solution phase) peptide synthesis methods, as is known in the art. In addition, the DNA encoding these peptides may be synthesized using commercially available oligonucleotide synthesis instrumentation and produced recombinantly using standard
15 recombinant production systems. The production using solid phase peptide synthesis is necessitated if non-gene-encoded amino acids are to be included.

Another class of agents of the present invention are antibodies immunoreactive with critical positions of proteins of the invention. Antibody agents are obtained by immunization of suitable mammalian subjects with peptides, containing as antigenic
20 regions, those portions of the protein intended to be targeted by the antibodies.

J. Uses for Agents that Modulate at Least One Activity of the S6 Kinase Protein.

As provided in the Examples, the proteins and nucleic acids of the invention,
25 such as the protein having the amino acid sequence of SEQ ID No.2, are involved in ribosomal function. Agents that modulate or down-regulate the expression of the protein or agents such as agonists or antagonists of at least one activity of the protein may be used to modulate biological and pathologic processes associated with the protein's function and activity.

As used herein, a subject can be any mammal, so long as the mammal is in need of modulation of a pathological or biological process mediated by a protein of the invention. The term "mammal" is meant an individual belonging to the class Mammalia. The invention is particularly useful in the treatment of human subjects.

5 As used herein, a biological or pathological process mediated by a protein of the invention may include binding of substrates such as ATP, GTP or calmodulin or phosphorylation of a substrate, such as the S6 protein.

Pathological processes refer to a category of biological processes which produce a deleterious effect. For example, expression or up-regulation of expression of a
10 protein of the invention may be associated with certain diseases. As used herein, an agent is said to modulate a pathological process when the agent reduces the degree or severity of the process. For instance, a disease may be prevented or disease progression modulated by the administration of agents which reduce or modulate in some way the expression or at least one activity of a protein of the invention.

15 The agents of the present invention can be provided alone, or in combination with other agents that modulate a particular pathological process. As used herein, two agents are said to be administered in combination when the two agents are administered simultaneously or are administered independently in a fashion such that the agents will act at the same time.

20 The agents of the present invention can be administered via parenteral, subcutaneous, intravenous, intramuscular, intraperitoneal, transdermal, or buccal routes. Alternatively, or concurrently, administration may be by the oral route. The dosage administered will be dependent upon the age, health, and weight of the recipient, kind of concurrent treatment, if any, frequency of treatment, and the nature of the effect
25 desired.

The present invention further provides compositions containing one or more agents which modulate expression or at least one activity of a protein of the invention. While individual needs vary, determination of optimal ranges of effective amounts of each component is within the skill of the art. Typical dosages comprise about 0.1 to

100 µg/kg body weight. The preferred dosages comprise about 0.1 to 10 µg/kg body weight. The most preferred dosages comprise about 0.1 to 1 µg/kg body weight. In tissue culture, optimal dosage ranges for drugs such as wortmannin and rapamycin range from about 500 pM to about 1000 nM. Less optimum ranges include about 10
5 pM to about 10 mg.

In addition to the pharmacologically active agent, the compositions of the present invention may contain suitable pharmaceutically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically for delivery to the site of action.

10 Suitable formulations for parenteral administration include aqueous solutions of the active compounds in water-soluble form, for example, water-soluble salts. In addition, suspensions of the active compounds as appropriate oily injection suspensions may be administered. Suitable lipophilic solvents or vehicles include fatty oils, for example, sesame oil, or synthetic fatty acid esters, for example, ethyl oleate or triglycerides.

15 Aqueous injection suspensions may contain substances which increase the viscosity of the suspension include, for example, sodium carboxymethyl cellulose, sorbitol, and/or dextran. Optionally, the suspension may also contain stabilizers. Liposomes can also be used to encapsulate the agent for delivery into the cell.

The pharmaceutical formulation for systemic administration according to the
20 invention may be formulated for enteral, parenteral or topical administration. Indeed, all three types of formulations may be used simultaneously to achieve systemic administration of the active ingredient.

Suitable formulations for oral administration include hard or soft gelatin capsules, pills, tablets, including coated tablets, elixirs, suspensions, syrups or
25 inhalations and controlled release forms thereof.

In practicing the methods of this invention, the compounds of this invention may be used alone or in combination, or in combination with other therapeutic or diagnostic agents. In certain preferred embodiments, the compounds of this invention may be coadministered along with other compounds typically prescribed for these

conditions according to generally accepted medical practice. The compounds of this invention can be utilized *in vivo*, ordinarily in mammals, such as humans, sheep, horses, cattle, pigs, dogs, cats, rats and mice, or *in vitro*.

Without further description, it is believed that one of ordinary skill in the art can, using the preceding description and the following illustrative examples, make and utilize the compounds of the present invention and practice the claimed methods. The following working examples therefore, specifically point out preferred embodiments of the present invention, and are not to be construed as limiting in any way the remainder of the disclosure.

10

EXAMPLES

EXAMPLE 1

Amino Acid Sequence of p70 β ^{S6k} and comparison with p70 α ^{S6k}

Materials and Methods. Restriction enzymes and DNA modification enzymes were obtained from standard commercial sources and used according to manufacturer's recommendations. Oligonucleotides which were used for sequencing of p70 β ^{S6k} and various PCR fragments were synthesized by Genosys or Japan Bioservice, Inc. The pcDNA1 and pcDNA3 mammalian expression vectors were from Invitrogen. The pGEX-4T vector, glutathione-Sepharose-4B and HiTrapQ columns were purchased from Pharmacia. cDNA of rat p70 α -I was a gift from Dr. Joseph Avruch (Diabetes Unit, Massachusetts General Hospital). Rapamycin and PDGF BB were purchased from Calbiochem. Wortmannin was purchased from Sigma.

Cell cultures and Antibodies. A porcine aortic endothelial cell line (PAE-PDGF-R), stably expressing the human PDGF- β receptor, was maintained in HAM's F12 medium containing 10% fetal calf serum (FCS). CHO cells stably overexpressing human insulin receptors (CHO-IR cells) and HEK293 cells were maintained and cultured as described earlier (Hara *et al.*, 1998 J. Biol. Chem. 273: 14484-14494) in HAM's F12 medium or Dulbecco's modified Eagles minimal essential medium (DMEM) supplemented with 10% FCS, respectively. Anti-FLAG monoclonal M2

antibody was purchased from Eastman Kodak Corp. Anti-phosphopeptide antibodies against proline-directed site Ser434 of p70 α -I were purchased from New England Biolabs. Polyclonal antibodies raised against the C-terminal 104 amino acids fragment of p70 α ^{S6k} were from Dr. Joseph Avruch. A GST fusion protein containing amino acids 443-495 of p70 β ^{S6k} (p70 β C Ab) was used to raise polyclonal antibodies specific for p70 β ^{S6k}. Immunoreactive sera were affinity-purified on an Affigel matrix containing the GST/p70 β ^{S6k}-terminal fusion protein.

Fractionation of cell extracts. HEK293 cells were starved in DMEM medium for 16 h and then treated with 15% FCS for 10 min or 200 nM rapamycin for 30 min. After treatment, cells were lysed in ice-cold buffer A (20mM Tris/HCl pH 7.5, 20 mM NaCl, 1 mM EDTA, 5 mM EGTA, 20 mM β -glycerophosphate, 1 mM-DTT, 1 mM PMSF, 2 mg/ml aprotinin, 10 mg/ml leupeptin) and the lysates centrifuged at 4°C for 20 min at 10,000xg. Supernatants were filtered through a 0.45 μ M filter and then loaded onto a HighTrapQ Sepharose column (1.0 ml column volume) equilibrated in Buffer A. The column was washed extensively in buffer A and bound proteins eluted with a linear gradient of NaCl (20 - 500 mM). Aliquots of eluted proteins were subjected to SDS- PAGE and immunoblotted with anti-phosphopeptide antibodies directed against proline-directed site Ser-434 of p70 α ^{S6k} or anti-peptide antibodies against the carboxyl terminal end of p70 α ^{S6k}.

Construction and screening of a HEK293 Uni-ZAP library and DNA sequencing analysis. Total RNA was isolated from HEK293 cells as described (Hara *et al.*, 1998; Chomczynski *et al.*, 1987 Analytical Biochem. 162: 156-159), and poly(A)+ mRNA was selected by using Dynabeads mRNA purification kit (Dyna). An oligo(dT)-primed library was constructed in UNI-ZAP XR vector from 5 mg of HEK293 mRNA, using the Uni-ZAP cDNA synthesis kit (Stratagene). Packaging into phages was carried out by using Gigapack III Gold Packaging extracts (Stratagene). The cDNA encoding full length p70 β ^{S6k} kinase was isolated by screening 1x10⁶ primary phages from HEK293 Uni-ZAP library with a ³²P-labeled 0.65 Kb *EcoRI/NotI* fragment derived from the EST clone GenBank Accession No. AA410355 (Hillier *et al.*,

published on GenBank, 1997). Positive clones were confirmed, isolated in second-round screening and rescued as Bluescript plasmids by *in vivo* excision (Stratagene). PCR amplification and restriction mapping were used for primary characterization of isolated clones. Sequencing analysis of selected clones was performed on an Applied Biosystem 373A DNA automatic sequencer (PE Applied Biosystems).

Results. The p70 α^{S6k} is activated by multiple phosphorylation within the pseudosubstrate and catalytic domains in response to extracellular stimuli, including serum, growth factors and hormones. Phosphospecific antibodies directed against phosphorylated sites of p70 α^{S6k} have been recently developed: Phospho-p70 α^{S6k} (Ser434) and Phospho-p70 α^{S6k} (Thr444/Ser447). Both antibodies were shown to recognize specifically phosphorylated forms of p70 α^{S6k} , and this recognition was found to be sensitive to rapamycin. To compare the phosphorylation state and chromatographic behavior of p70 α^{S6k} from cells stimulated with serum and treated with or without rapamycin, HEK293 cells were starved in DMEM medium for 16 h and then stimulated with 15% serum for 10 min prior treatment with or without 200 nM of rapamycin for 30 min. Cell extracts were fractionated using HighTrapQ Sepharose columns. Proteins were resolved on SDS-PAGE and immunoblotted with anti-phosphopeptide antibodies Ser434 and S444/T447 or antibodies specific for p70 α^{S6k} . In total lysates of serum stimulated HEK293 cells, this antibody recognizes specifically phosphorylated versions of p70 α^{S6k} isoforms (p70 and p85). However, when cell lysates were fractionated and separated on SDS-PAGE, several additional bands appeared on the immunoblot together with the p70 and p85 isoforms of p70 α^{S6k} , including p190, p110, p90 and p60 (not shown). It is important to note that the recognition of these proteins by phosphospecific S434 antibodies was sensitive to rapamycin, indicating the specificity for the phosphorylated epitope. As expected, the anti-peptide antibodies specific for the p70 α^{S6k} recognized 85-kDa and 70-kDa bands, which correspond to p70 α -I and p70 α -II, respectively. S434 is located in the autoinhibitory region of the p70 α^{S6k} , which is highly conserved among different species of p70 α^{S6k} , including *Drosophila* (Stewart *et al.*, 1996 Proc. Natl Acad. Sci. USA 93:

10791-10796; Watson *et al.*, 1996 Proc. Natl Acad. Sci. USA 93: 13694-13698). As phosphorylation of the S434 site is sensitive to rapamycin, it is possible to speculate that p190, p110, p90 and/or p60 may represent novel rapamycin-sensitive $p70\alpha^{S6k}$ -related kinases.

5 *Molecular cloning of novel $p70\alpha^{S6k}$* . Peptide sequences which were used for raising anti-phosphopeptide antibodies S434 of $p70\alpha$ -I were taken to search the expressed sequence tag (EST) databases. This search generated hundreds of EST clones that showed high degree of homology to the query sequence. Extensive analysis of these clones allowed us to isolate several clones which were highly homologous to
10 the 434 peptide, but did not match to cDNA clones from EMBL or Swissprot databases. Further characterization of these sequences indicated that two nearly identical clones (GenBank Accession Nos. AA284234 and AA410355) exhibited strong homology to the kinase extension domain of the protein kinase A (PKA) family of serine/threonine (S/T) kinases. Additionally, the homology in the kinase extension domain extended
15 into the putative autoinhibitory domain, which is unique for the $p70\alpha^{S6k}$ (less than 75% identity between $p70\alpha^{S6k}$ and the unknown potential S6 kinase). However, the homology with $p70\alpha^{S6k}$ dropped significantly downstream of the kinase extension and autoinhibitory domains, suggesting that these clones encoded a novel kinase of this family. Based on these data, we decided to further characterize these clones. Both EST
20 clones were obtained from the UK HGMP Resource Center. Restriction mapping indicated that the GenBank Accession Nos. AA284234 and AA410355 clones contain short inserts of 0.6 kB and 0.65 kB respectively. Sequence analysis showed that these clones are identical to each other in an overlapping region and may encode a partial open reading frame (ORF), which shows very strong homology to the kinase extension
25 and autoinhibitory domains of the $p70\alpha^{S6k}$. These ESTs did not contain a full gene nor was there a protein coding sequence previously identified in these ESTs. Furthermore, four of the five proline-directed Ser/Thr phosphorylation sites located in an autoinhibitory pseudo-substrate domain of $p70\alpha^{S6k}$ were conserved in the clones of $p70\beta^{S6k}$. Immediately after the autoinhibitory pseudo-substrate domain, the homology

between p70 α^{S6k} and p70 β^{S6k} was very low (12% identity). Taking in account these findings, we proceeded to clone the full length cDNA clone encoding this potentially novel kinase.

Since several rapamycin-sensitive bands were found in the HEK293 cells with
5 the use of anti-Ser434 phosphospecific antibodies, a library from this cell line was created. We screened 10⁶ primary clones from the Uni-Zap/HEK293 library with a full length insert from EST clone AA410355 and isolated 12 positive clones. Sequence analysis of rescued plasmids allowed us to identify one clone, which contained an open reading frame of 495 amino acids (Figure 2A). The C-terminus of this clone was found
10 to be identical to the sequence of the EST clone AA410355, which was used for screening.

By analogy to p70 α^{S6k} , the novel cDNA, encoding p70 β^{S6k} , could potentially encode two isoforms as a result of alternative start codons. If this is the case, the shorter isoform may utilize an ATG codon which is 13 amino acids (aa) downstream of
15 the first methionine and may encode a protein of 482 amino acids. Two potential isoforms were termed p70 β -I (495 aa long) and p70 β -II (482 aa long). The presence of additional 13 aa at the N-terminus of p70 β -I isoform may determine its subcellular localization in the nucleus due to the presence of a putative nuclear localization sequence (RGRRARG, amino acid numbers 3-9 of SEQ ID No. 2). The overall
20 structure of p70 β^{S6k} is similar to that of p70 α^{S6k} . p70 α^{S6k} and p70 β^{S6k} share 70% identity and 85% similarity on protein level. The p70 β^{S6k} kinase consists of the amino-terminal non-catalytic region, a catalytic domain, a kinase extension and a carboxyl-terminal non-catalytic tail, whose amino acid identity corresponds to domains of p70 α^{S6k} is 40%, 83%, 80%, and 47%, respectively (Figure 2B). The strong argument
25 that this clone encodes a novel p70 S6 kinase is the presence of the autoinhibitory pseudosubstrate domain, which is not present in any other known kinases.

p70 α^{S6k} undergoes a multi-site phosphorylation in response to stimulation by insulin or mitogens. Such multiple phosphorylation sites are also well conserved in p70 β^{S6k} (Figure 2B). It also contains 3 sets of phosphorylation sites, similar to p70 α^{S6k} :

(i) a set of Ser/Thr-Pro motifs clustered in an autoinhibitory pseudosubstrate domain (Ser423, Ser430, Ser436, Ser441 in p70 β^{S6k} correspond to Ser 434, 441, and 447, Ser 452 in p70 α^{S6k} ; (ii) a second set includes Ser383 and Thr401 which is located in the kinase extension domain and corresponds to Ser394 and Thr412 in p70 α^{S6k} ; (iii) a third set consists of Thr251 which resides in the activation T-loop of kinase domain and corresponds to Thr252 in p70 α^{S6k} . The greatest difference between the p70 α^{S6k} and the p70 β^{S6k} sequences are in the amino-terminal non-catalytic region (40% identity and 60% similarity) and the carboxyl-terminal non-catalytic tail (47% identity and 66% similarity). p70 β^{S6k} also contains proline-rich sequences at the C-terminus, that may mediate the interaction with SH3-domain-containing molecules.

EXAMPLE 2

Tissue Specific Expression of p70 β^{S6k}

Materials and Methods. Northern blot analysis was performed using commercial nylon membranes pre-bound with 2 μ g of gel-separated poly(A)+ RNA samples obtained from various human tissues or tumor cell lines from Clontech. The following probes were used for the detection of p70 α^{S6k} and p70 β^{S6k} messages: (i) a 476-base pair (bp) *HindIII* fragment spanning 56 bp of 3' end coding region and 420 bp of 3' non-coding region of the human p70 α^{S6k} (EST clone, AA425599), (ii) a 650-bp fragment spanning 518 bp upstream of the stop codon and about 130 bp of non-coding region of the human p70 β^{S6k} (EST clone, AA410355). Human β -actin cDNA probe was used as a negative control (Clontech). These probes were labeled by Multiprime DNA labeling system (Amersham) and separated from unincorporated [γ^{32} P]dCTP by Nucletrap push columns (Stratagene). Northern blots were pre-hybridized with ExpressHyb solution and hybridized with labeled probes according to manufacturer's recommendations. After extensive washing with 2X SSC, 0.05% sodium dodecyl sulfate (SDS) at room temperature, and twice with 0.1X SSC, 0.1% SDS at 50°C, the localization of bound probes on membranes was identified by autoradiography or with the use of the PhosphorImager.

Results. In order to compare expression patterns of p70 α^{S6k} and p70 β^{S6k} in human tissues and cell lines, 3' prime coding and non-coding regions, which exhibit low level of homology between both the α and β S6 kinases, were used as probes. Northern blot analysis using poly(A)+ RNA isolated from human tissues revealed a single 2.2 kb transcript for p70 β^{S6k} , while p70 α^{S6k} probe specifically hybridized to 3.4 kb and 7.4 kb transcripts (Figure 3A). The expression pattern of p70 α^{S6k} and p70 β^{S6k} transcripts is remarkably similar, showing ubiquitous expression in all tissues. Highest expression levels were found in spleen, skeletal muscle and peripheral blood leukocytes, whereas brain, lung and kidney showed the lowest expression of transcripts for both S6 kinases. The only significant difference on the level of mRNA expression between p70 α^{S6k} and p70 β^{S6k} was found in liver. The expression of p70 β^{S6k} mRNA in liver is 2-3 times higher than that of p70 α^{S6k} . Liver possesses a high concentration of p70 α^{S6k} and was originally used by several groups to purify p70 α^{S6k} for biochemical studies and protein sequencing analysis (Banerjee *et al.*, 1990 Proc. Natl Acad. Sci. USA 87: 8550-8554; Kozma *et al.*, 1990 Proc. Natl Acad. Sci. USA 87: 7365-7369).

We also analyzed the expression of p70 β^{S6k} mRNA in tumor cell lines using the same probe as for the analysis of tissue distribution. A single transcript of the same size as in human tissues, 2.2 kb, was found to be highly expressed in HeLa and K562 cells, but was barely detectable in HL-60, MOLT-4 and melanoma G361 cell lines (Figure 3B).

EXAMPLE 3

Phosphorylation of the ribosomal protein S6 and its C-terminal synthetic peptide by p70 α^{S6k} and p70 β^{S6k}

Materials and Methods. Expression of GST/p70 β^{S6k} fusion protein in bacteria. A PCR-based strategy was used to make a bacterial expression plasmid for GST/p70 β^{S6k} fusion protein. A cDNA fragment encoding 443-495 amino acids of p70 β^{S6k} was amplified by PCR and cloned into the pGEX-4T expression vector (Pharmacia). This construct was transformed into *E. coli* XL1-Blue competent cells

(Stratagene) and the expression of the GST/p70 β^{S6k} fusion protein was induced by isopropyl β -D-thiogalactopyranoside (IPTG). The GST/p70 β^{S6k} fusion protein was purified by using glutathione-Sepharose-4B beads according to manufacturer's recommendation (Pharmacia). After SDS-PAGE analysis, affinity purified fusion
5 proteins were dialyzed against 20 mM (Tris pH 7.4), 150 mM NaCl, 50% Glycerol and stored at -20°C. This preparation of the GST/p70 β^{S6k} C-terminal fragment was used for the production of polyclonal antibodies specific for p70 β^{S6k} .

Construction of mammalian expression plasmids. The full length coding sequence, corresponding to the p70 β -I (I-495 amino acids) was amplified by PCR using
10 human cDNA clone N53 isolated from HEK293 library as a template and a panel of specific oligonucleotides. Amplified constructs were digested with appropriate enzymes, gel purified and cloned into the pcDNA1 vector in-frame with N-terminal FLAG epitope.

Amino-terminal EE-tagged p70 α -II and p70 β -II constructs were created by a
15 PCR-based cloning strategy. This was achieved by using specific oligonucleotides containing EE-tag sequence and appropriate restriction sites. The cDNA encoding full length human p70 β^{S6k} (clone 53) and rat p70 α^{S6k} were used as templates. The resulting PCR fragments were digested with restriction enzymes, gel purified and cloned into the pcDNA3 expression vector. The construction of the pMT2 FLAG p70 α -I was
20 described previously (Hara *et al.*, 1998). All constructs generated by a PCR-based approach were verified by sequencing. A Qiagen plasmid Midi kit was used to purify plasmid DNAs for transient transfections. The introduction of the FLAG-tag and the EE-tag sequences at the N-terminus of p70 α^{S6k} and p70 β^{S6k} allows the study of recombinant proteins via the use of specific antibodies.

25 **Results.** To test if the isolated p70 β^{S6k} cDNA would encode a functional kinase capable of phosphorylating ribosomal protein S6, a cDNA fragment encoding a short version of p70 β^{S6k} (p70 β -II) was subcloned into mammalian expression vector in frame with EE-tag or Flag-tag epitopes. These constructs were transfected into HEK293 cells using lipofectAMINE under conditions recommended by the manufacturer. The

expression of recombinant $p70\beta^{S6k}$ was analyzed by immunoprecipitation or western blotting with EE-tag or Flag-tag antibodies. Both constructs express the protein of approximately 60kDa. The expression level of $p70\beta^{S6k}$ was comparable to that of $p70\alpha$ -I and $p70\alpha$ -II isoforms, when expressed in HEK293 cells.

5 Anti- $p70\beta^{S6k}$ polyclonal antibodies were generated using synthetic peptides corresponding to the carboxy terminal 15 amino acids of $p70\beta^{S6k}$. These peptides were coupled to KLH and then injected into rabbits using standard procedures. Immune sera was purified using Affigel beads containing covalently cross-linked carboxy terminal peptide.

10 To determine whether the putative $p70\beta^{S6k}$ was indeed a novel ribosomal protein S6 kinase, the recombinant $p70\beta^{S6k}$ was expressed in HEK293 cells, immunoprecipitated with anti-EE-tag antibodies and an *in vitro* kinase reaction performed in the presence of purified 40S ribosomal subunit. As shown in Figure 4A, $p70\beta^{S6k}$ ($p70\beta$ -II isoform) phosphorylates the S6 protein *in vitro* nearly as efficiently as
15 $p70\alpha^{S6k}$. We also tested the ability of $p70\beta^{S6k}$ ($p70\beta$ -II isoform) to phosphorylate a synthetic peptide representing C-terminus of S6 protein, which contains all sites known to be phosphorylated by $p70\alpha^{S6k}$. Figure 4B demonstrates that $p70\beta^{S6k}$ ($p70\beta$ -II isoform) also phosphorylates this peptide but with slightly lower efficiency than observed with $p70\alpha^{S6k}$. Therefore, $p70\beta^{S6k}$ ($p70\beta$ -II isoform) may not phosphorylate
20 the same sites of the ribosomal protein S6 as does $p70\alpha^{S6k}$.

The intrinsic activity of the $p70\beta^{S6k}$ is significantly lower than $p70\alpha^{S6k}$. The absence of one phosphorylation site in the autoinhibitory domain of $p70\beta^{S6k}$ may be responsible for this decrease in intrinsic activity.

25

EXAMPLE 4

Stimulation of $p70\beta^{S6k}$ Activity by insulin, serum and TPA

Materials and Methods. HEK293 cells or CHO-IR cells were transfected with plasmids containing $p70\alpha^{S6k}$ and $p70\beta^{S6k}$ sequences using lipofectAMINE under conditions recommended by the manufacturer (Gibco-BRL). Two days later,

transfected cells were frozen in liquid nitrogen and stored until lysis. After cell extraction, the lysates were subjected to immunoprecipitation and/or immunoblot analysis. If cells were to be stimulated, they were starved in medium without FCS for 16 h and then stimulated with 10^{-7} M insulin for 10 min, 15% FCS for 10 min, 500 nM TPA for 30 min or vehicle alone. PAE-PDGF-R cells were transfected with appropriate plasmids using lipofectAMINE under conditions recommended by the manufacturer. After 24 h transfected cells were serum-starved for 16 h and stimulated with 20 ng/ml PDGF BB (Calbiochem) for 20 min. Control cells were treated with the vehicle under the same conditions.

10 **Results.** The effect of various extracellular stimuli on the $p70\beta^{S6k}$ activity was studied in different cell lines, transiently transfected with Flag-tagged or EE-tagged versions of $p70\beta^{S6k}$. The activation of $p70\beta^{S6k}$ ($p70\beta$ -II isoform) by insulin was analyzed in CHO-IR cells, which stably over expresses the insulin receptor. As shown in Figure 5A, treatment of CHO-IR cells with insulin induces $p70\beta^{S6k}$ ($p70\beta$ -II isoform) activity towards ribosomal S6 protein by 2.8 fold. In the same cell line and under the same conditions, the activity of $p70\alpha^{S6k}$ was activated 3.5 fold with insulin treatment (Figure 5A). Almost equal amounts of $p70\alpha^{S6k}$ and $p70\beta^{S6k}$ ($p70\beta$ -II isoform) were expressed in cells and used in an *in vitro* kinase assay after immunoprecipitation. In addition, both serum and TPA also stimulated $p70\beta^{S6k}$ ($p70\beta$ -II isoform) phosphorylation of the ribosomal protein S6 (Figure 5A).

20 Using PAE-PDGF-R cells, the activation of the $p70\alpha^{S6k}$ and $p70\beta^{S6k}$ ($p70\beta$ -II isoform) by PDGF was examined. This cell line stably over expresses the PDGF receptor, and the activation of $p70\alpha^{S6k}$ in response to PDGF was shown to be very efficient (Figure 5B). We found that PDGF stimulation of these cells leads to a rapid activation of recombinant $p70\beta^{S6k}$ ($p70\beta$ -II isoform).

These data indicate that $p70\beta^{S6k}$ is activated by a number of extracellular stimuli in a very similar way as $p70\alpha^{S6k}$. However, activation in the PAE-PDGF-R cells was 30 fold for $p70\beta^{S6k}$ and only 3.4 fold for $p70\alpha^{S6k}$.

EXAMPLE 5

Effects of rapamycin and wortmannin on p70 β ^{S6k} and p70 α ^{S6k}

Materials and Methods. Treatment of transfected cells with rapamycin or wortmannin was performed as follows: 48 h after transfection, the cells were treated
5 with various concentrations of rapamycin or wortmannin for 30 min.

Results. These data in Examples 4 and 5 indicate that p70 β ^{S6k} is activated by a number of extracellular stimuli in a similar fashion to p70 α ^{S6k}. The two fungal inhibitors, wortmannin and rapamycin, specifically inhibit activation of p70 α ^{S6k} via PI3-kinase- and mTOR-dependent pathways respectively. Thus, the effects of both
10 inhibitors on p70 β ^{S6k} activity were examined. After p70 α -I and p70 β -II were transiently expressed in HEK293 cells, cells were maintained in DMEM containing 10% FCS and then treated with various concentrations of rapamycin or wortmannin. We found that the activity of p70 α ^{S6k} and p70 β ^{S6k} were inhibited by rapamycin and wortmannin in a dose dependent manner (Figures 6A and B, upper panel). However, it
15 appears that p70 β ^{S6k} is less sensitive to rapamycin and wortmannin, when compared with p70 α ^{S6k}. This difference is more obvious at lower concentration of inhibitors. In the presence of 20 nM rapamycin the inhibition of the p70 α ^{S6k} is 92%, while only 46% for p70 β ^{S6k}. Addition of 100 nM of wortmannin inhibits 86% of p70 α ^{S6k} activity and 62% of p70 β ^{S6k} activity. The inhibition of p70 β ^{S6k} by rapamycin and wortmannin is
20 lower than that observed for p70 α ^{S6k} indicating different mechanisms of regulation exist for p70 β ^{S6k}.

EXAMPLE 6

Interaction of the p70 β ^{S6k} with different GST/SH3 fusion proteins

25 **Materials and Methods.** The EE-tag/p70 β ^{S6k} was transiently over expressed in HEK293 cells as described above. Transfected cells were lysed in buffer A (50 mM-Tris/HCl pH = 8.0, 1% NP-40, 120 mM NaCl, 20 mM NaF, 1 mM EDTA, 6 mM EGTA, 20 mM sodium β -glycerophosphate, 1 mM DTT, 1 mM PMSF, 10 μ g/ml leupeptin, 10 μ g/ml pepstatin and 2 μ g/ml aprotinin) two days after transfection. After

centrifugation at 12,000 rpm for 20 min, the supernatants were incubated for 2 hrs with Protein A beads pre-coupled with anti-EE antibodies. Beads were washed with lysis buffer before different GST/SH3 fusion proteins (1.5 mg each) were added to separate immunoprecipitation reactions. Two hours later, beads were washed extensively in lysis buffer, bound proteins separated on the SDS-PAGE and transferred to the PVDF membrane. Specific interaction of the GST/SH3 domains with pre-bound EE-tag/p70 β^{S6k} was assessed by immunoblotting with the anti-GST antibodies.

Results. The C-terminus of the p70 β^{S6k} contains proline-rich sequences which are not present in p70 α^{S6k} . Src-homology region 3 domains (SH3 domain) are present in many signaling and cytoskeletal molecules and interact specifically with proline-rich sequences which form left-handed helices. Sequence analysis of the proline-rich region in p70 β^{S6k} indicates the presence of several putative SH3 domain binding motifs. Therefore, the ability of p70 β^{S6k} (p70 β -II isoform) to interact with a panel of SH3 domains was examined. In this experiment, the EE-tag/p70 β^{S6k} was transiently over expressed in HEK293 cells and immunoprecipitated with anti-EE antibodies coupled to Protein G Sepharose. The resulting immunoprecipitates were incubated with different GST/SH3 domain fusion proteins. After extensive washing, specific interaction between p70 β^{S6k} and SH3 domains was analyzed by SDS-PAGE and immunoblotting with anti-GST antibodies. As shown in Figure 7, several SH3 domains, including those of GAP, Src, Fgr exhibited specific interaction towards p70 β^{S6k} .

EXAMPLE 7

Immunoprecipitation and Western blot analysis of transiently expressed p70 β -I and p70 β -II

Materials and Methods. Anti-p70 β^{S6k} polyclonal antibodies were generated using a synthetic peptide corresponding to the C-terminal tail of p70 β^{S6k} . The peptide was coupled to KLH, and rabbits were immunized using standard procedures. Immune sera harvested obtained from the immunized rabbits was purified using affinity chromatography on Affigel beads containing covalently cross-linked C-terminal

peptides of p70 β^{S6k} .

HEK293 cells were transfected with pcDNA1 along, pcDNA1/Flag-p70 α -I, pcDNA1/Flag-p70 β -I, or pcDNA1/Flag-p70 β -II. Two days after transfection with one of these plasmids, cell lysates were prepared. Proteins were immunoprecipitated using the p70 β^{S6k} C-terminal affinity purified polyclonal antibodies or anti-Flag monoclonal antibodies. Immunoprecipitates were resolved on SDS PAGE and proteins transferred to PVDF membranes. The PVDF membranes were immunoblotted using anti-Flag monoclonal antibodies or p70 β^{S6k} C-terminal antibodies as indicated in Figure 8.

Results. The expression of both p70 β^{S6k} isoforms was analyzed in HEK293 cells using anti-p70 β^{S6k} C-terminus specific polyclonal antibodies. Both p70 β^{S6k} isoforms were found to be specifically immunoprecipitated with anti-p70 β^{S6k} antibodies, but not p70 α -I, as confirmed by anti-Flag and anti-p70 β^{S6k} immunoblotting. It was found that the p70 β -I isoform which encodes a 495 amino acid protein, is translated into a protein which migrates in a SDS-PAGE gel at approximately 70 kD. The p70 β -II isoform, which is a truncated form of p70 β -I lacking 13 amino acids at the amino terminus of p70 β -II, migrates in a SDS-PAGE gel at approximately 60 kD.

EXAMPLE 8

Generation of activated variants of p70 β^{S6k} (T401D) and p70 α^{S6k} (T412D).

Materials and Method. Activated variants of p70 β^{S6k} and p70 α^{S6k} were made by site-directed mutagenesis. Oligonucleotide primers, specific to the site to be mutated and complimentary to opposite strands of p70 β^{S6k} and p70 α^{S6k} sequences were generated as recommended by manufacturer (Stratagene). Site-directed mutagenesis was carried out using pcDNA3/ Glu-tag-p70 β^{S6k} and pcDNA3/Glu-tag- p70 α^{S6k} expression vector/plasmids as templates, according to the recommended protocol (Stratagene). All mutations were verified by DNA sequencing. Expression of mutated forms of both kinases was analyzed by immunoblotting with anti-Glu-tag antibodies. The activity of normal and mutated forms of both kinases was measured by in vitro S6 kinase assay. 40S ribosomal subunit was used as a substrate in this reaction.

Results. Studies on $p70\alpha^{S6k}$ demonstrate that this kinase is activated by multiple phosphorylations in response to growth factors or hormones (Fig. 9). A number of kinases that can phosphorylate $p70\alpha^{S6k}$ *in vitro* and *in vivo* have been identified, including cdc2, MAPK, SAPK, p38, TOR and PDK1. However, very little
5 is known about the process of dephosphorylation, which is essential for the inactivation of the kinase.

We have generated an activated form of $p70\beta^{S6k}$ by substituting putative phosphorylation site Thr 401 with Aspartic acid (Asp) (" $p70\beta^{S6k}$ (T402D)") as shown in Fig 10. Transfection studies in HEK293 cells and S6 kinase assays indicated that
10 $p70\beta^{S6k}$ (T401D) mutant is in an activated state in unstimulated cells, when compared with wild type kinase (3 times higher activity, as shown in Fig 11). We have also created an activated version of $p70\alpha^{S6k}$ (T412D), which showed a greater state of activation (18 fold activation, Fig. 12).

It will be apparent to the skilled artisan that activated variants of both kinases
15 such as disclosed above can be used in the search for binding partners. Binding partners or molecules, such as phosphatases, are considered to form tighter and more stable complexes with such irreversibly activated kinases.

EXAMPLE 9

Identification of $p70\beta^{S6k}$ -binding partners.

20

Materials and Methods. HEK293 cells are transfected using lipofectAMINE (as recommended by manufacturer, Gibco-BRL) with pcDNA3 expression vectors encoding activated variants of $p70\beta^{S6k}$ (T401D) and $p70\alpha^{S6k}$ (T412D). Binding partners that preferentially associate with $p70\beta^{S6k}$ may be identified by comparing the profile of
25 proteins precipitated from activated $p70\beta^{S6k}$ expressing cells to the profile of activated $p70\alpha^{S6k}$ expressing cells and/or negative control cells. Cells transfected with the pcDNA3 plasmid alone, may be used as a negative control in this experiment. Two days after transfection, cells are lysed in extraction buffer: 50 mM Tris/HCl (pH8.0); 120 mM NaCl; 20 mM NaF; 20 mM b-glycerophosphate; 1 mM EDTA, (pH 8.0); 6

mM EGTA; 1% NP-40; 1 mM DTT. The following protease and phosphatase inhibitors are added to the extraction buffer just before cell lysis: 5 mM Benzamidine; 1 mM PMSF; 1mg/ml of aprotinin; 0.125 mM NaVO₄; Pepstatin; and Leupeptin.

The resulting cell lysate is centrifuged at 14,000 rpm for 20 min at 4°C to
5 remove the insoluble fraction. If the lysate is not used immediately it is stored at -80°C until needed. The protein concentration of the samples is measured using a Coomassie Protein Assay reagent (Pierce) at 595 nm. An equal amount of supernatant from each sample is added to fresh 1.5 ml tubes and the volumes is equalized using lysis buffer. Affinity purified anti-Glu antibody is added to the supernatant and incubated on the
10 wheel for 1 hr at 4°C. Protein-G sepharose beads, pre-washed in lysis buffer, are used to bring down immune complexes.

After extensive washing in lysis buffer (4x), 2x sample buffer is added to the beads. Bound proteins are eluted from the beads by boiling and separated by SDS-PAGE electrophoresis. Separated proteins are silver stained and the pattern of
15 associated proteins is analyzed.

Results. The pattern of associated proteins are compared between activated variants of p70β^{S6k} and p70α^{S6k} kinases. Mutated variants of both kinases are transiently expressed in HEK293 cells as Glu-tag fusion proteins. The presence of a Glu-tag epitope at the N-terminus of p70β^{S6k} and p70α^{S6k} allows specific
20 immunoprecipitation of activated kinases from transfected cells. The skilled practitioner will recognize that the Glu-tag fusion is not necessary to the invention and that similar results could be obtained with antibodies specific to each or both of the activated variants in the absence of a fusion epitope.

The skilled practitioner will recognize that binding partners or polypeptides that
25 preferentially bind to activated P70β^{S6K} can be isolated by one or more standard techniques such as immunoprecipitation, hplc, fplc, column chromatography or preparative electrophoresis.

Although the present invention has been described in detail with reference to examples above, it is understood that various modifications can be made without

departing from the spirit of the invention. Accordingly, the invention is limited only by the following claims. All cited patents and publications referred to in this application are herein incorporated by reference in their entirety.

WHAT IS CLAIMED:

1. An isolated nucleic acid molecule selected from the group consisting of a nucleic acid molecule comprising the sequence of SEQ ID No.1 (the nucleotide sequence of the p70 β^{S6k}); and a nucleic acid molecule which encodes a p70 β^{S6k} and which hybridizes to a nucleic acid molecule having the sequence of SEQ ID No.1 under stringent conditions.
2. An isolated nucleic acid molecule which encodes a protein having SEQ ID No.2 (the p70 β^{S6k}) or a protein having one or more conservative amino acid substitutions in SEQ ID No.2.
3. An isolated nucleic acid molecule selected from the group consisting of a nucleic acid molecule comprising the sequence of SEQ ID No.1 (the nucleotide sequence of the p70 β^{S6k}); a nucleic acid molecule which encodes a p70 β^{S6k} and which hybridizes to a nucleic acid molecule having the sequence of SEQ ID No.1 under stringent conditions, and a nucleic acid molecule at least about 65% sequence identity with SEQ ID No.1.
4. An isolated nucleic acid molecule which encodes a protein having SEQ ID No.2 (the p70 β^{S6k}), a protein with at least 75% identity to SEQ ID No.2, or a polypeptide fragment of SEQ ID No.2.
5. An isolated polypeptide which phosphorylates a ribosomal S6 protein and is encoded by a nucleic acid molecule of claim 1 or claim 2.
6. A method of identifying an agent which modulates p70 β^{S6k} mediated phosphorylation of a ribosomal S6 subunit comprising the steps of:
exposing p70 β^{S6k} and a ribosomal S6 subunit to the agent; and

determining whether the agent modulates $p70\beta^{S6k}$ mediated phosphorylation of the ribosomal S6 subunit.

7. A method of modulating protein synthesis or cellular proliferation comprising the step of administering an agent which modulates $p70\beta^{S6k}$ phosphorylation of a ribosomal S6 subunit.

8. A method of identifying an agent that modulates a kinase or a phosphatase induced regulation of $p70\beta^{S6k}$ activity comprising the steps of:
exposing $p70\beta^{S6k}$ and the kinase which phosphorylates $p70\beta^{S6k}$ to an agent; and
determining whether the agent modulates the kinase or the phosphatase induced regulation of $p70\beta^{S6k}$ activity.

9. The method of claim 8, wherein the kinase which phosphorylates $p70\beta^{S6k}$ is PKC.

10. A method of modulating protein synthesis or cellular proliferation comprising the step of administering an agent which modulates the phosphorylation of $p70\beta^{S6k}$.

11. A method of modulating cell cycle comprising the step of administering an agent which regulates the ability $p70\beta^{S6k}$ to bind with a ligand.

12. An antibody or antibody fragment which specifically binds to an epitope of $p70\beta^{S6k}$.

13. The antibody of claim 11, wherein the antibody is selected from the group consisting of a monoclonal antibody, human antibody, chimeric antibody, and humanized antibody.

14. An antibody of claim 11 wherein the epitope is a proline rich epitope of a $p70\beta^{S6k}$ protein.
15. A fusion protein comprising SEQ ID No.2 or a polypeptide fragment thereof fused to a heterologous protein.
16. A cell transformed with a nucleic acid molecule of any of claims 1-3.
17. A method of identifying a substrate of $p70\beta^{S6k}$ comprising the steps of: exposing $p70\beta^{S6k}$ or a polypeptide fragment thereof to an agent; and determining whether $p70\beta^{S6k}$ binds to the agent.
18. A method of identifying a substrate of $p70\beta^{S6k}$ comprising the steps of: forming a mixture comprising $p70\beta^{S6k}$ and a candidate agent; incubating said mixture under conditions conducive to phosphorylation by $p70\beta^{S6k}$; and determining whether the candidate agent is phosphorylated.
19. A method of indentifying binding partners of $p70\beta^{S6K}$ comprising the step of incubating a first cellular extract with $p70\beta^{S6K}$, activated variants of $p70\beta^{S6K}$ or a fusion protein of claim 15.
20. The method of claim 19 further comprising incubating a second cellular extract with $p70\alpha^{S6K}$, activated variants of $p70\alpha^{S6K}$ or a fusion protein of $p70\alpha^{S6K}$ and comparing the first and second cellular extracts.
21. A method of indentifying binding partners of $p70\beta^{S6K}$ comprising the step of isolating a first a first cellular extract from a cell containing $p70\beta^{S6K}$, activated variants of $p70\beta^{S6K}$ or a fusion protein of claim 15.

22. The method of claim 19 further comprising isolating a second cellular extract from a cell containing p70 α^{S6K} , activated variants of p70 α^{S6K} or a fusion protein of p70 α^{S6K} and comparing the first and second cellular extracts.
23. An isolated polypeptide comprising an activated p70 β^{S6k} .
24. The isolated polypeptide of claim 23 further comprising a mutation of Threonine 401 to Aspartic acid.
25. An isolated polypeptide that preferentially binds to an activated p70 β^{S6K} of claim 23.
26. The isolated polypeptide of claim 25 that preferentially binds to an activated p70 β^{S6k} of claim 24.
27. An antibody or antibody fragment that specifically binds to the isolated polypeptide of claims 25 or 26.
28. A method of determining whether a cell expresses aberrant cellular levels of p70 β^{S6k} comprising:
 - (a) determining the level of p70 β^{S6k} in a normal cell type;
 - (b) determining the level of p70 β^{S6k} in a test cell;
 - (c) comparing the level of p70 β^{S6k} in the normal cell to the p70 β^{S6k} level in the test cell.
29. The method of claim 28 wherein the level of p70 β^{S6k} is determined by finding the level p70 β^{S6k} RNA in a cell.

30. The method of claim 28, wherein the level of $p70\beta^{S6k}$ is determined by finding the level of $p70\beta^{S6k}$ protein in a cell.
31. A method of determining whether a cell expresses aberrant cellular levels of a $p70\beta^{S6k}$ binding partner comprising:
 - (a) determining the level of said binding partner in a normal cell;
 - (b) determining the level of said binding partner in a test cell;
 - (c) comparing the level of said binding partner in the normal cell to the binding partner level in the test cell.
32. A vector comprising the isolated nucleic acid of claim 2, operably linked to a promotor or transcription.
33. The vector of claim 32, further comprising one or more enhancers or upstream activating sequences.
34. The vector of claim 32, wherein the vector comprises pcDNA3.
35. A vector which encodes an activated $p70\beta^{S6k}$ of claims 23 or 24.
36. A DNA vector comprising a nucleic acid encoding a $p70\beta^{S6k}$ or an activated $p70\beta^{S6k}$ fusion protein.

FIG. 1A

p70a.hum...	1	- - - - -	- - - - -	G C A C G A G G C T G C G G C G G	17
p70b.hum...	1	G A G A G A G A G A G A G A G A G A G			33
p70a.hum...	18	G T C C G G G C C C A	T G A G G C G A C G A A G G A G C G G A		50
p70b.hum...	34	A G A G A G A G A G A G A G A G A G A G A			66
p70a.hum...	51	C G G C T T T T A C C C A G C C C C G G A C T T C C G A G		- - - A	80
p70b.hum...	67	C T C G T G C C G A A T G G C A C G A G G C C G A C C G G C C C G			99
p70a.hum...	81	C A G G G A A G C T G A G G A C A T G G C A G G A G T G T T T G A			113
p70b.hum...	100	C G G G C C G G C C G C C C A T G G C G G C C G T G T T T G A			132
p70a.hum...	114	C A T A G A C C T G G A C C A G C C C A G A G G A C G C G G G C T C			146
p70b.hum...	133	T T T G G A T T T G G A G A C G G G A G G A G G C A G C G A G G G			165
p70a.hum...	147	T G A G G A T G A G C T G G A G G A G G G G G T C A G T T A A A			179
p70b.hum...	166	C G A G G G C G A G C C A G A - - - - - G C T C A G C C C C G			191

FIG. 1B

p70a.hum...	180	T	G	A	A	A	G	C	A	T	G	G	A	C	C	A	T	G	G	G	G	A	G	T	T	-	-	-	G	G	A	C	208				
p70b.hum...	192	C	G	G	A	C	G	C	A	T	G	T	C	C	C	C	T	T	G	C	C	G	A	G	T	T	G	A	G	G	C	A	G	224			
p70a.hum...	209	C	A	T	A	T	G	A	A	C	T	T	G	G	C	A	T	G	G	A	A	C	A	T	T	G	T	G	A	G	A	A	T	241			
p70b.hum...	225	C	T	G	G	C	C	T	A	G	A	G	C	C	T	G	T	G	G	G	A	C	A	C	T	A	T	G	A	A	G	A	G	257			
p70a.hum...	242	T	T	G	A	A	A	T	C	T	C	A	G	A	A	A	C	T	A	G	T	G	T	G	A	A	C	A	G	A	G	G	C	274			
p70b.hum...	258	T	T	G	A	G	C	T	G	A	C	T	G	A	G	A	C	A	C	A	G	C	A	G	T	G	A	A	C	G	T	T	G	G	C	290	
p70a.hum...	275	C	A	G	A	A	A	A	A	T	C	A	G	A	A	C	C	A	G	A	A	T	G	T	T	T	T	G	A	G	C	T	A	C	307		
p70b.hum...	291	C	A	G	A	G	C	C	A	T	C	A	T	C	G	G	C	C	A	C	T	G	C	T	T	T	T	G	A	G	C	T	G	C	323		
p70a.hum...	308	T	T	C	G	G	G	T	A	C	T	T	G	G	T	A	A	A	G	G	G	G	G	C	T	A	T	G	G	A	A	A	G	G	340		
p70b.hum...	324	T	T	G	C	G	T	G	T	G	C	T	G	G	C	A	A	A	G	G	G	G	G	C	T	A	T	G	G	C	A	A	A	G	G	356	
p70a.hum...	341	T	T	T	T	C	A	A	G	T	A	C	G	A	A	A	A	A	G	T	A	A	C	A	G	G	A	G	C	A	A	A	T	A	373		
p70b.hum...	357	T	T	G	T	T	C	C	A	G	G	T	G	C	G	A	A	A	A	G	G	T	G	C	A	A	G	G	C	A	C	C	A	A	C	T	389

2/30

FIG. 1C

p70a.hum...	374	C	T	G	G	G	A	A	A	T	A	T	T	T	G	C	C	A	T	G	A	A	G	T	G	C	T	T	A	A	A	A	406			
p70b.hum...	390	T	G	G	G	C	A	A	A	T	A	T	A	T	T	G	C	C	A	T	G	A	A	A	G	T	C	C	T	A	A	G	A	422		
p70a.hum...	407	A	G	G	C	A	A	T	G	A	T	A	G	T	A	A	G	A	A	A	T	G	C	T	A	A	A	G	A	T	A	C	A	G	439	
p70b.hum...	423	A	G	G	C	C	A	A	A	T	T	G	T	G	C	G	C	A	A	T	G	C	C	A	A	G	G	A	C	A	C	A	G	455		
p70a.hum...	440	C	T	C	A	T	A	C	A	A	A	G	C	A	G	A	A	C	G	G	A	A	T	A	T	T	C	T	G	G	A	G	G	472		
p70b.hum...	456	C	A	C	A	C	A	C	A	C	G	G	G	C	T	G	A	G	C	G	G	A	A	C	A	T	T	C	T	A	G	A	G	T	488	
p70a.hum...	473	A	A	G	T	A	A	A	G	C	A	T	C	C	C	T	T	C	A	T	C	G	T	G	G	A	T	T	T	A	A	T	T	T	505	
p70b.hum...	489	C	A	G	T	G	A	A	G	C	A	C	C	C	C	T	T	T	A	T	T	G	T	G	G	A	A	C	T	G	G	C	C	T	521	
p70a.hum...	506	A	T	G	C	C	T	T	T	C	A	G	A	C	T	G	G	T	G	G	A	A	A	A	C	T	C	T	A	C	C	T	C	A	538	
p70b.hum...	522	A	T	G	C	C	T	T	C	C	A	G	A	C	T	G	G	T	G	G	C	A	A	A	A	C	T	C	T	A	C	C	T	C	A	554
p70a.hum...	539	T	C	C	T	T	G	A	G	T	A	T	C	T	C	A	G	T	G	G	A	G	G	A	G	A	C	T	A	T	T	T	A	571		
p70b.hum...	555	T	C	C	T	T	G	A	G	T	G	C	C	T	C	A	G	T	G	G	T	G	G	C	G	A	G	C	T	C	T	T	C	A	587	

3/30

FIG. 1D

4/30

p70a.hum...	572	T	G	C	A	G	T	T	A	G	A	A	G	A	G	G	G	A	A	T	T	T	A	T	G	G	A	A	G	604						
p70b.hum...	588	C	G	C	A	T	C	T	G	A	G	C	G	A	G	G	G	C	A	T	C	T	T	C	C	T	G	G	A	A	G	620				
p70a.hum...	605	A	C	A	C	T	G	C	C	T	G	C	T	T	T	A	C	T	T	G	G	C	A	G	A	A	T	C	C	A	637					
p70b.hum...	621	A	T	A	C	G	G	C	C	T	G	C	T	T	C	T	A	C	C	T	G	G	C	T	G	A	G	A	T	C	A	C	G	C	653	
p70a.hum...	638	T	G	G	C	T	T	T	G	G	G	G	C	A	T	T	T	A	C	A	T	C	A	A	A	A	G	G	G	G	A	T	C	A	670	
p70b.hum...	654	T	G	G	C	C	C	T	G	G	G	C	C	A	T	C	T	C	C	A	C	T	C	C	C	A	G	G	C	A	T	C	A	686		
p70a.hum...	671	T	C	T	A	C	A	G	A	G	A	C	C	T	G	A	A	G	C	C	G	A	G	A	A	T	A	T	C	A	T	G	C	703		
p70b.hum...	687	T	C	T	A	C	C	G	G	A	C	C	T	C	A	A	G	C	C	C	G	A	G	A	A	C	A	T	C	A	T	G	C	719		
p70a.hum...	704	T	T	A	A	T	C	A	C	C	A	A	G	G	T	C	A	T	G	T	G	A	A	A	C	T	A	A	C	A	G	A	C	T	736	
p70b.hum...	720	T	C	A	A	G	C	A	G	C	C	A	A	G	G	C	C	A	C	A	T	C	A	A	A	C	T	G	A	C	C	G	A	C	T	752
p70a.hum...	737	T	T	G	G	A	C	T	A	T	G	C	A	A	A	G	A	A	T	C	T	A	T	T	C	A	T	G	A	T	G	G	A	A	769	
p70b.hum...	753	T	T	G	G	A	C	T	C	T	G	C	A	A	G	G	A	G	T	C	T	A	T	C	C	A	T	G	A	G	G	C	G	785		

4/30

FIG. 1E

p70a.hum...	770	C	A	G	T	C	A	C	A	C	A	C	A	T	T	T	T	G	T	G	G	A	A	C	A	A	T	A	G	A	T	802		
p70b.hum...	786	C	C	G	T	C	A	C	T	C	A	C	A	C	T	T	C	T	G	C	G	C	A	C	A	T	T	G	A	G	T	818		
p70a.hum...	803	A	C	A	T	G	G	C	C	C	T	G	A	A	A	T	C	T	T	G	A	T	G	A	G	A	A	G	T	G	G	C	835	
p70b.hum...	819	A	C	A	T	G	G	C	C	C	T	G	A	G	A	T	C	T	T	G	T	G	C	G	C	A	G	T	G	G	C	851		
p70a.hum...	836	A	C	A	A	T	C	G	T	G	C	T	G	T	G	G	A	T	T	G	G	T	G	G	A	G	T	T	T	G	G	A	G	868
p70b.hum...	852	A	C	A	A	C	C	G	G	C	T	G	T	G	G	A	C	T	T	G	G	T	G	G	A	G	C	C	T	T	G	G	G	884
p70a.hum...	869	C	A	T	T	A	A	T	G	T	A	T	G	A	C	A	T	G	C	T	G	A	C	T	G	G	A	G	C	A	C	C	C	901
p70b.hum...	885	C	C	C	T	G	A	T	G	T	A	C	G	A	C	A	T	G	C	T	C	A	C	T	G	G	A	T	C	G	C	C	G	917
p70a.hum...	902	C	A	T	T	C	A	C	T	G	G	G	A	G	A	A	T	A	G	A	A	A	A	A	C	A	A	T	T	G	A	T	G	934
p70b.hum...	918	C	C	T	T	A	C	C	G	C	A	G	A	G	A	A	C	C	G	G	A	A	G	A	A	A	C	C	A	T	G	G	G	950
p70a.hum...	935	A	C	A	A	A	A	T	C	C	T	C	A	A	A	T	G	T	A	A	A	C	T	C	A	A	T	T	T	G	C	C	T	967
p70b.hum...	951	A	T	A	A	G	A	T	C	A	T	C	A	G	G	G	C	A	A	G	C	T	G	G	C	A	C	T	G	C	C	C	983	

FIG. 1F

p70a.hum...	968	C	C	T	A	C	C	T	C	A	C	A	A	G	A	A	G	C	C	A	G	A	T	C	T	G	C	T	A	1000				
p70b.hum...	984	C	C	T	A	C	C	T	C	A	C	C	A	G	A	T	G	C	C	C	G	G	A	C	C	T	T	G	T	C	A	1016		
p70a.hum...	1001	A	A	A	G	C	T	G	C	T	G	A	A	A	G	A	A	A	T	G	C	T	T	C	T	C	G	T	C		1033			
p70b.hum...	1017	A	A	A	A	G	T	T	C	T	G	A	A	A	C	G	G	A	A	T	C	C	A	G	C	C	A	G	C	G	A	1049		
p70a.hum...	1034	T	G	G	A	G	C	T	G	G	T	C	C	T	G	G	G	A	C	G	C	T	G	A	A	G	T	T	C		1066			
p70b.hum...	1050	T	T	G	G	G	G	T	G	G	C	C	C	A	G	G	G	A	T	G	C	T	G	A	T	G	T	G	C		1082			
		6/30																																
p70a.hum...	1067	A	A	G	C	T	C	A	T	C	C	A	T	T	C	T	T	A	G	A	C	A	C	A	T	T	A	A	C	T	G	G	1099	
p70b.hum...	1083	A	G	A	G	A	C	A	T	C	C	C	T	T	T	C	C	G	G	C	A	C	A	T	G	A	A	T	T	G	G	1115		
p70a.hum...	1100	A	A	G	A	A	C	T	T	C	T	G	G	C	T	C	G	A	A	A	G	G	T	G	G	A	G	C	C	C	C	T	1132	
p70b.hum...	1116	A	C	G	A	C	C	T	T	C	T	G	G	C	C	T	G	G	C	T	G	T	G	G	A	C	C	C	C	C	T	1148		
p70a.hum...	1133	T	T	A	A	A	C	C	T	C	T	G	T	T	G	C	A	A	T	C	T	G	A	A	G	A	G	A	T	G	T	A	A	1165
p70b.hum...	1149	T	C	A	G	G	C	C	C	T	G	T	C	T	G	C	A	G	T	C	A	G	A	G	A	G	A	C	G	T	G	A	A	1181

6/30

FIG. 1G

p70a.hum...	1166	G	T	C	A	G	T	T	G	A	T	T	C	C	A	A	G	T	T	T	C	A	C	G	T	C	A	G	A	C	A	C	1198		
p70b.hum...	1182	G	C	C	A	G	T	T	T	G	A	T	A	C	C	C	G	C	T	T	C	A	C	A	C	G	G	C	A	G	A	C	G	1214	
p70a.hum...	1199	C	T	G	T	C	G	A	C	A	G	C	C	C	A	G	A	T	G	A	C	T	C	A	C	T	C	T	C	A	G	T	G	1231	
p70b.hum...	1215	C	G	G	T	G	G	A	C	A	G	T	C	C	T	G	A	T	G	A	C	A	C	A	G	C	C	C	T	C	A	G	C	G	1247
p70a.hum...	1232	A	A	A	G	T	G	C	C	A	A	T	C	A	G	G	T	C	T	T	T	C	T	G	G	G	T	T	T	A	C	A	T	1264	
p70b.hum...	1248	A	G	A	G	T	G	C	C	A	A	C	C	A	G	G	C	C	T	T	C	C	T	G	G	G	C	T	T	C	A	C	A	T	1280
p70a.hum...	1265	A	T	G	T	G	G	C	T	C	C	A	T	C	T	G	T	A	C	T	T	G	A	A	A	G	T	G	T	G	A	A	A	G	1297
p70b.hum...	1281	A	C	G	T	G	G	C	G	C	C	G	T	C	T	G	T	C	C	T	G	G	A	C	A	G	C	A	T	C	A	A	A	G	1313
p70a.hum...	1298	A	A	A	A	G	T	T	T	C	C	C	T	T	T	G	A	A	C	C	A	A	A	A	A	T	C	C	G	A	T	C	A	C	1330
p70b.hum...	1314	A	G	G	G	C	T	T	C	T	C	C	T	T	C	C	A	G	C	C	C	A	A	G	C	T	G	C	G	C	T	C	A	C	1346
p70a.hum...	1331	C	T	C	G	A	A	G	A	T	T	A	T	T	G	G	C	A	G	C	C	C	A	C	G	A	A	C	A	C	C	T	G	1363	
p70b.hum...	1347	C	C	A	G	G	C	C	C	T	C	A	A	C	A	G	T	A	G	C	C	C	C	C	G	G	G	T	C	C	C	C	G	1379	

FIG. 1H

p70a.hum...	1364	T	C	A	G	C	C	C	A	G	T	C	A	A	A	T	T	T	C	T	C	C	T	-	-	-	-	G	G	G	A	T	1392		
p70b.hum...	1380	T	C	A	G	C	C	C	C	C	T	C	A	A	G	T	T	C	T	C	C	C	T	T	T	T	G	A	G	G	G	T	1412		
p70a.hum...	1393	T	T	C	T	G	G	G	A	A	G	A	G	G	T	G	C	T	T	C	G	G	C	C	A	G	C	A	C	A	G	C	A	1425	
p70b.hum...	1413	T	T	C	G	G	C	C	C	A	G	C	C	C	A	G	C	C	T	G	C	C	G	A	G	C	C	C	A	C	G	G	1445		
p70a.hum...	1426	A	A	T	C	C	T	C	A	G	A	C	A	C	C	T	G	T	G	G	A	A	T	A	C	C	C	A	A	T	G	G	A	A	1458
p70b.hum...	1446	A	G	C	T	A	C	C	T	C	T	A	C	C	T	C	C	A	C	T	C	C	T	G	C	C	A	C	C	G	C	C	G	C	1478
p70a.hum...	1459	A	C	A	A	G	T	G	G	C	A	T	A	G	A	G	C	A	G	A	T	G	G	A	T	G	T	G	A	C	A	A	T	G	1491
p70b.hum...	1479	C	G	C	C	T	C	G	A	C	C	A	C	C	G	C	C	C	T	C	T	C	C	C	A	T	C	C	G	T	C	G	T	C	1511
p70a.hum...	1492	A	G	T	G	G	G	A	A	G	C	A	T	C	G	G	C	A	C	C	A	C	T	T	C	C	A	A	T	A	C	G	A	1524	
p70b.hum...	1512	C	C	C	C	T	C	A	G	G	A	-	-	-	C	C	A	A	G	A	A	G	T	C	C	A	A	G	A	G	G	G	1541		
p70a.hum...	1525	C	A	G	C	C	G	A	A	C	T	C	T	G	G	G	C	C	A	T	A	C	A	A	A	A	A	C	A	A	G	C	T	1557	
p70b.hum...	1542	G	C	C	G	T	G	G	C	G	T	C	C	A	G	G	C	G	C	T	A	G	G	A	A	G	A	A	C	C	G	G	T	1574	

8/30

FIG. 11

p70a.hum...	1558	T	T	T	C	C	C	A	T	G	A	T	C	T	C	C	A	A	A	C	G	G	C	C	A	G	A	G	C	A	C	C	T	G	1590
p70b.hum...	1575	G	G	G	G	T	G	A	G	G	G	T	A	G	C	C	C	T	T	G	A	G	C	C	C	T	G	T	C	C	C	T	G	1607	
p70a.hum...	1591	C	G	T	A	T	G	A	A	T	C	T	A	T	G	A	C	A	G	C	A	A	T	G	C	T	T	T	A	A	T	1623			
p70b.hum...	1608	C	G	G	C	T	G	T	G	A	G	C	A	G	C	A	G	A	C	C	C	T	G	G	C	C	A	G	T	T	1640				
p70a.hum...	1624	G	A	A	T	T	A	A	G	G	C	A	A	A	A	G	G	T	G	G	A	G	A	G	G	G	A	G	A	T	G	T	1656		
p70b.hum...	1641	C	C	A	G	A	C	C	T	G	G	G	G	T	G	T	G	T	C	T	G	G	G	T	G	G	G	T	G	G	G	T	1673		
p70a.hum...	1657	G	T	G	A	G	C	A	T	C	C	T	G	C	A	A	G	G	T	G	A	A	C	A	A	G	A	C	T	C	A	A	1689		
p70b.hum...	1674	G	T	G	A	G	T	G	C	G	T	A	T	G	A	A	A	G	T	G	T	G	T	C	T	G	C	T	G	G	G	G	1706		
p70a.hum...	1690	A	T	G	A	C	A	G	T	T	T	C	A	G	A	G	A	G	T	C	A	A	T	G	T	C	A	T	T	A	C	A	1722		
p70b.hum...	1707	C	A	G	-	C	T	G	T	G	C	C	C	T	G	A	A	T	C	A	T	G	G	C	A	C	G	G	A	G	G	G	1738		
p70a.hum...	1723	G	A	A	C	A	C	T	T	C	G	G	A	C	A	C	-	-	A	G	G	A	A	A	A	T	A	A	A	C	G	T	G	1753	
p70b.hum...	1739	C	C	G	C	C	C	G	C	C	A	C	A	C	C	C	G	C	G	C	T	C	A	A	C	T	G	C	T	C	C	C	G	1771	

9/30

FIG. 1J

p70a.hum...	1754	G	A	T	T	T	A	A	A	A	T	C	A	A	T	C	A	A	A	A	A	A	A	1786
p70b.hum...	1772	T	G	G	A	A	G	A	T	T	A	A	A	G	G	C	T	G	A	T	G	C	A	1804
p70a.hum...	1787	A	A	C	T	T	A	A	A	G	C	A	A	A	A	T	A	G	T	A	T	T	G	1819
p70b.hum...	1805	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	1816	
p70a.hum...	1820	G	G	C	A	C	A	T	C	A	A	T	T	A	A	T	T	G	A	T	T	C	C	1852
																							10/30	
p70a.hum...	1853	T	T	C	T	C	A	A	C	C	T	T	A	T	C	A	A	G	G	A	T	T	T	1885
p70a.hum...	1886	A	C	T	C	G	A	A	A	C	T	G	A	C	A	G	T	A	T	T	A	A	G	1918
p70a.hum...	1919	G	C	T	C	T	G	A	A	T	C	A	C	T	G	T	G	A	G	T	C	T	G	1951

FIG. 1K

p70a.hum... 1952 AGGGTATCCCTTTCATTAGGGCAAGTACAAATTGC 1984

p70a.hum... 1985 CTATAATACTTGCAACTAAGGACAAATTAGCAT 2017

p70a.hum... 2018 GCAAGCTTGGTCAAACTTTTCCCAGGC AAAATG 2050

p70a.hum... 2051 GGAAGGC AAAGACAAAGAACTTACCAATTGA 2083

p70a.hum... 2084 TGTTTTACGTGCAAAACAACCTGAATCTTTT 2116

p70a.hum... 2117 TATAATAATAATTTTCAAAATAGATTTTG 2149

11/30

FIG. 1L

p70a.hum... 2150 ATTCAGCTCATTATGAAACATCCCAAACTTT 2182

p70a.hum... 2183 AAAATGCGAAATTATTGGTTGGTGTGAAGAAAG 2215

p70a.hum... 2216 CCAGACAACCTTCTGTCTTCTCTCTTGGTGAAAT 2248^{12/30}

p70a.hum... 2249 AATAAATGCAAATGAATCATTTGTTAACACAGC 2281

p70a.hum... 2282 TGTGGCTCGTTTGAAGGGAATTGGGGTGGACCTGG 2314

p70a.hum... 2315 GGTTTATTTTCAGTAACCCAGCTGCGGAGCCT 2346

FIG. 2A-I

p70a.Prot.t...	1	M	R	R	R	R	R	D	G	F	Y	P	A	P	D	F	R	H	R	E	A	E	D	M	A	G	V	F	D	I	D	L	D	33	
p70b.Prot.t...	1	-	-	-	-	-	-	-	-	-	-	M	A	R	G	R	R	A	R	G	A	A	M	A	V	F	D	L	D	L	E	23			
p70a.Prot.t...	34	Q	P	E	D	A	G	S	E	D	E	L	E	E	G	G	Q	L	N	E	S	M	D	H	G	G	V	G	P	Y	E	L	G	M	66
p70b.Prot.t...	24	T	E	E	G	S	E	G	E	P	E	L	S	P	A	D	A	C	P	L	A	E	L	R	A	A	G	L	E	-	P	V	55		
p70a.Prot.t...	67	E	H	C	E	K	F	E	I	S	E	T	S	V	N	R	G	P	E	K	I	R	P	E	C	F	E	L	L	R	V	L	G	K	99
p70b.Prot.t...	56	G	H	Y	E	E	V	E	L	T	E	T	S	V	N	V	G	P	E	R	I	G	P	H	C	F	E	L	L	R	V	L	G	K	88
p70a.Prot.t...	100	G	G	Y	G	K	V	F	Q	V	R	K	V	T	G	A	N	T	G	K	I	F	A	M	K	V	L	K	K	A	M	I	V	R	132
p70b.Prot.t...	89	G	G	Y	G	K	V	F	Q	V	R	K	V	Q	G	T	N	L	G	K	I	Y	A	M	K	V	L	R	K	A	K	I	V	R	121
p70a.Prot.t...	133	N	A	K	D	T	A	H	T	K	A	E	R	N	I	L	E	E	V	K	H	P	F	I	V	D	L	I	Y	A	F	Q	T	G	165
p70b.Prot.t...	122	N	A	K	D	T	A	H	T	R	A	E	R	N	I	L	E	S	V	K	H	P	F	I	V	E	L	A	Y	A	F	Q	T	G	154
p70a.Prot.t...	166	G	K	L	Y	L	I	L	E	Y	L	S	G	G	E	L	F	M	Q	L	E	R	E	G	I	F	M	E	D	T	A	C	F	Y	198
p70b.Prot.t...	155	G	K	L	Y	L	I	L	E	C	L	S	G	G	E	L	F	T	H	L	E	R	E	G	I	F	L	E	D	T	A	C	F	Y	187

FIG. 2A-2

p70a.Prot.t...	199	L A E I S M A L G H L H Q K G I I Y R D L K P E N I M L N H Q Q G H	231
p70b.Prot.t...	188	L A E I T L A L G H L H S Q G I I Y R D L K P E N I M L S S Q Q G H	220
p70a.Prot.t...	232	V K L T D F G L C K E S I H D G T V T H T F C G T I E Y M A P E I	264
p70b.Prot.t...	221	I K L T D F G L C K E S I H E G A V T H T F C G T I E Y M A P E I	253
p70a.Prot.t...	265	L M R S G H N R A V D W W S L G A L M Y D M L T G A P P F T G E N	297
p70b.Prot.t...	254	L V R S G H N R A V D W W S L G A L M Y D M L T G S P P F T A E N	286 ^{14/30}
p70a.Prot.t...	298	R K K T I D K I L K C K L N L P P Y L T Q E A R D L L K K L L K R	330
p70b.Prot.t...	287	R K K T M D K I I R G K L A L P P Y L T P D A R D L V K K F L K R	319
p70a.Prot.t...	331	N A A S R L G A G P G D A G E V Q A H P F F R H I N W E E L L A R	363
p70b.Prot.t...	320	N P S Q R I G G G P G D A A D V Q R H P F F R H M N W D D L L A W	352
p70a.Prot.t...	364	K V E R P F K P L L Q S E E D V S Q F D S K F T R Q T P V D S P D	396
p70b.Prot.t...	353	R V D P P F R P C L Q S E E D V S Q F D T R F T R Q T P V D S P D	385

FIG. 2A-3

p70a.Prot.t...	397	D	S	T	L	S	E	S	A	N	Q	V	F	L	G	F	T	Y	V	A	P	S	V	L	E	S	V	K	E	K	F	S	F	E	429
p70b.Prot.t...	386	D	T	A	L	S	E	S	A	N	Q	A	F	L	G	F	T	Y	V	A	P	S	D	S	I	K	E	G	F	S	F	Q	418		
p70a.Prot.t...	430	P	K	I	R	S	P	R	R	F	I	G	S	P	R	T	P	V	S	P	V	K	F	S	P	G	D	F	W	G	R	G	A	S	462
p70b.Prot.t...	419	P	K	L	R	S	P	R	R	L	N	S	S	P	R	V	P	V	S	P	L	K	F	S	P	-	-	F	E	G	F	R	P	S	449
p70a.Prot.t...	463	A	S	T	A	N	P	Q	T	P	V	E	Y	P	M	E	T	S	G	I	E	Q	M	D	V	T	T	S	G	E	A	S	A	P	495
p70b.Prot.t...	450	P	S	-	L	-	P	E	-	P	T	E	L	P	L	-	P	P	-	L	-	-	L	P	P	P	P	P	-	S	T	T	A	P	474
p70a.Prot.t...	496	L	P	I	R	Q	P	N	S	G	P	Y	K	K	Q	A	F	P	M	I	S	K	R	P	E	H	L	R	M	N	L				525
p70b.Prot.t...	475	L	P	I	R	P	P	S	G	T	K	K	S	K	R	G	R	G	R	P	G	R													495

15/30


FIG. 2B

SEQUENCE IDENTITY BETWEEN p70 α AND p70 β ISOFORMS




17/30

FIG. 3A




18/30

FIG. 3B**Expression pattern of the p70 β mRNAs in
tumour cell lines**


- 1 Promyelocytic leukemia HL-60
- 2 HeLa cell S3
- 3 chronic myelogenous leukemia K562
- 4 Lymphoblastic leukemia MOLT-4
- 5 Burkitt's lymphoma Raji
- 6 colorectal adenocarcinoma SW480
- 7 Lung carcinoma A549
- 8 Melanoma G361

19/30

FIG. 4A




20/30

FIG. 4B**PHOSPHORYLATION OF THE RIBOSOMAL S6 PROTEIN
C-TERMINAL PEPTIDES BY p70 α AND β KINASES**

21/30

FIG. 5A

ACTIVATION OF THE P70 α AND β KINASES IN
RESPONSE TO VARIOUS STIMULI IN VIVO



- 1 MOCK TRANSFECTION
- 2 p70 α (STARVED AND NONTREATED)
- 3 p70 α (STARVED AND INSULIN STIMULATED)
- 4 p70 β (STARVED AND NONTREATED)
- 5 p70 β (STARVED AND INSULIN STIMULATED)
- 6 p70 β (STARVED AND SERUM STIMULATED)
- 7 p70 β (STARVED AND TPA STIMULATED)

22/30

FIG. 5B

ACTIVATION OF THE P70 α AND β KINASES BY PDGF IN
TRANSIENTLY TRANSFECTED PAE CELLS






FIG. 6A




25/30

FIG. 7


**INTERACTION OF P70S6K β WITH
DIFFERENT GST/SH3 FUSION
PROTEINS IN VITRO**




26/30


FIG. 8**IMMUNOPRECIPITATION AND WESTERN BLOT ANALYSIS
OF P70 β I AND β II TRANSIENTLY OVEREXPRESSED
IN HEK 293 CELLS**

27/30






29/30

FIG. 11COMPARISON BETWEEN THE ACTIVITY
OF P70 β WT AND P70 β 401

30/30

FIG. 12

COMPARISON BETWEEN THE ACTIVITY
OF P70 α WT AND P70 α 412



SEQUENCE LISTING

<110> Ludwig Institute for Cancer Research

<110> Gout, Ivan
Hara, Kenta
Waterfield, Michael
Yonezawa, Kazu

<120> Identification and Functional Characterization of a
Novel Ribosomal S6 Protein Kinase

<130> 40750-5002

<140> Unassigned

<141> 1999-08-04

<150> 60/095,268

<151> 1998-08-04

<160> 8

<170> PatentIn Ver. 2.0

<210> 1

<211> 1816

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (77)..(1561)

<223> p70(beta) S6 Kinase gene

<400> 1

gagagagaga gagagagaga gagagagaga gagagagaga gagagagaga 60

gagagactcg tgccga atg gca cga ggc cga cgg gcc cgc ggg gcc ggc gcc 112
Met Ala Arg Gly Arg Arg Ala Arg Gly Ala Gly Ala
1 5 10

gcc atg gcg gcc gtg ttt gat ttg gat ttg gag acg gag gaa ggc agc 160
Ala Met Ala Ala Val Phe Asp Leu Asp Leu Glu Thr Glu Glu Gly Ser
15 20 25

gag ggc gag ggc gag cca gag ctc agc ccc gcg gac gca tgt ccc ctt 208
Glu Gly Glu Gly Glu Pro Glu Leu Ser Pro Ala Asp Ala Cys Pro Leu
30 35 40

gcc gag ttg agg gca gct ggc cta gag cct gtg gga cac tat gaa gag 256
Ala Glu Leu Arg Ala Ala Gly Leu Glu Pro Val Gly His Tyr Glu Glu
45 50 55 60

gtg gag ctg act gag acc agc gtg aac gtt ggc cca gag cgc atc ggg 304
Val Glu Leu Thr Glu Thr Ser Val Asn Val Gly Pro Glu Arg Ile Gly
65 70 75

ccc cac tgc ttt gag ctg ctg cgt gtg ctg ggc aag ggg ggc tat ggc	352
Pro His Cys Phe Glu Leu Leu Arg Val Leu Gly Lys Gly Gly Tyr Gly	
80 85 90	
aag gtg ttc cag gtg cga aag gtg caa ggc acc aac ttg ggc aaa ata	400
Lys Val Phe Gln Val Arg Lys Val Gln Gly Thr Asn Leu Gly Lys Ile	
95 100 105	
tat gcc atg aaa gtc cta agg aag gcc aaa att gtg cgc aat gcc aag	448
Tyr Ala Met Lys Val Leu Arg Lys Ala Lys Ile Val Arg Asn Ala Lys	
110 115 120	
gac aca gca cac aca cgg gct gag cgg aac att cta gag tca gtg aag	496
Asp Thr Ala His Thr Arg Ala Glu Arg Asn Ile Leu Glu Ser Val Lys	
125 130 135 140	
cac ccc ttt att gtg gaa ctg gcc tat gcc ttc cag act ggt ggc aaa	544
His Pro Phe Ile Val Glu Leu Ala Tyr Ala Phe Gln Thr Gly Gly Lys	
145 150 155	
ctc tac ctc atc ctt gag tgc ctc agt ggt ggc gag ctc ttc acg cat	592
Leu Tyr Leu Ile Leu Glu Cys Leu Ser Gly Gly Glu Leu Phe Thr His	
160 165 170	
ctg gag cga gag ggc atc ttc ctg gaa gat acg gcc tgc ttc tac ctg	640
Leu Glu Arg Glu Gly Ile Phe Leu Glu Asp Thr Ala Cys Phe Tyr Leu	
175 180 185	
gct gag atc acg ctg gcc ctg ggc cat ctc cac tcc cag ggc atc atc	688
Ala Glu Ile Thr Leu Ala Leu Gly His Leu His Ser Gln Gly Ile Ile	
190 195 200	
tac cgg gac ctc aag ccc gag aac atc atg ctc agc agc cag ggc cac	736
Tyr Arg Asp Leu Lys Pro Glu Asn Ile Met Leu Ser Ser Gln Gly His	
205 210 215 220	
atc aaa ctg acc gac ttt gga ctc tgc aag gag tct atc cat gag ggc	784
Ile Lys Leu Thr Asp Phe Gly Leu Cys Lys Glu Ser Ile His Glu Gly	
225 230 235	
gcc gtc act cac acc ttc tgc ggc acc att gag tac atg gcc cct gag	832
Ala Val Thr His Thr Phe Cys Gly Thr Ile Glu Tyr Met Ala Pro Glu	
240 245 250	
att ctg gtg cgc agt ggc cac aac cgg gct gtg gac tgg tgg agc ctg	880
Ile Leu Val Arg Ser Gly His Asn Arg Ala Val Asp Trp Trp Ser Leu	
255 260 265	
ggg gcc ctg atg tac gac atg ctc act gga tgc ccg ccc ttt acc gca	928
Gly Ala Leu Met Tyr Asp Met Leu Thr Gly Ser Pro Pro Phe Thr Ala	
270 275 280	
gag aac cgg aag aaa acc atg gat aag atc atc agg ggc aag ctg gca	976
Glu Asn Arg Lys Lys Thr Met Asp Lys Ile Ile Arg Gly Lys Leu Ala	
285 290 295 300	

```

ctg ccc ccc tac ctc acc cca gat gcc cgg gac ctt gtc aaa aag ttt 1024
Leu Pro Pro Tyr Leu Thr Pro Asp Ala Arg Asp Leu Val Lys Lys Phe
      305                      310                      315

ctg aaa cgg aat ccc agc cag cgg att ggg ggt ggc cca ggg gat gct 1072
Leu Lys Arg Asn Pro Ser Gln Arg Ile Gly Gly Gly Pro Gly Asp Ala
      320                      325                      330

gct gat gtg cag aga cat ccc ttt ttc cgg cac atg aat tgg gac gac 1120
Ala Asp Val Gln Arg His Pro Phe Phe Arg His Met Asn Trp Asp Asp
      335                      340                      345

ctt ctg gcc tgg cgt gtg gac ccc cct ttc agg ccc tgt ctg cag tca 1168
Leu Leu Ala Trp Arg Val Asp Pro Pro Phe Arg Pro Cys Leu Gln Ser
      350                      355                      360

gag gag gac gtg agc cag ttt gat acc cgc ttc aca cgg cag acg ccg 1216
Glu Glu Asp Val Ser Gln Phe Asp Thr Arg Phe Thr Arg Gln Thr Pro
365                      370                      375                      380

gtg gac agt cct gat gac aca gcc ctc agc gag agt gcc aac cag gcc 1264
Val Asp Ser Pro Asp Asp Thr Ala Leu Ser Glu Ser Ala Asn Gln Ala
      385                      390                      395

ttc ctg ggc ttc aca tac gtg gcg ccg tct gtc ctg gac agc atc aag 1312
Phe Leu Gly Phe Thr Tyr Val Ala Pro Ser Val Leu Asp Ser Ile Lys
      400                      405                      410

gag ggc ttc tcc ttc cag ccc aag ctg cgc tca ccc agg cgc ctc aac 1360
Glu Gly Phe Ser Phe Gln Pro Lys Leu Arg Ser Pro Arg Arg Leu Asn
      415                      420                      425

agt agc ccc cgg gtc ccc gtc agc ccc ctc aag ttc tcc cct ttt gag 1408
Ser Ser Pro Arg Val Pro Val Ser Pro Leu Lys Phe Ser Pro Phe Glu
      430                      435                      440

ggg ttt cgg ccc agc ccc agc ctg ccg gag ccc acg gag cta cct cta 1456
Gly Phe Arg Pro Ser Pro Ser Leu Pro Glu Pro Thr Glu Leu Pro Leu
445                      450                      455                      460

cct cca ctc ctg cca ccg ccg ccg ccc tcg acc acc gcc cct ctc ccc 1504
Pro Pro Leu Leu Pro Pro Pro Pro Pro Ser Thr Thr Ala Pro Leu Pro
      465                      470                      475

atc cgt ccc ccc tca ggg acc aag aag tcc aag agg ggc cgt ggg cgt 1552
Ile Arg Pro Pro Ser Gly Thr Lys Lys Ser Lys Arg Gly Arg Gly Arg
      480                      485                      490

cca ggg cgc taggaagccg ggtgggggtg agggtagccc ttgagccctg 1601
Pro Gly Arg
      495

tccctgcggc tgtgagagca gcaggaccct gggccagttc cagagacctg ggggtgtgtc 1661

tgggggtggg gtgtgagtgc gtatgaaagt gtgtgtctgc tggggcagct gtgccctga 1721

```

atcatgggca cggagggccg cccgccacac cccgcgctca actgctcccg tggaagatta 1781
 aagggctgaa tcatgaaaaa aaaaaaaaaa aaaaaa 1816

<210> 2
 <211> 495
 <212> PRT
 <213> Homo sapiens

<220>
 <223> p70(beta) S6 Kinase protein

<400> 2
 Met Ala Arg Gly Arg Arg Ala Arg Gly Ala Gly Ala Ala Met Ala Ala
 1 5 10 15
 Val Phe Asp Leu Asp Leu Glu Thr Glu Glu Gly Ser Glu Gly Glu Gly
 20 25 30
 Glu Pro Glu Leu Ser Pro Ala Asp Ala Cys Pro Leu Ala Glu Leu Arg
 35 40 45
 Ala Ala Gly Leu Glu Pro Val Gly His Tyr Glu Glu Val Glu Leu Thr
 50 55 60
 Glu Thr Ser Val Asn Val Gly Pro Glu Arg Ile Gly Pro His Cys Phe
 65 70 75 80
 Glu Leu Leu Arg Val Leu Gly Lys Gly Gly Tyr Gly Lys Val Phe Gln
 85 90 95
 Val Arg Lys Val Gln Gly Thr Asn Leu Gly Lys Ile Tyr Ala Met Lys
 100 105 110
 Val Leu Arg Lys Ala Lys Ile Val Arg Asn Ala Lys Asp Thr Ala His
 115 120 125
 Thr Arg Ala Glu Arg Asn Ile Leu Glu Ser Val Lys His Pro Phe Ile
 130 135 140
 Val Glu Leu Ala Tyr Ala Phe Gln Thr Gly Gly Lys Leu Tyr Leu Ile
 145 150 155 160
 Leu Glu Cys Leu Ser Gly Gly Glu Leu Phe Thr His Leu Glu Arg Glu
 165 170 175
 Gly Ile Phe Leu Glu Asp Thr Ala Cys Phe Tyr Leu Ala Glu Ile Thr
 180 185 190
 Leu Ala Leu Gly His Leu His Ser Gln Gly Ile Ile Tyr Arg Asp Leu
 195 200 205
 Lys Pro Glu Asn Ile Met Leu Ser Ser Gln Gly His Ile Lys Leu Thr
 210 215 220

Asp Phe Gly Leu Cys Lys Glu Ser Ile His Glu Gly Ala Val Thr His
 225 230 235 240
 Thr Phe Cys Gly Thr Ile Glu Tyr Met Ala Pro Glu Ile Leu Val Arg
 245 250 255
 Ser Gly His Asn Arg Ala Val Asp Trp Trp Ser Leu Gly Ala Leu Met
 260 265 270
 Tyr Asp Met Leu Thr Gly Ser Pro Pro Phe Thr Ala Glu Asn Arg Lys
 275 280 285
 Lys Thr Met Asp Lys Ile Ile Arg Gly Lys Leu Ala Leu Pro Pro Tyr
 290 295 300
 Leu Thr Pro Asp Ala Arg Asp Leu Val Lys Lys Phe Leu Lys Arg Asn
 305 310 315 320
 Pro Ser Gln Arg Ile Gly Gly Gly Pro Gly Asp Ala Ala Asp Val Gln
 325 330 335
 Arg His Pro Phe Phe Arg His Met Asn Trp Asp Asp Leu Leu Ala Trp
 340 345 350
 Arg Val Asp Pro Pro Phe Arg Pro Cys Leu Gln Ser Glu Glu Asp Val
 355 360 365
 Ser Gln Phe Asp Thr Arg Phe Thr Arg Gln Thr Pro Val Asp Ser Pro
 370 375 380
 Asp Asp Thr Ala Leu Ser Glu Ser Ala Asn Gln Ala Phe Leu Gly Phe
 385 390 395 400
 Thr Tyr Val Ala Pro Ser Val Leu Asp Ser Ile Lys Glu Gly Phe Ser
 405 410 415
 Phe Gln Pro Lys Leu Arg Ser Pro Arg Arg Leu Asn Ser Ser Pro Arg
 420 425 430
 Val Pro Val Ser Pro Leu Lys Phe Ser Pro Phe Glu Gly Phe Arg Pro
 435 440 445
 Ser Pro Ser Leu Pro Glu Pro Thr Glu Leu Pro Leu Pro Pro Leu Leu
 450 455 460
 Pro Pro Pro Pro Pro Ser Thr Thr Ala Pro Leu Pro Ile Arg Pro Pro
 465 470 475 480
 Ser Gly Thr Lys Lys Ser Lys Arg Gly Arg Gly Arg Pro Gly Arg
 485 490 495

<210> 3

<211> 2346

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (28)..(1602)

<223> p70(alpha) S6 Kinase gene

<400> 3

```

gcacgaggct gcggcgggctc cgggccc atg agg cga cga agg agg cgg gac ggc 54
                        Met Arg Arg Arg Arg Arg Asp Gly
                          1                      5

ttt tac cca gcc ccg gac ttc cga gac agg gaa gct gag gac atg gca 102
Phe Tyr Pro Ala Pro Asp Phe Arg Asp Arg Glu Ala Glu Asp Met Ala
 10                      15                      20                      25

gga gtg ttt gac ata gac ctg gac cag cca gag gac gcg ggc tct gag 150
Gly Val Phe Asp Ile Asp Leu Asp Gln Pro Glu Asp Ala Gly Ser Glu
                      30                      35                      40

gat gag ctg gag gag ggg ggt cag tta aat gaa agc atg gac cat ggg 198
Asp Glu Leu Glu Glu Gly Gly Gln Leu Asn Glu Ser Met Asp His Gly
                      45                      50                      55

gga gtt gga cca tat gaa ctt ggc atg gaa cat tgt gag aaa ttt gaa 246
Gly Val Gly Pro Tyr Glu Leu Gly Met Glu His Cys Glu Lys Phe Glu
                      60                      65                      70

atc tca gaa act agt gtg aac aga ggg cca gaa aaa atc aga cca gaa 294
Ile Ser Glu Thr Ser Val Asn Arg Gly Pro Glu Lys Ile Arg Pro Glu
                      75                      80                      85

tgt ttt gag cta ctt cgg gta ctt ggt aaa ggg ggc tat gga aag gtt 342
Cys Phe Glu Leu Leu Arg Val Leu Gly Lys Gly Gly Tyr Gly Lys Val
 90                      95                      100                      105

ttt caa gta cga aaa gta aca gga gca aat act ggg aaa ata ttt gcc 390
Phe Gln Val Arg Lys Val Thr Gly Ala Asn Thr Gly Lys Ile Phe Ala
                      110                      115                      120

atg aag gtg ctt aaa aag gca atg ata gta aga aat gct aaa gat aca 438
Met Lys Val Leu Lys Lys Ala Met Ile Val Arg Asn Ala Lys Asp Thr
                      125                      130                      135

gct cat aca aaa gca gaa cgg aat att ctg gag gaa gta aag cat ccc 486
Ala His Thr Lys Ala Glu Arg Asn Ile Leu Glu Glu Val Lys His Pro
                      140                      145                      150

ttc atc gtg gat tta att tat gcc ttt cag act ggt gga aaa ctc tac 534
Phe Ile Val Asp Leu Ile Tyr Ala Phe Gln Thr Gly Gly Lys Leu Tyr
                      155                      160                      165

ctc atc ctt gag tat ctc agt gga gga gaa cta ttt atg cag tta gaa 582
Leu Ile Leu Glu Tyr Leu Ser Gly Gly Glu Leu Phe Met Gln Leu Glu
170                      175                      180                      185

aga gag gga ata ttt atg gaa gac act gcc tgc ttt tac ttg gca gaa 630
Arg Glu Gly Ile Phe Met Glu Asp Thr Ala Cys Phe Tyr Leu Ala Glu

```


190										195					200					
atc	tcc	atg	gct	ttg	ggg	cat	tta	cat	caa	aag	ggg	atc	atc	tac	aga	678				
Ile	Ser	Met	Ala	Leu	Gly	His	Leu	His	Gln	Lys	Gly	Ile	Ile	Tyr	Arg					
205					210					215										
gac	ctg	aag	ccg	gag	aat	atc	atg	ctt	aat	cac	caa	ggg	cat	gtg	aaa	726				
Asp	Leu	Lys	Pro	Glu	Asn	Ile	Met	Leu	Asn	His	Gln	Gly	His	Val	Lys					
220					225					230										
cta	aca	gac	ttt	gga	cta	tgc	aaa	gaa	tct	att	cat	gat	gga	aca	gtc	774				
Leu	Thr	Asp	Phe	Gly	Leu	Cys	Lys	Glu	Ser	Ile	His	Asp	Gly	Thr	Val					
235					240					245										
aca	cac	aca	ttt	tgt	gga	aca	ata	gaa	tac	atg	gcc	cct	gaa	atc	ttg	822				
Thr	His	Thr	Phe	Cys	Gly	Thr	Ile	Glu	Tyr	Met	Ala	Pro	Glu	Ile	Leu					
250					255					260					265					
atg	aga	agt	ggc	cac	aat	cgt	gct	gtg	gat	tgg	tgg	agt	ttg	gga	gca	870				
Met	Arg	Ser	Gly	His	Asn	Arg	Ala	Val	Asp	Trp	Trp	Ser	Leu	Gly	Ala					
270					275					280										
tta	atg	tat	gac	atg	ctg	act	gga	gca	ccc	cca	ttc	act	ggg	gag	aat	918				
Leu	Met	Tyr	Asp	Met	Leu	Thr	Gly	Ala	Pro	Pro	Phe	Thr	Gly	Glu	Asn					
285					290					295										
aga	aag	aaa	aca	att	gac	aaa	atc	ctc	aaa	tgt	aaa	ctc	aat	ttg	cct	966				
Arg	Lys	Lys	Thr	Ile	Asp	Lys	Ile	Leu	Lys	Cys	Lys	Leu	Asn	Leu	Pro					
300					305					310										
ccc	tac	ctc	aca	caa	gaa	gcc	aga	gat	ctg	ctt	aaa	aag	ctg	ctg	aaa	1014				
Pro	Tyr	Leu	Thr	Gln	Glu	Ala	Arg	Asp	Leu	Leu	Lys	Lys	Leu	Leu	Lys					
315					320					325										
aga	aat	gct	gct	tct	cgt	ctg	gga	gct	ggg	cct	ggg	gac	gct	gga	gaa	1062				
Arg	Asn	Ala	Ala	Ser	Arg	Leu	Gly	Ala	Gly	Pro	Gly	Asp	Ala	Gly	Glu					
330					335					340					345					
gtt	caa	gct	cat	cca	ttc	ttt	aga	cac	att	aac	tgg	gaa	gaa	ctt	ctg	1110				
Val	Gln	Ala	His	Pro	Phe	Phe	Arg	His	Ile	Asn	Trp	Glu	Glu	Leu	Leu					
350					355					360										
gct	cga	aag	gtg	gag	ccc	ccc	ttt	aaa	cct	ctg	ttg	caa	tct	gaa	gag	1158				
Ala	Arg	Lys	Val	Glu	Pro	Pro	Phe	Lys	Pro	Leu	Leu	Gln	Ser	Glu	Glu					
365					370					375										
gat	gta	agt	cag	ttt	gat	tcc	aag	ttt	aca	cgt	cag	aca	cct	gtc	gac	1206				
Asp	Val	Ser	Gln	Phe	Asp	Ser	Lys	Phe	Thr	Arg	Gln	Thr	Pro	Val	Asp					
380					385					390										
agc	cca	gat	gac	tca	act	ctc	agt	gaa	agt	gcc	aat	cag	gtc	ttt	ctg	1254				
Ser	Pro	Asp	Asp	Ser	Thr	Leu	Ser	Glu	Ser	Ala	Asn	Gln	Val	Phe	Leu					
395					400					405										
ggg	ttt	aca	tat	gtg	gct	cca	tct	gta	ctt	gaa	agt	gtg	aaa	gaa	aag	1302				
Gly	Phe	Thr	Tyr	Val	Ala	Pro	Ser	Val	Leu	Glu	Ser	Val	Lys	Glu	Lys					

```

410                               415                               420                               425
ttt tcc ttt gaa cca aaa atc cga tca cct cga aga ttt att ggc agc 1350
Phe Ser Phe Glu Pro Lys Ile Arg Ser Pro Arg Arg Phe Ile Gly Ser
                               430                               435                               440

cca cga aca cct gtc agc cca gtc aaa ttt tct cct ggg gat ttc tgg 1398
Pro Arg Thr Pro Val Ser Pro Val Lys Phe Ser Pro Gly Asp Phe Trp
                               445                               450                               455

gga aga ggt gct tcg gcc agc aca gca aat cct cag aca cct gtg gaa 1446
Gly Arg Gly Ala Ser Ala Ser Thr Ala Asn Pro Gln Thr Pro Val Glu
                               460                               465                               470

tac cca atg gaa aca agt ggc ata gag cag atg gat gtg aca atg agt 1494
Tyr Pro Met Glu Thr Ser Gly Ile Glu Gln Met Asp Val Thr Met Ser
                               475                               480                               485

ggg gaa gca tcg gca cca ctt cca ata cga cag ccg aac tct ggg cca 1542
Gly Glu Ala Ser Ala Pro Leu Pro Ile Arg Gln Pro Asn Ser Gly Pro
490                               495                               500                               505

tac aaa aaa caa gct ttt ccc atg atc tcc aaa cgg cca gag cac ctg 1590
Tyr Lys Lys Gln Ala Phe Pro Met Ile Ser Lys Arg Pro Glu His Leu
                               510                               515                               520

cgt atg aat cta tgacagagca atgcttttaa tgaatttaag gcaaaaaggt 1642
Arg Met Asn Leu
                               525

ggagagggag atgtgtgagc atcctgcaag gtgaaacaag actcaaaatg acagtttcag 1702
agagtcaatg tcattacata gaacacttcg gacacaggaa aaataaacgt ggattttaaa 1762
aaatcaatca atgggtgcaaa aaaaaactta aagcaaaata gtattgctga actcttaggc 1822
acatcaatta attgattcct cgcgacatct ttctcaacct tatcaaggat tttcatgttg 1882
atgactcgaa actgacagta ttaagggtag gatgttgctc tgaatcactg tgagtctgat 1942
gtgtgaagaa ggggtatcctt tcattaggca agtacaaatt gcctataata cttgcaacta 2002
aggacaaatt agcatgcaag cttgggtcaaa cttttcccag gcaaaatggg aaggcaaaga 2062
caaaagaaac ttaccaattg atgtttttacg tgcaaaacaac ctgaatcttt tttttatata 2122
aatatatatt tttcaaatag atttttgatt cagctcatta tgaaaaacat cccaaacttt 2182
aaaatgcgaa attattgggtt ggtgtgaaga aagccagaca acttctgttt cttctcttgg 2242
tgaaataata aaatgcaaat gaatcattgt taacacagct gtggctcgtt tgagggattg 2302
gggtggacct ggggtttatt ttcagtaacc cagctgcgga gcct 2346

```

<210> 4

<211> 525

<212> PRT

<213> Homo sapiens

<220>

<223> p70(alpha) S6 Kinase protein

<400> 4

Met Arg Arg Arg Arg Arg Arg Asp Gly Phe Tyr Pro Ala Pro Asp Phe
 1 5 10 15

Arg Asp Arg Glu Ala Glu Asp Met Ala Gly Val Phe Asp Ile Asp Leu
 20 25 30

Asp Gln Pro Glu Asp Ala Gly Ser Glu Asp Glu Leu Glu Glu Gly Gly
 35 40 45

Gln Leu Asn Glu Ser Met Asp His Gly Gly Val Gly Pro Tyr Glu Leu
 50 55 60

Gly Met Glu His Cys Glu Lys Phe Glu Ile Ser Glu Thr Ser Val Asn
 65 70 75 80

Arg Gly Pro Glu Lys Ile Arg Pro Glu Cys Phe Glu Leu Leu Arg Val
 85 90 95

Leu Gly Lys Gly Gly Tyr Gly Lys Val Phe Gln Val Arg Lys Val Thr
 100 105 110

Gly Ala Asn Thr Gly Lys Ile Phe Ala Met Lys Val Leu Lys Lys Ala
 115 120 125

Met Ile Val Arg Asn Ala Lys Asp Thr Ala His Thr Lys Ala Glu Arg
 130 135 140

Asn Ile Leu Glu Glu Val Lys His Pro Phe Ile Val Asp Leu Ile Tyr
 145 150 155 160

Ala Phe Gln Thr Gly Gly Lys Leu Tyr Leu Ile Leu Glu Tyr Leu Ser
 165 170 175

Gly Gly Glu Leu Phe Met Gln Leu Glu Arg Glu Gly Ile Phe Met Glu
 180 185 190

Asp Thr Ala Cys Phe Tyr Leu Ala Glu Ile Ser Met Ala Leu Gly His
 195 200 205

Leu His Gln Lys Gly Ile Ile Tyr Arg Asp Leu Lys Pro Glu Asn Ile
 210 215 220

Met Leu Asn His Gln Gly His Val Lys Leu Thr Asp Phe Gly Leu Cys
 225 230 235 240

Lys Glu Ser Ile His Asp Gly Thr Val Thr His Thr Phe Cys Gly Thr
 245 250 255

Ile Glu Tyr Met Ala Pro Glu Ile Leu Met Arg Ser Gly His Asn Arg
 260 265 270
 Ala Val Asp Trp Trp Ser Leu Gly Ala Leu Met Tyr Asp Met Leu Thr
 275 280 285
 Gly Ala Pro Pro Phe Thr Gly Glu Asn Arg Lys Lys Thr Ile Asp Lys
 290 295 300
 Ile Leu Lys Cys Lys Leu Asn Leu Pro Pro Tyr Leu Thr Gln Glu Ala
 305 310 315 320
 Arg Asp Leu Leu Lys Lys Leu Leu Lys Arg Asn Ala Ala Ser Arg Leu
 325 330 335
 Gly Ala Gly Pro Gly Asp Ala Gly Glu Val Gln Ala His Pro Phe Phe
 340 345 350
 Arg His Ile Asn Trp Glu Glu Leu Leu Ala Arg Lys Val Glu Pro Pro
 355 360 365
 Phe Lys Pro Leu Leu Gln Ser Glu Glu Asp Val Ser Gln Phe Asp Ser
 370 375 380
 Lys Phe Thr Arg Gln Thr Pro Val Asp Ser Pro Asp Asp Ser Thr Leu
 385 390 395 400
 Ser Glu Ser Ala Asn Gln Val Phe Leu Gly Phe Thr Tyr Val Ala Pro
 405 410 415
 Ser Val Leu Glu Ser Val Lys Glu Lys Phe Ser Phe Glu Pro Lys Ile
 420 425 430
 Arg Ser Pro Arg Arg Phe Ile Gly Ser Pro Arg Thr Pro Val Ser Pro
 435 440 445
 Val Lys Phe Ser Pro Gly Asp Phe Trp Gly Arg Gly Ala Ser Ala Ser
 450 455 460
 Thr Ala Asn Pro Gln Thr Pro Val Glu Tyr Pro Met Glu Thr Ser Gly
 465 470 475 480
 Ile Glu Gln Met Asp Val Thr Met Ser Gly Glu Ala Ser Ala Pro Leu
 485 490 495
 Pro Ile Arg Gln Pro Asn Ser Gly Pro Tyr Lys Lys Gln Ala Phe Pro
 500 505 510
 Met Ile Ser Lys Arg Pro Glu His Leu Arg Met Asn Leu
 515 520 525

<210> 5

<211> 31

<212> PRT

<213> Homo sapiens

<220>

<223> Sequence derived from C-terminus of ribosomal S6 protein

<400> 5

Lys Glu Ala Lys Glu Lys Arg Gln Glu Gln Ile Ala Arg Arg Arg Leu
 1 5 10 15

Ser Ser Leu Arg Ala Ser Thr Ser Lys Ser Glu Ser Ser Gln Lys
 20 25 30

<210> 6

<211> 19

<212> PRT

<213> Homo sapiens

<220>

<223> Sequence derived from C-terminus of ribosomal S6 protein

<400> 6

Arg Arg Arg Leu Ser Ser Leu Arg Ala Ser Thr Ser Lys Ser Glu Ser
 1 5 10 15

Ser Gln Lys

<210> 7

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic protease target substrate for p70(alpha) S6 Kinase isoforms

<400> 7

Lys Lys Arg Asn Arg Thr Leu Ser Val Ala
 1 5 10

<210> 8

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic protease target substrate for p70(beta) S6 Kinase isoforms

<400> 8

Arg Arg Leu Ser Ser Leu Arg Ala Ser Thr Ser Lys Ser Glu Ser Ser
 1 5 10 15

Gln Lys

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 99/17595

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/54 C12N15/62 C12N9/12 C12N5/10 C07K16/40
 G01N33/50 G01N33/566 C12Q1/68

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C07K G01N C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	GOUT I. ET AL.: "Molecular cloning and characterization of a novel p70 S6 kinase beta containing a proline-rich region" J. BIOL. CHEM., vol. 273, no. 46, 13 November 1998 (1998-11-13), pages 30061-30064, XP002124654 the whole document	1-36
P,X	SAITOH M. ET AL.: "Cloning and characterization of p70(S6 beta) defines a novel family of p70 S6 kinases" BIOCHEM. BIOPHYS. RES. COMMUN., vol. 253, no. 2, 18 December 1998 (1998-12-18), pages 471-476, XP002124655 the whole document	1-36

-/-

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"Z" document member of the same patent family

Date of the actual completion of the international search

20 December 1999

Date of mailing of the international search report

11/01/2000

Name and mailing address of the ISA

European Patent Office, P.B. 6818 Patentaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax (+31-70) 340-3016

Authorized officer

Galli, I

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	WO 99 24463 A (INCYTE PHARMA INC ; MATHUR PREETE (US); REDDY ROOPA (US); AU YOUNG) 20 May 1999 (1999-05-20) compare nt 180-1450 of seq. ID 10 and nt 101-1370 of seq. ID 1 of present application	1-4
A	WO 98 18935 A (CIBA GEIGY AG ; THOMAS GEORGE (FR); KOZMA SARA (FR)) 7 May 1998 (1998-05-07) abstract claims 1-11	1-36
A	WO 93 19752 A (DANA FARBER CANCER INST INC) 14 October 1993 (1993-10-14) abstract	1-36
A	MUKHOPADHYAY N.K. ET AL.: "An array of insulin-activated, proline-directed serine/threonine kinases phosphorylate the p70 S6 kinase" J. BIOL. CHEM., vol. 267, no. 5, 15 February 1995 (1995-02-15), pages 3325-3335, XP002124656 the whole document	1-36
A	WENG Q.P. ET AL.: "Regulation of the p70 S6 kinase by phosphorylation in vivo" J. BIOL. CHEM., vol. 273, no. 26, 26 June 1998 (1998-06-26), pages 16621-16629, XP002124657 the whole document	1-36
A	ALESSI D.R. ET AL.: "3-Phosphoinositide-dependent protein kinase 1 (PDK1) phosphorylates and activates the p70 S6 kinase in vivo and in vitro" CURRENT BIOLOGY, vol. 8, 10 December 1997 (1997-12-10), pages 69-81, XP000857264 the whole document	1-36
	— -/-	

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>HAN J -W ET AL: "RAPAMYCIN, WORTMANNIN, AND THE METHYLXANTHINE SQ20006 INACTIVATE P70S6K BY INDUCING DEPHOSPHORYLATION OF THE SAME SUBSET OF SITES"</p> <p>JOURNAL OF BIOLOGICAL CHEMISTRY,US,AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, vol. 270, no. 36, page 21396-21403 XP002057557 ISSN: 0021-9258 the whole document</p>	1-36
A	<p>PEARSON R B ET AL: "THE PRINCIPAL TARGET OF RAPAMYCIN-INDUCED P70S6K INACTIVATION IS A NOVEL PHOSPHORYLATION SITE WITHIN A CONSERVED HYDROPHOBIC DOMAIN"</p> <p>EMBO JOURNAL,GB,OXFORD UNIVERSITY PRESS, SURREY, vol. 14, no. 21, page 5279-5287 XP000561164 ISSN: 0261-4189 the whole document</p>	1-36
A	<p>DENNIS P B ET AL: "THE PRINCIPAL RAPAMYCIN-SENSITIVE P70S6K PHOSPHORYLATION SITES, T-229 AND T-389, ARE DIFFERENTIALLY REGULATED BY RAPAMYCIN-INSENSITIVE KINASE KINASES"</p> <p>MOLECULAR AND CELLULAR BIOLOGY,US,AMERICAN SOCIETY FOR MICROBIOLOGY, WASHINGTON, vol. 16, no. 11, page 6242-6251 XP002057559 ISSN: 0270-7306 the whole document</p>	1-36
A	<p>WO 98 03662 A (CIBA GEIGY AG ;STEWART MARY (CH); THOMAS GEORGE (FR); KOZMA SARA ()) 29 January 1998 (1998-01-29) abstract claims 1-9</p>	1-36
A	<p>PROUD C G: "P70 S6 KINASE: AN ENIGMA WITH VARIATIONS"</p> <p>TIBS TRENDS IN BIOCHEMICAL SCIENCES,EN,ELSEVIER PUBLICATION, CAMBRIDGE, vol. 21, no. 5, page 181-185 XP002057556 ISSN: 0968-0004 the whole document</p>	1-36

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 99/ 17595

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claims 10-11, as far as methods in vivo are concerned are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☒ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
See FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐ The additional search fees were accompanied by the applicant's protest.

☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims 10-11 refer to modulating compounds, and claims 25-26 refer to binding partners of p70 S6K (beta) without giving a true technical characterization. Moreover, no such compounds are defined in the application. In consequence, the scope of said claims is ambiguous and vague, and their subject-matter is not sufficiently disclosed and supported (Art. 5 and 6 PCT). No search can be carried out for such purely speculative claims whose wording is, in fact, a mere recitation of the results to be achieved.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 99/17595

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
WO 9924463	A	20-05-1999	US	5932445 A	03-08-1999
			AU	1309599 A	31-05-1999
WO 9818935	A	07-05-1998	AU	5314598 A	22-05-1998
			EP	0942990 A	22-09-1999
WO 9319752	A	14-10-1993	AU	3922493 A	08-11-1993
WO 9803662	A	29-01-1998	AU	4113897 A	10-02-1998
			EP	0915982 A	19-05-1999